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Abstract 
Although mitochondrial disorders are the most common inherited form of 
neuromuscular disease, there are currently limited effective treatments that directly 
improve mitochondrial function – either by modulation of the effects of mutated genes 
or by increasing the proportion of healthy mitochondria. In this work, two different 
approaches were employed to develop treatments for mitochondrial diseases: the design 
of mitochondrially targeted anti-sense oligonucleotides and the development of a high 
throughput screen of a unique library of bacterial extracts. 
 
The heteroplasmic nature of mitochondrial DNA (mtDNA) enables the use of anti-
genomic strategies to specifically prevent the replication, transcription or translation of 
mutated molecules of mtDNA or mitochondrial mRNA in patients with heteroplasmic 
mtDNA mutations. In conjunction with an industrial partner (Ugichem GmbH), a 
mitochondrial targeting oligonucleotide was developed using cell membrane crossing 
oligomers (CMCOs) – a new class of oligonucleotide with the ability to enter and 
accumulate within the cytoplasm. By conjugating “mitochondrial targeting” molecules 
to the CMCOs, translocation to mitochondria was shown, potentially enabling the use of 
anti-sense therapies in the treatment of mtDNA diseases.  
 
To complement the mutation specific approach of anti-sense oligonucleotide therapies a 
large scale screen was carried out to discover compounds that could cause a general 
improvement in mitochondrial function. A library of unique bacterial extracts, provided 
by Demuris Ltd, was screened for effects on mitochondrial biogenesis in HeLa cells. To 
that end, a high throughput assay, which used fluorescent markers to detect changes in 
relative mitochondrial mass, was designed and validated using mitochondrially active 
control compounds. The screen of bacterial extracts discovered several one extract 
which caused mitochondrial mass to increase 2 fold after 48 hours incubation. 
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1 Introduction 
1.1. MITOCHONDRIA 
The mitochondrion is a cytoplasmic organelle found within a large reticular network in 
eukaryotic cells. Each organelle has a double membrane structure, which houses the 
machinery needed for mitochondria to not only produce ATP (adenosine triphosphate), 
but also to fulfil their roles in apoptosis, calcium handling and the formation of iron 
sulphur clusters along with numerous other functions. Mitochondria are the only non-
nuclear source of DNA in humans and although the mitochondrial genome encodes vital 
proteins for mitochondria function, the vast majority of mitochondrial proteins are 
nuclear encoded (Anderson et al. 1981). However, the fact that mitochondria encode 
their own proteins also means that they are susceptible to a set of diseases caused by 
mutations in mitochondrial DNA (mtDNA), which not only affect mitochondria, but 
cellular function as a whole (Park and Larsson 2011). 
 
1.2. ORIGINS OF MITOCHONDRIA 
The origin of mitochondria is generally believed to stem from a symbiotic relationship 
between a eubacterium and a primitive eukaryotic cell in order to take advantage of 
increasing concentrations of atmospheric O2, which eventually led to the bacterium 
being permanently housed within the cell. The original hypothesis for this was proposed 
by Margulis in 1971 who suggested that this relationship occurred after the formation of 
the nucleus (Margulis 1971). Martin and Muller offered an alternative theory that the 
mitochondrion and nucleus were formed simultaneously as a result of fusion between a 
hydrogen dependent archaebacterium and a hydrogen producing eubacterium (Martin 
and Muller 1998). These theories, known as the endosymbiotic theory and hydrogen 
hypothesis respectively, both believe that the majority of the genetic material contained 
within mitochondria was transferred to the nucleus. Whole genome sequencing of the α-
proteobacterium, Rickettsia prowazekii, found that a complete set of tricarboxylic acid 
cycle (TCA) genes and respiratory-chain enzymes were encoded, genes that are 
essential for mitochondrial based respiration (Andersson et al. 1998).
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1.3. STRUCTURE  
The mammalian mitochondrion has been traditionally viewed as an ovoid organelle 
compartmentalised by a double plasma membrane. The “baffle” model of mitochondrial 
structure was developed using early electron microscopy (EM) studies and described a 
folded inner membrane contained within an outer membrane. The broad folds of inner 
membrane were named “cristae” (Palade 1952). This model has since been updated 
using EM tomography studies, which shows that the cristae do not have wide openings 
at the intermembrane space, but in fact show a much narrower and tubular like structure 
(Mannella et al. 1994) (figure 1.1).  
 
The outer mitochondrial membrane compartmentalises the organelle from the cytosol 
and contains abundant levels of the mitochondrial voltage dependant anion channel 
(VDAC). This protein forms a channel through which molecules up to 10kDa can enter 
the intermembrane space (Alberts et al. 2008). The inner membrane is cardiolipin rich 
and separates the intermembrane space from the matrix and consequently contains a 
number of transport proteins that regulate the flow of material into the matrix (these 
proteins are vital as the membrane is essentially impermeable). The inner membrane not 
only forms the scaffold for oxidative phosphorylation proteins, but also helps maintain 
the electrochemical gradient between the intermembrane space and the matrix, which is 
essential for ATP formation (Mitchell 1961).  
 
The mitochondrial matrix is the site of many of the enzymatic processes required for 
oxidative metabolism, such as the TCA cycle and β-oxidation of fatty acids. It also 
contains mtDNA and is the site of replication, transcription and translation of this 
genome. 
 
Transport of compounds into the matrix is highly regulated in order to maintain the 
proton electrochemical gradient (Alberts et al. 2008). As the majority of mitochondrial 
proteins are produced in the cytosol, there is a dedicated peptide transport system across 
the outer and inner membranes; TOM (translocase of the outer membrane) and TIM 
(translocase of the inner membrane), respectively. These multi-subunit translocases 
recognise mitochondrial targeting sequences located primarily at the N-terminal of the 
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peptide, allowing the peptide to enter the matrix, after which the targeting sequence is 
cleaved by a matrix processing peptidase (Hawlitschek et al. 1988; Pfanner et al. 1988). 
The most abundant transport protein in the inner membrane is the adenine nucleotide 
translocator (ANT). This protein enables the transport of ATP and ADP between the 
matrix and inner membrane space (Pfaff and Klingenberg 1968).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 – Mitochondrial structure.  
An electron micrograph (upper panel) shows the fine structure of 
an ovoid mitochondrion. The lower panel shows a schematic of the 
image with labelled compartments and structures. Scale represents 
500nm. Image courtesy of Dr. Amy Reeve.  
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1.3.1. Mitochondrial dynamics 
With the advent of live cell microscopy studies, it became clear that mitochondria are 
not static organelles, but are in fact highly dynamic and undergo processes of fission 
and fusion (Bereiter-Hahn 1978; Nunnari et al. 1997). Fusion and fission are essential 
for the transport of mitochondria into daughter cells, removal of damaged mitochondria 
and may also play a role in modulation of ATP production (Skulachev 2001). 
 
 Mitochondrial fusion 1.3.1.1.
Mitochondrial fusion is mediated by members of the Dynamin family of proteins, the 
first of which to be characterised was outer mitochondrial membrane protein Fzo (fuzzy 
onion), found in Drosophila sperm cells where it controls the formation of giant 
mitochondria (Hales and Fuller 1997). A second outer membrane protein that was 
characterised in other Drosophila cell types was Marf, which also mediates fusion 
(Dorn et al. 2011).  
 
The Mitofusins – Mfn1 & Mfn2 – are the mammalian outer membrane fusion proteins. 
These proteins are large GTPases which interact via hydrophobic heptad repeat regions 
(HR2) that are found on the cytosolic face of the protein. Mitofusins tether to each other 
via HR2 interactions, after which GTPase is involved in the fusion of mitochondria, 
(Koshiba et al. 2004). Although they are expressed in the same cell lines, each protein is 
capable of controlling fusion on its own (Chen et al. 2003). Fusion of the inner 
mitochondrial membrane is controlled by the GTPase Opa1 in humans (so called for its 
involvement in dominant Optic atrophy), which requires Mfn1 in order to promote 
fusion, but not Mfn2 (Cipolat et al. 2004).  
 
 Mitochondrial fission 1.3.1.2.
Unlike fusion proteins that require both an inner and outer membrane protein in order 
for complete fusion to occur, the process of fission is controlled in yeast by one 
Dynamin protein (Dnm1). Genetic screens of yeast found that Dnm1 was responsible 
for mitochondrial fission (Bleazard et al. 1999), as is its mammalian homolog; Drp1 
(Shin et al. 1997). All of the homologs contain a GTPase domain and a variable domain, 
which is required to bind to a target membrane. Drp1 is thought to be recruited to the 
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mitochondrial membrane by another protein (possibly Fis1). It is postulated that it then 
forms a ring like structure and pinches mitochondria using its GTPase domain (Hoppins 
et al. 2007). Fis1, a small outer membrane bound protein, is required for the recruitment 
of Dmn1 in yeast (Mozdy et al. 2000), however its function in mammalian fission is not 
clear as its depletion does not affect Drp1 (Otera et al. 2010). 
 
1.3.2. Mitochondrial Biogenesis 
As the energy requirements of the cell change, so does its need for mitochondria, 
therefore mitochondrial biogenesis is tightly regulated (figure 1.2) in order to produce 
sufficient ATP. The primary controller of biogenesis is the peroxisome proliferator-
activated receptor  coactivator 1 (PGC-1) a cofactor for transcription factors that 
regulate the expression of nuclear-encoded mitochondrial proteins; nuclear respiratory 
factors (NRF1 and 2) and oestrogen related receptor  (ERRα), as well as forkhead box 
class-O (FoxO1) and peroxisome proliferator activated receptors (PPARs) (Puigserver 
and Spiegelman 2003). Overexpression of PGC-1α in “mutator mouse” models (see 
section 1.7.6) has been shown to increase the quantity of mitochondrially encoded 
OXPHOS subunits detected by western blotting by up to 50%. mtDNA copy number 
doubled in the overexpression mice, and there was also a decrease in the number of 
COX-deficient fibres seen in their skeletal muscle (Dillon et al. 2012). 
 
1.3.3. Transcriptional control 
Control of PGC-1 is tightly regulated and its activity essentially depends on the energy 
requirement of the cell at a given time. For example, in skeletal muscle during exercise, 
PGC-1 can be activated in response to Ca2+ signalling through either Ca2+/calmodulin 
dependent kinase IV (CaMKIV) or calcineurin A (CnA). CaMKIV phosphorylates 
CREB (cAMP response element binding protein), which binds CRE (CREB response 
element) and increases PGC-1 expression (Herzig et al. 2001). CnA activates the 
myocyte enhancer factors (MEF2C & D) that drive myogenesis and also induce PGC-
1. The mitogen activated protein kinase p38 (MAPK) can also activate MEF2 during 
exercise, along with ATF2 (activating factor 2) which both go on to induce expression 
(Michael et al. 2001; Handschin et al. 2003; Akimoto et al. 2005).  
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In brown adipose tissue cold temperatures are sensed by the sympathetic nervous 
system and activate 3 adrenergic receptors (Puigserver et al. 1998). This increases 
cAMP activating PKA (protein kinase A). PKA’s primary target is CREB, which 
activates and subsequently goes on to increase PGC-1 expression (Cao et al. 2004). 
 
1.3.4. Functional control 
During exercise the level of AMP in relation to ATP increases, which triggers the 
activation of AMPK (AMP activated protein kinase) (Jorgensen et al. 2005). This 
kinase activates cellular processes in order to increase ATP production, one of which is 
to increase mitochondrial biogenesis. The amount of PGC-1 has been shown to 
increase in an AMPK dependent manner in skeletal muscle, as has the proportion that is 
activated (Jager et al. 2007). Although the mechanism of PGC-1 induction by AMPK 
is unclear, treatment of skeletal muscle cells with AICAR (5-aminoimidazole-4-
carboxamide 1-β-D-ribofuranoside), an AMPK activator, has also been shown to 
increase PGC-1 activation (Jorgensen et al. 2005).  
 
Acetylation also plays a role in the regulation of PGC-1 as the deacetylase enzyme 
Sirtuin 1 (SIRT1) has been shown to increase its activity. SIRT1 is largely thought to 
sense the energy status of the cell, as it needs the cofactor NAD
+
 in order to function 
(Houtkooper et al. 2010). The NAD
+
/NADH ratio swings in favour of high NAD
+
 in 
low energy situations, which increases the activity of SIRT1 and therefore PGC-1 
(Canto et al. 2009). Work in mice has shown that SIRT1 knockdowns have lower levels 
of PGC-1 induced gluconeogenesis proteins, whereas SIRT1 overexpression mice 
have increased levels. -oxidation of fatty acids, in response to starvation, also increases 
the level of NAD
+
 and increases the activity of SIRT1 (Rodgers et al. 2005; Rodgers 
and Puigserver 2007).  
Down-regulation of PGC-1 is caused by histone acetyltransferase (GCN5) both in 
vitro and in vivo when the cell has a high energy status (Lerin et al. 2006). Insulin also 
plays a role in PGC-1 regulation. In the presence of insulin (when the cell has a high 
energy status) Akt (protein kinase B) phosphorylates FoxO1, preventing it from 
inducing PGC-1 and sequestering it into the cytosol (Southgate et al. 2005). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.2 - Transcriptional and functional control of PGC-1α in response to various 
cell stimuli.  
 
Activation of PGC-1α is controlled by AMP-activated protein kinase (AMPK) which 
phosphorylates PGC-1α in response to high AMP. Sirtuin 1 (SIRT1) deacetylates PGC-1α in 
response to high NAD
+
. Histone acetyltransferase (GCN5) acetylates PGC-1α in response to 
caloric excess, inhibiting its action. Mammalian target of rapamycin (mTOR) inhibits 
AMPK in response to insulin or excess amino acids, preventing phosphorylation. AMPK is 
also inhibited by high levels of ATP / low AMP levels.  
 
Transcription of PGC-1α occurs in response to exercise by increasing calcium signalling via 
calcineurin A (CnA) and calmodulin dependent protein kinase IV (CaMKIV). p38 signalling 
also increases in response to exercise activating myocyte enhancer factor 2 (MEF2) 
activation along with activation of activating transcription factor 2 (ATF2). As part of 
thermogenesis during cold conditions stimulation by β3 adrenergic receptors (β-AR) 
activates transcription of PGC-1α via cyclic AMP (cAMP), protein kinase A (PKA) and 
cAMP response element binding protein (CREB) binding. Glucagon activation of glucagon 
receptors (GLGN-R) via the PKA /CREB pathway also causes transcription of PGC-1α.  
Insulin is thought to cause cytosolic sequestration of forkhead box class –O (FoxO1) via 
protein kinase B (Akt), decreasing transcription.  
 
Figure adapted from (Andreux et al. 2013) 
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1.4. MITOCHONDRIAL FUNCTIONS 
Mitochondria are most commonly associated with the production of ATP; however they 
are also the site of reactive oxygen species generation and iron-sulphur cluster 
formation. They also play important roles in calcium handling, β-oxidation of fatty 
acids and apoptosis, all of which makes mitochondria an essential organelle for the 
health of the cell.  
1.4.1. Respiration 
Mitochondria are sometimes referred to as the “powerhouses” of the cell, an apt 
description as they are the production sites of the majority of cellular ATP. Several 
intermediate steps are required to produce substrates for oxidative phosphorylation 
(OXPHOS), the major ATP source. This begins in the cytosol with the conversion of 
glucose into pyruvate during glycolysis (equation 1.1), which also generates a net gain 
of 2 ATP molecules (Berg 2011).  
 
                       
                                
Equation 1.1 – Glycolysis 
 
Pyruvate is transported across the double mitochondrial membrane into the matrix 
where it is converted into acetyl CoA by pyruvate dehydrogenase (equation 2).  
 
                                         
Equation 1.2 – Pyruvate decarboxylation 
 
Acetyl CoA feeds into the matrix localised TCA cycle, a series of reactions that produce 
reduced electron carriers: NADH and FADH2 along with ATP and CO2. Acetyl CoA 
enters the cycle by reacting with oxaloacetate to form citrate. Several intermediate 
reactions occur until oxaloacetate is reformed. The overall reaction is shown in equation 
1.3 (Berg 2011).  
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Equation 1.3 - Overall TCA cycle 
 
The production of the electron carriers NADH and FADH2 is essential for the final 
stage of respiration – OXPHOS. During this process they donate electrons to complexes 
I and II, which are transferred to complexes III and IV, releasing energy which is used 
to transport H
+
 into the intermembrane space, generating an electro-chemical gradient 
which is harnessed by the ATP synthase (complex V) to produce ATP (figure 1.3) (Berg 
2011). 
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 Oxidative Phosphorylation 1.4.1.1.
Complex I (NADH: Ubiquinone Oxidoreductase) is made up of ~38 subunits, 7 of 
which are encoded by mtDNA (Hirst et al. 2003). The complex comprises of three 
modules (N, Q and P) each with a different function. NADH is oxidised in a reaction 
occurring in module N, during which two electrons are donated to flavin 
mononucleotide (FMN) (Walker et al. 1992). The electrons are transferred along a chain 
of iron sulphur (Fe-S) clusters through to module Q where the electrons are used to 
reduce ubiquinone (Q) to ubiquinol (QH2), creating a pool of ubiquinol in the 
intermembrane space (Sazanov 2007).  
During electron transport it is thought that a conformational change occurs in complex I 
enabling module P, which is embedded in the inner membrane, to open pores and allow 
4 protons to cross into the intermembrane space (Efremov et al. 2010; Baradaran et al. 
2013). The overall reaction is shown in equation 1.4.  
               
                
  
Equation 1.4 – Complex I reaction 
Complex II (Succinate ubiquinone oxidoreductase) is entirely encoded by the nuclear 
genome and consists of 4 subunits (SDHC & SDHD, which anchor the complex to the 
inner membrane and SDHA & SDHB - the matrix located catalytic core) (Hagerhall 
1997).  
 
No protons are transferred into the intermembrane space by complex II, however it does 
play a crucial role in the TCA cycle as it catalyses the conversion of succinate to 
fumarate, generating FADH2 in the process (Berg 2011). FADH2 is then oxidised to 
FAD
+
, the electrons from which are transported along Fe-S clusters and then used to 
reduce ubiquinone to ubiquinol (equation 1.5) (Hagerhall 1997).  
 
                         
Equation 1.5- Complex II reaction 
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Complex III- (Ubiquinol: cytochrome c oxidoreductase) consists of 11 subunits, only 
one of which (apocytochrome b) is encoded by the mitochondrial genome, and is 
responsible for the transfer of 2 electrons from ubiquinol to cytochrome c. Its function 
requires a number of cytochromes that contain haem along with a Rieske Fe-S cluster 
(Xia et al. 1997).  
 
The transfer of electrons is carried out during the Q cycle, which couples the reduction 
of ubiquinol to the movement of two H
+
 ions into the intermembrane space (Mitchell 
1976). A ubiquinol binds the Q0 site where it releases two electrons and two H
+
 ions, 
one electron binds the Rieske Fe-S and passes onto cytochrome c1 before reducing 
cytochrome c and releasing it. The other is transferred to cytochrome b where it passes 
across haem groups before reducing ubiquinone to form ubisemiquinone at the Q1 site. 
The second ubiquinol then binds the Q0 site releasing two electrons and H
+
 ions. One 
electron is transferred to new cytochrome c and the other is used to fully reduce the 
ubisemiquinone to ubiquinone (Berg 2011). This is summarised by equation 1.6.  
 
                       
                       
  
Equation 1.6- The Q cycle 
 
Complex IV- Cytochrome c oxidase is comprised of 13 subunits (subunits I - III are 
encoded by mtDNA) and is responsible for the reduction of O2 and the formation of 
H2O. Electrons are initially transferred from cytochrome c to the primary electron donor 
CuA and then to haema. The electron is then transferred to the catalytic site of haema3 
and CuB (Tsukihara et al. 1996; Faxen et al. 2005).  
 
The formation of H2O occurs in two stages of electron transfer – one molecule of H2O 
requires the transfer of 4 electrons from 4 cytochrome c molecules (one electron each). 
The first two electrons travel to the catalytic site where the first electron reduces CuB 
and the second reduces haema3. A peroxide bridge is formed between the two groups by 
the addition of molecular oxygen (Faxen et al. 2005).  
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The next round of electrons follows the same pattern, however this time the metal 
groups are bound by 2H
+
 ions, releasing the peroxide bridge. The formation of two 
molecules of H2O is completed by the addition of 2H
+
 ions. As this occurs, 4H
+
 ions are 
transferred to the intermembrane space (Faxen et al. 2005). This is summarised in 
equation 1.7. 
 
           
                       
  
Equation 1.7 – Complex IV reaction 
 
Complex V- the FoF1 ATP Synthase utilizes the proton gradient that is generated by 
three of the four complexes to produce ATP. Complex V is composed of two domains; 
Fo which is located in the membrane and F1 which extends into the matrix (Yoshida et 
al. 2001). Fo contains 8 hydrophobic c-subunits forming a c-ring through which protons 
pass. F1 consists of five subunits in total (, , ,  and ), with a stationary ring 
consisting of 3 and 3 subunits with the remaining subunits forming the central rotary 
stalk (Wittig and Schagger 2008; Wittig et al. 2008).  
 
The movement of H
+
 ions through Fo generates rotary torque that is used by F1 to drive 
the formation of ATP from ADP and Pi. As H
+
 ions move through the c-ring, glutamate 
residues on the c-subunits are protonated and deprotonated which causes rotation of F1 
subunits  and . As F1 rotates, the  subunits (to which ATP and Pi bind) undergo 
conformational changes (Noji et al. 1997). Continued rotation generates enough energy 
to convert ADP and Pi to ATP, after which ATP is released. A full 360
o
 rotation 
generates 3 molecules of ATP for the transfer of 8 H
+
 ions; therefore each molecule of 
ATP produced costs 2.7 H
+
 ions (Watt et al. 2010; Berg 2011).  
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1.4.2. Generation of reactive oxygen species 
Reactive oxygen species (ROS) produced by mitochondria play an important role in 
redox signalling from the organelle to the rest of the cell, and are also implicated in 
causing oxidative damage to the organelle. Work by Loschen and colleagues in isolated 
pigeon heart mitochondria showed that production of H2O2 is linked to OXPHOS 
respiration (Loschen et al. 1971). Subsequent work has shown that H2O2 is produced 
after the action of superoxide dismutase II on superoxide anions (O2
·-
) in the matrix 
(Brand 2010). Complex I produces the majority of O2
·-
, which is produced in a reaction 
of molecular oxygen with fully reduced FMN (Kussmaul and Hirst 2006). Although it 
has been shown that complex III can produce more ROS than complex I under 
conditions such as antimycin inhibition, the physiological relevance of this is unclear 
(Murphy 2009). However, it is likely that basal levels of ROS are produced during 
normal OXPHOS (Murphy 2009). It should be noted that superoxide produced by 
complex III is released on both sides of the inner membrane unlike complex I which 
releases superoxide into the matrix (St-Pierre et al. 2002), potentially making complex 
III ROS more important for cell signalling as ROS have easier access to the cytosol than 
other ROS sources – they do not have to cross the inner mitochondrial membrane. 
Glycerol 3-phosphate dehydrogenase, an inner membrane bound enzyme which is 
involved in lipid metabolism, has also been shown to be produce ROS on both sides of 
the inner membrane, although the exact production site is unclear (Brand 2010).  
Hydroxyl radicals are produced during the Fenton reaction in which H2O2 reacts 
oxidises iron to form hydroxide ions and hydroxyl radicals. The hydroxyl radical is 
particularly reactive and has been shown to damage most biological molecules. Due to 
its reactivity it is relatively short lived with a half-life of 10
-9
 seconds when compared to 
superoxide anions and H2O2 which both have half lives in the microsecond range, 
although these depend on their enzymatic detoxification rates (Sies 1993). Nitric oxide 
is also produced in the mitochondria by conversion of L-arginine to L-citrulline by 
nitric oxide synthase. It can bind in a reversible and dose dependent manner the O2 
binding site of cytochrome c synthase, preventing the flow of electrons and decreasing 
OXPHOS. Reaction of NO with superoxide generates peroxynitrite (half-life 0.05-1s), 
accounting for consumption of 15% of the superoxide produced by mitochondria. This 
radical can damage mitochondria by oxidising lipid membranes and has also been 
linked to the induction of apoptosis (Ghafourifar and Cadenas 2005).  
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Redox signalling from mitochondrially produced ROS is important for reporting the 
status of mitochondria to the rest of the cell. H2O2 can oxidise thiol groups on cysteine 
residues, altering the activity of proteins involved in signalling cascades. Regulation by 
H2O2 has been shown to occur by oxidising residues in the catalytic site of phosphatases 
such as PTPb1, PTEN and MAPK, inhibiting their ability to dephosphorylate their 
respective targets (Rhee et al. 2000; Tonks 2005). MAPK is part of the signalling 
cascade which leads to the transcription of PGC1α –the master regulator of 
mitochondrial biogenesis as discussed previously. Interestingly, it has also been shown 
that PGC1α also acts as a transcription factor of antioxidants, enabling the balance 
between ROS and mitochondria to be maintained (St-Pierre et al. 2006).  
 
To prevent cell damage or aberrant cell signalling, ROS are tightly regulated. 
Consequently there are several mechanisms to reduce ROS in order to detoxify them. 
Reduction of O2
·- 
to H2O2 is catalysed by SOD1 in the intermembrane space and 
cytosol, SOD2 in the matrix and SOD3 in the extracellular space. Several mechanism 
are used to reduce H2O2.Catalse is present in peroxisomes and converts H2O2 to H2O 
and O2 (Sena and Chandel 2012). The peroxiredoxins (PRX), of which there are 6 
isoforms in mammalian cells, also reduce H2O2. Reduced PRX is converted to an 
inactive, oxidised form via the oxidation of a cysteine residue by H2O2, converting it to 
H2O. Oxidised PRX is converted back into its active reduced form by thioredoxin. 
Glutathione peroxidases are also responsible for reduction of H2O2, catalysing the 
oxidation of glutathione to glutathione disulphide by H2O2 (Sena and Chandel 2012).  
 
1.4.3. Calcium Handling 
Cellular Ca
2+
 signalling is essential for the control of inter cell communication, 
programmed cell death and ATP production (Duchen 2000). Mitochondria act as Ca
2+ 
buffers in the cell, preventing changes in extracellular Ca
2+
 concentration from 
damaging cellular components. Mitochondria have the ability to accumulate up to 
1000nmol Ca
2+
/mg of mitochondrial protein via the calcium uniporter located in the 
inner membrane (Kirichok et al. 2004). Modulation of Ca
2+
 is critical in neuronal pre-
synaptic terminals where Ca
2+
 plays a crucial role in synaptic transmission (Jacobson 
and Duchen 2004; Abramov and Duchen 2010). Increased mitochondrial Ca
2+
 has also 
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been shown to increase the activity of the TCA cycle and ATP production (McCormack 
et al. 1990; Jouaville et al. 1999). 
 
1.4.4. Apoptosis 
Apoptosis, or programmed cell death, is controlled by an extrinsic, cell receptor 
mediated pathway, or an intrinsic, cell damage mediated pathway. Cytochrome c is an 
integral factor of apoptosis, the release of which from mitochondria enables the 
formation of an apoptosome with APAF1 which goes on to activate caspase-9, leading 
to apoptosis (Wang and Youle 2009).  
 
Release of cytochrome c is a stringently regulated process that requires the binding of 
pro-apoptotic Bcl2 family proteins Bax and Bak to the outer mitochondrial membrane, 
causing membrane permeablisation and cytochrome c release (Wei et al. 2001). 
Oligomerisation and membrane localisation of these proteins is normally inhibited by 
Bcl-2, however during apoptosis Bcl-2 is inhibited by the BH3 family of proteins 
(Willis et al. 2007). Exactly how these pores form is currently unknown.  
 
1.4.5. Iron Sulphur cluster formation 
Iron sulphur clusters are essential cofactors for OXPHOS, facilitating the transfer of 
electrons by repeatedly changing the redox status of iron from Fe
2+
 to Fe
3+
. Reduced 
iron is transported into the mitochondrial matrix by mitoferrins (Paradkar et al. 2009), 
after which iron is donated to scaffold proteins Isu1 and Nfu via frataxin and an iron-
sulphur cluster is formed (Tong et al. 2003; Yoon and Cowan 2003). Sulphur is 
provided in the form of sulphide ions formed from the release of sulphur from cysteine 
by cysteine desulphurase (Tong and Rouault 2000). The production of iron sulphur 
clusters is the only conserved function of mitochondria and mitosomes (primitive 
mitochondria) across all eukaryotes.  
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1.5. MITOCHONDRIAL DNA 
Mitochondria contain their own 16,569bp circular, intronless genome situated in the 
mitochondrial matrix. Of the 37 genes encoded by the genome, 13 encode hydrophobic 
proteins that are essential for OXPHOS. To enable translation of these proteins, mtDNA 
also encodes 22tRNAs and 2rRNAs (Anderson et al. 1981). The majority of the genes 
(12 proteins, 14tRNAs and both rRNAs) are transcribed from the outer “heavy” strand- 
so called because of the abundance of guanine. The remaining protein-encoding gene 
(MTND6) and 8 tRNAs are transcribed from the “light” strand figure 1.4.  
 
Unlike the nuclear genome, which contains two copies of most genes, mitochondrial 
genomes are found in multiple copies within the cell. Depending on cell type this 
number can range from no mtDNA copies  in erythrocytes to 100,000s in oocytes 
(Shoubridge and Wai 2007). Within the matrix but associated with the inner membrane 
(Albring et al. 1977), current work by Brown and colleagues using super resolution 
microscopy suggests that single genomes are packaged together in nucleoprotein 
complexes termed nucleoids, which contain some of the protein machinery essential for 
the replication and transcription of mtDNA (mitochondrial transcription factor A, 
single-stranded DNA binding protein and twinkle helicase) (Garrido et al. 2003; Wang 
and Bogenhagen 2006; Brown et al. 2011). Mgm101p is also present in the nucleoids of 
yeast and is thought to play a role in mtDNA repair (Meeusen et al. 1999). 
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 Figure 1.4 – The mitochondrial genome. 
 Protein encoding genes are colour coded to signify which complex they produce subunits for: 
Complex I (orange), Complex III (red), Complex IV (green), Complex V (brown). Ribosomal 
RNAs genes are light blue, tRNA genes are dark blue. The origins of replication; OH (heavy 
strand) and OL
 
(light strand) and transcription are also shown (HSP – heavy strand promoter which 
contains two translation initiation sites; H1 and H2 and LSP- light strand promoter). Black lines 
signify the boundary of protein encoding genes when they are not separated by tRNA genes.  
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1.5.1. Transcription 
Transcription of mtDNA occurs bi-directionally and is initiated from three promoter 
sites. The light strand promoter (LSP) initiates transcription of the light strand and the 
heavy strand promoter (HSP) initiates transcription for the heavy strand at two sites (H1 
and H2). Initiation at H1 generates a short transcript containing the two rRNAs, 
tRNA
Phe 
and tRNA
Val
, whereas initiation at H2 generates a transcript covering almost 
the full genome (Montoya et al. 1982; Chang and Clayton 1984; Zollo et al. 2012). 
According to the tRNA punctuation model, cloverleaf folds induced in the polycistronic 
transcripts by tRNA act as targets for RNA processing enzymes after transcription 
(Ojala et al. 1981) with RNase P and RNase Z cleaving the 5’ and 3’ ends of the tRNAs 
respectively (Dubrovsky et al. 2004; Holzmann et al. 2008). However this model does 
not apply to all mitochondrial mRNA species and it is still unclear how MT-ATP6/8 and 
MT-ND6 transcripts are processed as they are not separated by a tRNA gene. Due to the 
overlap of MT-ATP6 and MT-ATP8, it is essential that this bicistronic mRNA is not 
cleaved by RNases as it would involve the truncation of either of the proteins or 
removal of the MT-ATP6 start codon. It is currently unclear how translation of ATP6 
occurs to produce a separate protein, as its start codon is contained within MT-ATP8, 
but it if the mitochondrial ribosome scans mRNA and binds start codons, it may be 
possible to translate MT-ATP6 from the intact bicistronic mRNA.  
 
Figure 1.5 – A schematic of mitochondrial translation promoter sites.  
Transcription is initiated from three distinct sites. Heavy (H) strand transcription initiates from two sites 
- H1 (which generates short transcripts) and H2 (which generates whole genome transcripts). Light 
strand transcription is initiated at LSP. Conserved sequence blocks (CSBs) and termination associated 
sequence sites are also shown. Image adapted from (Taanman 1999). Numbers represent the nucleotide 
positions of the sites within mtDNA. 
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Transcripts are produced by the mitochondrial RNA polymerase (POLMRT) that works 
in conjunction with other key components of the transcription machinery: mitochondrial 
transcription factor A (TFAM) and mitochondrial transcription factor B2 (TFB2M) 
(Falkenberg et al. 2002; Litonin et al. 2010).  
 
When TFAM was originally identified, it was found that it bound LSP and HSP and it 
was therefore assumed that its activity was essential for transcription initiation (Fisher 
and Clayton 1988). However recent work suggests that TFAM may not be an essential 
component. While it has been shown that TFAM unwinds DNA to expose promoter 
regions (Fisher et al. 1992), overexpression of TFAM inhibits transcription by causing 
increased packaging into nucleoids, which is thought to prevent the access of other 
transcription factors to mtDNA (Rebelo et al. 2009). The yeast homologue of TFAM, 
Abf2, is not required for transcription (Xu and Clayton 1992), and work in E. coli has 
shown that different levels of TFAM within nucleoids influence which promoter site is 
used, but is not essential for initiation (Shutt et al. 2010; Lodeiro et al. 2012). However, 
this has been disputed by Shi et al. who believe that TFAM is in fact essential for 
initiation of transcription in conditions that closely replicate physiological conditions 
(Shi et al. 2012). Recent work using ChIP-seq has shown that TFAM coats the whole 
mitochondrial genome as part of its role in packaging mtDNA (Wang et al. 2013).  
 
For transcription to occur, POLRMT has to form a heterodimer with either TFB1M or 
TFB2M, however the levels of transcription are 10-fold lower when the heterodimer 
consists of TFB1M and POLRMT rather than with TFB2M. It has been suggested that 
TFB1M may assist in promoter melting at the transcription start site (Sologub et al. 
2009) while TFB2M has been postulated to stabilize ssDNA formed during mtDNA 
unwinding (Falkenberg et al. 2007). Thus the evidence suggests that the only two 
essential components of the initiation complex are TFAM and TFB2M (Litonin et al. 
2010).  
 
Termination of transcription is controlled by the mitochondrial termination factors, of 
which four have been identified (mTERF 1-4). The first factor to be discovered, 
mTERF1, was thought to be essential for termination of transcripts from all three 
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promoters, as it was shown to bind a 28bp region down-stream of the 16SrRNA where 
the H1 transcript terminates (Kruse et al. 1989). Binding of mTERF1 is thought to cause 
DNA unwinding and base flipping, as shown by the crystal structure of DNA bound 
mTERF1 (Yakubovskaya et al. 2010), which is likely to interfere with the elongation 
machinery. It has also been shown to have a role in the pausing of replication after it 
was determined that overexpression of mTERF1 increased the incidence of replication 
intermediates (Hyvarinen et al. 2007). Recently it has been shown that mTERF1 
knockouts in mice are viable, indicating that mTERF1s main function may be to prevent 
L-stand transcripts from proceeding around mtDNA (Terzioglu et al. 2013). 
Two of the mTERF1 homologues, mTERF2 and mTERF3, are thought to be involved in 
the regulation of termination and have been shown to bind to promoter regions (Wenz et 
al. 2009), however another report also suggests that mTERF2 is a nucleoid component 
which binds mtDNA in a non-sequence specific manner with one mTERF2 monomer 
present every ~265bp (Pellegrini et al. 2009). Decreases in mTERF2 have been shown 
to cause decreased mitochondrial transcription in mice (Wenz et al. 2009), which leads 
to OXPHOS impairment. However, depletion of mTERF3 actually increases 
transcription levels, suggesting that it may be an inhibitor of transcription (Park et al. 
2007), although their exact functions are unknown. Experiments in mTERF3 heart 
knockout mice have shown that mTERF3 may have a role in ribosomal biogenesis due 
to the decreased presence of the assembled large ribosomal subunit, the authors also 
showed that mTERF3 may have this effect by binding to 16S rRNA (Wredenberg et al. 
2013). The final member of this family, mTERF4, has been shown to be involved in the 
regulation of mRNA translation. Work in mice has shown that mTERF4 forms a 
complex with NSUN4 (a member of the m5C RNA methyltransferases family), 
recruiting NSUN4 to the mitochondrial ribosome, a process essential for ribosome 
assembly (Camara et al. 2011).  
 
1.5.2. Translation 
Mitochondrial mRNA translation has a number of key differences from cytosolic 
translation. First, it utilises only 22 tRNAs compared to the 31 essential for translation 
of the nuclear genome. This difference is explained by the “wobble hypothesis” which 
proposes that the first base of the anti-codon can form non Watson-Crick pairs with the 
third base of the codon, enabling flexible codon reading of mRNA (Crick 1966; Barrell 
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et al. 1980). Secondly, the mitochondrial ribosome is has a lower sedimentary 
coefficient at 55S when compared to bacterial ribosomes (70S), which is surprising 
considering the bacterial origin of mitochondria. The mammalian mitochondrial 
ribosome contains less than half the quantity of RNA that is seen in prokaryotic 
ribosomes but more protein (O'Brian 1971). The process of mitochondrial translation is 
discussed below and is shown in figure 1.6. 
 
Initiation of translation in mitochondria is controlled by two factors, IF2mt and IF3mt. 
Prior to mRNA binding, the ribosome is split into 39S and 28S subunits by 
mitochondrial ribosome recycling factor (mtRRF) and kept apart by the binding of IF3mt 
to the small ribosomal subunit (Koc et al. 2001; Suzuki et al. 2001). After mRNA has 
bound (in an orientation that ensures the start codon is located at the P (peptidyl) site), 
IF2mt facilitates the binding of tRNA
fmet
 (the initiating tRNA) (Ma and Spremulli 1996; 
Smits et al. 2010) to the ribosomal P-site. The formylated tRNA
fmet
 is only used for 
initiation and so mitochondria also maintain a pool of non-formylated tRNA
met
 for 
elongation (Takeuchi et al. 2001). Defects in formylation caused by mutations in 
MTFMT have recently been shown to cause Leigh syndrome, highlighting the 
importance of tRNA
fmet 
for efficient mitochondrial translation (Tucker et al. 2011). 
 
The mitochondrial elongation factor Tu (mtEFTu) forms a complex with GTP and then 
binds individual tRNAs, potentially protecting them from degradation. The tRNAs bind 
to the A (acceptor) site of the ribosome, hydrolysing GTP and releasing mtEFTu (which 
is subsequently recycled by mtEFTs) (Jeppesen et al. 2005). Elongation is achieved by 
the binding of mitochondrial elongation factor G1 (mtEFG1), which causes a 
conformational change in the ribosome, shifting mRNA by three nucleotides (Katunin 
et al. 2002). The codon that was at the P-site is replaced by the codon that was 
previously at the A-site, meanwhile the polypeptide moves through the ribosome and is 
inserted into the inner mitochondrial membrane (Smits et al. 2010).  
 
The presence of a stop codon in the A-site is required for the correct termination of 
translation. Rather than binding a tRNA, stop codons are recognised by mitochondrial 
translational release factor 1a (mtRF1a), which hydrolyses the ester bond holding the 
Chapter One  Introduction 
 
25 
 
polypeptide to the P-site tRNA. Initially four codons were assigned as stop codons 
(AGA, AGG, UAA & UAG) however mtRF1a only recognises the final two codons in 
this list, even though the first two (which were reassigned from arginine) are the final 
codons for MTCO1 and MTND6 mRNA (Soleimanpour-Lichaei et al. 2007). It has 
since been shown that AGA/AGG may in fact cause a -1 frameshift which moves the 
ribosome to a UAG stop codon, terminating translation (Temperley et al. 2010). 
Ribosomal disassembly is mediated by mtRRF and mitochondrial elongation factor G2 
(mtEFG2) which cause release of mRNA and tRNA (Rorbach et al. 2008; Tsuboi et al. 
2009). 
 
 
Figure 1.6 – Mitochondrial translation.  
The process of translation is shown above and is split into three distinct phases, initiation (green), 
elongation (purple) and termination (red). The mitochondrial ribosome is shown as blue ovals, E, P and 
A represent the various active sites of the ribosome. The various steps of translation are discussed in 
section 1.5.2. Image taken from (Smits et al. 2010) 
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1.5.3. Replication of mitochondrial DNA 
Replication of mtDNA propagates from the origin of H-strand replication (OH) and is 
initiated by RNA primers produced during transcription originating at the LSP (Chang 
and Clayton 1984). A region containing three conserved sequence blocks (CSB I, II and 
III), discovered using sequence analysis of vertebrates, is situated downstream of the 
LSP. Transition from the RNA primer to newly synthesised mtDNA has been mapped 
to regions near CSB II, which has also been found to increase the stability of 
RNA:DNA hybrids (Xu and Clayton 1996). Originally it was thought that the primers 
were formed by site specific cleavage of RNA by RNase MRP (Chang and Clayton 
1987) but recently it has been suggested that as the CSBII region is transcribed, a G-
quadruplex structure forms, weakening the interaction with POLRMT and terminating 
transcription (Wanrooij et al. 2010). The mitochondrial replisome is shown in figure 
1.7. 
 
The human mitochondrial DNA polymerase, POL, consists of a heterotrimer of three 
subunits; the catalytic subunit POLA, is a 140kDa enzyme which has polymerase, 3’-
5’ exonuclease and 5’-deoxyribose phosphate (dRP) lyase activities and two accessory 
subunits POLB, a 55kDa protein which binds regions of dsDNA longer than 45bp and 
increases both the catalytic activity and processing speed of POLA (Gray and Wong 
1992; Carrodeguas et al. 1999; Carrodeguas et al. 2002).  
 
The mitochondrial helicase (TWINKLE) catalyses the unwinding of the DNA duplex in 
an ATP dependent manner and together with POLA, TWINKLE represents the 
essential components of the mtDNA replication machinery, capable of synthesising 
regions of DNA up to 2kb in the absence of single stranded binding protein (mtSSB) 
(Falkenberg et al. 2007). In order to synthesise the entire mitochondrial genome, mtSSB 
is required (Korhonen et al. 2004). This 13-16kDa protein binds single stranded regions 
of mtDNA in a tetramer, protecting it from degradation and preventing the formation of 
stable secondary structures after unwinding by TWINKLE (Chase and Williams 1986). 
The interaction between mtSSB and TWINKLE stimulates the rate at which TWINKLE 
unwinds mtDNA and stimulates mtDNA synthesis by POL.  
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1.5.4. Modes of mtDNA replication 
Replication of mtDNA is independent of the nuclear replication and occurs throughout 
the cell cycle (Bogenhagen and Clayton 1977). It is thought to occur using one or more 
modes of replication; asynchronous and synchronous.  
 
 Asynchronous replication 1.5.4.1.
This model was first proposed by Clayton and colleagues in 1982. They showed that 
replication is initiated at OH and two thirds of the heavy strand is replicated before the 
OL is exposed, leaving the OL unbound and single stranded, which initiates light strand 
replication (Clayton 1982) via the formation of a stem loop structure (Hixson and 
Clayton 1985). More recently it has been shown that the formation of this stem loop 
structure enables the binding of POLRMT and the creation of a short ~25bp RNA 
primer which is used by Polγ to initiate replication (Wanrooij et al. 2008). Heavy strand 
replication continues in a clockwise direction, opposite to the direction of light strand 
replication. Light strand replication is completed after replication of the heavy strand. 
When the strands are completed they are circularised and supercoiled turns are 
introduced by mitochondrial topoisomerases. The D-loop is then replicated after the 
Figure 1.7 –Mitochondrial DNA replisome.  
The replisome is shown synthesising in the 5’ to 3’ direction; all the components are discussed in 
section 1.5.3.  
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formation of this supercoil, which is believed to serve as a template for its replication 
(Clayton 1982).  
 
 Synchronous replication 1.5.4.2.
Replication of the mitochondrial genome has also been shown to follow a synchronous, 
strand coupled mechanism of replication. Using 2D gel electrophoresis Holt and 
colleagues described a replication intermediate (RI) species, which showed resistance to 
digestion by a single strand nuclease (Holt et al. 2000). It was shown that mtDNA 
replication initiates at the OH where the heavy strand is replicated around the genome, 
which initiates light strand replication from nucleotide 16,184. Replication of the light 
strand was postulated to make use of short oligonucleotide Okazaki fragments as in 
replication of nuclear DNA. However the presence of Okazaki fragments has yet to be 
demonstrated in mitochondria (Wanrooij and Falkenberg 2010). Replication of both 
strands continues around the genome until both strands are complete (Holt et al. 2000). 
Evidence of a related mechanism, RITOLS (ribonucleotide incorporation throughout the 
lagging strand) has also been identified as a possible mechanism for mtDNA 
replication. The authors of this work discovered that RNA hybridises to the single 
stranded lagging strand during replication possibly to prevent transcription complexes 
from accessing mtDNA during replication. The authors hypothesised that after RNA 
incorporation, a RNase enzyme, possibly RNase H1, processed the RNA to create short 
RNA:DNA lagging strand hybrids which may act as primers for DNA polγ, completing 
lagging strand replication (Yasukawa et al. 2006). 
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Figure 1.8 –Models of mtDNA replication.  
The figure shows the two models of replication described in section 0 (Asynchronous 
replication) and section 1.5.4.2 (Synchronous replication). 
The left panel shows the OH (1) and the displacement of the L-strand as replication initiates 
(2) and replicates until it reaches OL (3 &4) where replication of the L-strand commences 
(4)and the remaining genome is replicated (5) until replication is complete (6).  
The right panel shows replication commencing from OH (2) after which L-strand synthesis 
commences. The dashed blue lines represent the generation of Okazaki fragments as 
replication proceeds bi-directionally (4 & 5) until two genomes are produced (6). Figure 
adapted from (Reeve 2007).  
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1.6. MITOCHONDRIAL GENETICS 
 
1.6.1. Heteroplasmy 
Cells contain multiple copies of the mitochondrial genome, some of which can contain 
polymorphic or even pathogenic variations. If an individual cell contains different 
mitochondrial genomes, it is said to be heteroplasmic. The level of heteroplasmy 
depends on the percentage of mutated molecules in relation to the person’s wild type 
sequence. In order to maintain a relatively constant number of molecules in the cell, 
mtDNA can be randomly replicated or degraded. Due to the stochastic nature of this 
process, a mutated molecule can be replicated until it reaches high levels in the cell 
(Taylor and Turnbull 2005).  
 
Initial investigations used Holstein cows, to monitor the change in heteroplasmy level of 
a point mutation across four generations. These animals were chosen as they had been 
shown in a previous study to harbour the mutation (Hauswirth and Laipis 1982). The 
study found that heteroplasmy levels change between generations, to a point where the 
mutation can be lost after just one generation. The study also reported that heteroplasmy 
can differ widely in siblings, with one cow with 35% heteroplasmy producing offspring 
with mutant heteroplasmy ranging from 20% to 80% (Ashley et al. 1989). It is also 
possible for mtDNA mutations to randomly segregate within tissues. These results 
indicated that there is unequal portioning of mtDNA mutations within the female 
germline, making it difficult to predict the likelihood of a mother passing on a mtDNA 
mutation to her offspring. 
 
1.6.2. Clonal Expansion 
The proportion of mutation containing mtDNA genomes within a cell can change over 
time through a process called clonal expansion. Although the mechanisms of this 
change are not clear, several theories have tried to explain this phenomenon. The first 
theory was put forward in 1992 by Wallace and colleagues and investigated the 
expansion of deleted species of mtDNA within single cells. They postulated that 
because these molecules were shorter than their wild type counterparts, they were 
replicated at a faster rate and could therefore expand their numbers within the cell 
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(Wallace 1992). The second model was evidenced by the observation that cybrid cells 
generated from patients with heteroplasmic m.3243A>G mutation showed a shift 
towards higher mutant heteroplasmy (Yoneda et al. 1992). The mechanism of this 
increases was discussed by the authors who postulated that mitochondria with high 
levels of mtDNA damage proliferated in an attempt to overcome the respiratory chain 
defect caused by the mutation, causing clonal expansion of the mutated mtDNA within 
a cell the so called “sick mitochondria” theory (Yoneda et al. 1992). 
 
In 1997 de Grey proposed that mitochondria with a mutation in mtDNA have lower 
oxidative phosphorylation and therefore produce less reactive oxygen species. They are 
therefore damaged less than ‘normal’ mitochondria which are degraded at a higher rate, 
as a result of this they expand within non-dividing cells (de Grey 1997). However, 
lower OXPHOS is also likely to cause a drop in membrane potential as less H
+
 ions are 
transported across the inner mitochondrial membrane. Lower membrane potential has 
been shown to cause autophagy of mitochondria, suggesting that mutated mtDNA 
would actually cause an increase in autophagy, rather than being preserved as the theory 
states. 
 
Clonal expansion could however be caused by random genetic drift where mutated and 
wild type molecules have an equal chance of replication. Elson and colleagues 
developed a model of post-mitotic cells based on 1,000 genomes per cell with a half-life 
of 10 days per genome. Genomes were randomly selected for degradation or replication 
and a constant number of gnomes per cell maintained in each cell. Each genome was 
also assigned a mutation rate which would induce a mutation after a defined number of 
bases had been replicated. The model simulated 600 cells over a period of 30 years. The 
majority of cells showed a gradual loss of mutated genomes over the 30 year period, 
however when mutations occurred early in the life of the cell clonal expansion to higher 
heteroplasmy levels occurred (Elson et al. 2001). This model showed that mutations in 
childhood or early adulthood were more detrimental as they were more likely to 
clonally expand to pathogenic levels.
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1.6.3. Threshold Effect 
Although mutations can increase in cells to a point where they reach high levels (>60%) 
or even homoplasmy, a threshold of mutated mtDNA needs to be reached before a cell 
shows a deficient phenotype (figure 1.9). Below this threshold, wild type mtDNA can 
compensate for the mutated molecules so the cell shows no biochemical deficit, above it 
the cell is unlikely to produce sufficient ATP to function correctly (Sciacco et al. 1994). 
The threshold varies between mutations and tissues, with tRNA mutations generally 
needing to be above 80% before wild type mtDNA can no longer compensate for their 
deficiencies (Taylor and Turnbull 2005). Low heteroplasmy pathogenic mutations have 
also been reported such as the mt-tRNA
Glu
 m.14723 T>C mutation which was shown to 
be pathogenic at 7% mutation heteroplasmy (Alston et al. 2010) and the tRNA
Trp
 
m.5545C>T mutation which is pathogenic at <25% mutation heteroplasmy (Sacconi et 
al. 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 – The threshold effect.  
Wild type mtDNA (red circles) can compensate for the effects of mutated genomes (brown 
circles) until a threshold is reached. Although this level varies depending on mutation and the 
patient, for deletions it is around 60% heteroplasmy. Point mutations tend to have a higher 
threshold due to the lower number of affected genes. Mitochondrial enzyme activity refers to 
OXPHOS enzymes.  
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1.6.4. Inheritance in Mammals 
mtDNA is clonally inherited down the maternal lineage (Giles et al. 1980), except in 
one documented case. A patient presented with a 2bp deletion (m.5132delAA) within 
MTND2 at homoplasmic levels in his skeletal muscle but undetectable in other tissues. 
Further investigation showed that his skeletal muscle mtDNA was the same as his 
father’s haplogroup and that he must have acquired the mutation early in 
embryogenesis, which subsequently segregated into the patient’s skeletal muscle 
(Schwartz and Vissing 2002). It was also found that the patient’s blood contained only 
mtDNA from his mother, showing that he had inherited mitochondria from both parents 
(Schwartz and Vissing 2002). After fertilisation the father’s mitochondria, present in the 
sperm, are degraded by ubiquitination (Sutovsky et al. 2000) although a recent paper 
showed that sperm mitochondria can also be degraded by non-ubiquitination mediated 
autophagy after entry of the spermatozoon into the oocyte (Al Rawi et al. 2011). 
Subsequent has shown that motile sperm in mice may also lose their mitochondria by an 
autophagic process prior to fertilisation (Luo et al. 2013). 
 
1.7. MITOCHONDRIAL DISEASE 
Mitochondrial diseases represent a range of disorders caused by mutations in either 
mtDNA or nuclear encoded mitochondrial genes that affect the ability of mitochondria 
to produce ATP. There are 577 reported mutations in mtDNA that have been associated 
with disease, some of which are highlighted in Figure1.10 (Mitomap, 2013). An 
epidemiological study in the North East of England found that 1 in 3500 adults are at 
risk of developing mitochondrial disease, with up to 1 in 200 carrying pathogenic 
mtDNA mutations, potentially making them one of the most commonly inherited 
neuromuscular diseases (Schaefer et al. 2008). This section will discuss the most 
common mitochondrial mutations.  
 
1.7.1. Phenotypic expression 
The ubiquitous nature of mitochondria means that multiple organs are often affected by 
mitochondrial disease, regardless of the mutation. Neuronal tissue is greatly affected 
due to its high energy requirements and unsurprisingly the most common symptoms in 
adults are seizures, myoclonic epilepsy and ataxia. However there is also large clinical 
variation in patients with identical mutations and heteroplasmy. Other common 
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symptoms include cardiomyopathy, diabetes, ophthalmoplegia and ptosis (McFarland et 
al. 2002). Children affected by mitochondrial disorders are more likely to experience 
severe symptoms such as liver failure along with seizures and developmental delay (Chi 
et al. 2010). 
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1.7.2. m.3243A>G mt-tRNALeu(UUR) mutation 
This mutation accounts for ~80% of cases of MELAS disease (mitochondrial 
encephalomyopathy with lactic acidosis and stroke like episodes) (Goto et al. 1990), 
although it is also associated with other mitochondrial diseases such as maternally 
inherited diabetes and deafness (MIDD) (Figure 1.10). The mutation prevents 5-
taurinomethyluridine modification of the uridine wobble-position in tRNA
Leu(UUR)
, 
which leads to a reduction in the translation. This was highlighted by the investigations 
of Kirino and colleagues which showed that wild-type tRNA
Leu(UUR)
 without the taurine 
modification have a reduced translation rate of UUG codons (Kirino et al. 2004). The 
authors also noted that when the m.3243A>G mutation is present, the translation of 
UUA and UUG were both reduced. Prevention of this modification has also been shown 
in other mutations associated with MELAS (m.3244A>G, m.3258T>C, m.3217T>C and 
m3219T>C) (Kirino and Suzuki 2005).  
  
Interestingly, the mutation occurs at the mTERF1 binding site, which decreases binding 
affinity in vitro, however there is no evidence that this has a pathogenic effect in vivo, 
possibly due to increased mTERF1 expression compensating for decreased affinity 
(Kruse et al. 1989; Chomyn et al. 1992).  
 
The level of aminoacylated tRNA
Leu(UUR)
 and total tRNA
Leu(UUR)
 are both decreased in 
cybrid cells, with work showing that the m.3243A>G mutation can cause the 
dimerization of the tRNA by encoding a self-complimentary region in the D-loop of the 
tRNA, which reduces the aminoacylation of the mutated species, which decreases the 
level of tRNA
Leu(UUR)
 available for translation (Wittenhagen and Kelley 2002). 
Decreased protein synthesis rate leads to a decrease in the availability of OXPHOS 
complexes available for oxidative phosphorylation, therefore lowering the overall 
OXPHOS activity (Ciafaloni et al. 1992).  
 
Symptoms commonly associated with MELAS include short statue, hemiparesis, 
seizures and lactic acidosis (Pavlakis et al. 1984) as well as ataxia and dementia (Hirano 
et al. 1992). Ragged red muscle fibres, caused by accumulation of mitochondria under 
the sarcolemma membrane are also found in muscle biopsies in affected patients 
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(Ciafaloni et al. 1992). There is also evidence to suggest that higher mutation loads may 
cause an earlier disease onset (Morgan-Hughes et al. 1995). Interestingly, analysis of 
type 2 diabetic populations has shown that between 1-3% of cases are due to the 
m.3243A>G mutation (Vionnet et al. 1993; Alcolado et al. 1994; Ohkubo et al. 2001). 
 
1.7.3. m.8344A>G tRNALys mutation.  
First identified in 1990, this mutation is most commonly associated with MERRF 
(Myoclonic Epilepsy with Ragged Red Fibres) (Shoffner et al. 1990; Yoneda et al. 
1990). The mutation is found in the TѱC loop of mitochondrial tRNALys and like 
m.3424A>G affects taurine modification of the uridine wobble-position (Yasukawa et 
al. 2000). Defective modification has been shown to decrease correct codon-anticodon 
binding due to a decreased stability of the codon-anticodon interaction, increasing 
lysine misincorporation into nascent peptides (Yasukawa et al. 2001).  
 
The exact cause of the decreased translation rate is not clear, however abnormal proteins 
have been detected in cybrids with the m.8344A>G mutation. This could be due to 
ribosome failure and detachment, which would lead to truncated proteins (Masucci et al. 
1995). Another possibility is that the poor codon-anticodon interaction causes ribosomal 
frame shifting leading to abnormal or truncated proteins (Masucci et al. 1995).  
 
MERRF patients show decreased OXPHOS which in turn leads to ataxia, convulsion 
and muscular atrophy (Fukuhara et al. 1980). Some patients also exhibit lipomas in 
areas associated with brown fat such as the upper back and neck regions, which have 
been shown to be homoplasmic for the m.8344A>G mutation (Holme et al. 1993).  
 
1.7.4. Mutations in mtDNA encoded protein genes 
The m.8993T>G mutation in ATPase subunit 6 was first associated with NARP 
(Neuropathy, ataxia, retinitis pigmentosa) disease, and has more recently been found to 
also cause MILS (maternally inherited Leigh’s syndrome), although MILS is also 
associated with m.9176T>C and m.9176T>G mutations (Thyagarajan et al. 1995; 
Carrozzo et al. 2001). Patients with MILS are usually paediatric cases that present with 
Chapter One  Introduction 
 
37 
 
respiratory abnormalities, dystonia and optic atrophy. Unfortunately the disease is often 
fatal and post mortem analysis shows necrotic lesions of the brain stem, basal ganglia 
and thalamus (Leigh 1951). 
 
The mutation causes a Leu 156 Arg amino acid change in ATP synthase subunit 6, 
which leads to the symptoms associated with NARP when heteroplasmy levels reach 
90-95% mutant or MILS when mutant heteroplasmy is greater than 95% (Tatuch et al. 
1992). It is generally accepted that these disorders arise due to impairment in the 
synthesis of ATP. The mutated amino acid is in close proximity to Glu-58 in subunit c 
of ATP synthase, an essential residue for the transport of protons, and it was originally 
hypothesised that the mutation affected the protonation and deprotonation of this 
residue, altering proton flow, however subsequent work has shown this to not be the 
case (Hartzog and Cain 1993). More recently it has been shown that the mutation alters 
the ability of the c ring subunits to rotate (Sgarbi et al. 2006) thus preventing the 
utilisation of rotational torque by the F1 subunit to generate ATP from ADP and Pi. 
 
At least 95% of cases of Leber’s hereditary optic neuropathy (LHON) are caused by 
mutations in mtDNA encoded complex I subunits. m.3460G>A, m.11778G>A and 
m.14484T>C mutations are found in MTND1, MTND4 and MTND6 respectively and 
cause the loss of retinal ganglion cells in the optic nerve. This leads to symptoms such 
as acute or subacute visual loss, with both eyes being affected generally within 2 
months, which primarily affects males aged 15-35 (Chinnery et al. 2000). LHON is one 
of the most common mitochondrial diseases with prevalence in the north east of 
England of ~1 in 25,000 (Chinnery et al. 2000).  
 
1.7.5. Rearrangements of mtDNA 
Mitochondrial diseases can also be caused by large scale rearrangements of mtDNA, 
such as single large scale deletions, multiple deletions and duplications. Deletions are 
thought to occur during replication, which may explain the high incidence of deletions 
occurring in the major-arc (Shoffner et al. 1989), although recent work has postulated 
that they may also occur during mtDNA repair (Krishnan et al. 2008). Single large scale 
deletions are typically inherited through the germ-line and are responsible for some 
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paediatric onset mitochondrial diseases such as Kearns-Sayres syndrome (KSS) 
(Lestienne and Ponsot 1988; Zeviani et al. 1988). This disorder is multi-systemic 
causing cerebellar ataxia and cognitive impairment and is linked to the development of 
PEO (retinitis pigmentosa and progressive external ophthalmoplegia) before the age of 
20 (Tuppen et al. 2010).  
 
Multiple deletions are associated with mutations in POLG or PEO1 and have been 
associated with CPEO (chronic progressive external ophthalmoplegia) – a disease 
characterised by progressive paresis of the eye, proximal weakness, bilateral ptosis and 
in some causes cardiac conduction problems (Agostino et al. 2003). This was first 
reported in 1989 with the discovery of an autosomal dominant inherited mutation that 
caused multiple mitochondrial deletions (Zeviani et al. 1989).  
 
Depletion of mtDNA is exhibited in patients with Alpers’ syndrome, a relatively 
uncommon autosomal recessive mitochondrial disorder caused by mutations in Polγ 
genes, which lower the activity of the enzyme (Naviaux et al. 1999). More than 180 
mutations in Polγ are associated with the Alpers’ phenotype; intractable seizures, 
developmental regression and liver dysfunction. Paediatric onset of Alpers’ disease is 
often fatal due to liver failure rather than any other symptom (Saneto et al. 2013). 
 
1.7.6. Animal models of mitochondrial disease 
Although cell culture models are available for mitochondrial disease such as 
transmitochondrial cybrids cells, cells which contain mtDNA mutations with a relevant 
nuclear background, the  need to study mitochondrial disease in whole organisms 
prompted the generation of mouse models (Wallace 2001).  
 
Although models of nuclear mutations are relatively easy to generate (TFAM, 
TWINKLE and ANT1 mutation models have been produced previously, each causing 
severe mitochondrial dysfunction) (Graham et al. 1997; Larsson et al. 1998; Tyynismaa 
et al. 2005), it is difficult to introduce mtDNA mutations into the germline due to an 
inability to transfect mitochondria (Wallace 2001; Lightowlers 2011). Mice with single 
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large scale deletions were generated by fusing zygotes with enucleated mutation 
containing cybrid cells. It was found that the mutation could be passed down the 
germline, the mutation led to respiratory defect in multiple tissues (Inoue et al. 2000). 
The “mtDNA mutator mouse”, which has a proof-reading deficient Polγ subunit α, 
progressively accumulates mutations in mtDNA over time creating a phenotype which 
has been suggested to mimic an early ageing/progeroid phenotype. This is the most 
successful model of mtDNA disease created so far, and may enable the generation of 
stable mtDNA mutations through crossing with wild type mice to select for certain 
mutations (Trifunovic et al. 2004). 
 
1.8. TREATMENTS 
The lack of effective treatments for the causes of mitochondrial disease means clinicians 
can only treat the symptoms of the disorders. There have been very few randomised 
clinical trials in which directly acting compounds have been investigated, none of which 
are suitable for treatment due to either low efficacy or toxicity in mitochondrial patients 
(Horvath et al. 2008). This section will discuss the treatment of the most common 
symptoms of mitochondrial diseases; a schematic diagram highlights potential and 
currently used treatments in figure 1.11, (page 44). 
 
1.8.1. Symptomatic therapy 
 Treatments for neurological symptoms of mitochondrial disease 1.8.1.1.
As mentioned previously one of the most common symptoms of mitochondrial disease 
in adults is seizures. There are several anticonvulsants on the market with valproate 
being one of the most commonly used. This has been shown to be effective in the 
treatment of seizures in mitochondrial patients. However, it is no longer indicated for 
use as it has been shown to prevent the uptake of carnitine, which can increase lactic 
acidosis in mitochondrial patients, particularly in those suffering from MELAS where it 
exacerbates both fatigue and lactic acidosis (Tein et al. 1993). In Alpers’ syndrome 
patients (those with mutations in POLG), the use of valproate is linked to liver failure, 
although the mechanism is not clear (Horvath et al. 2008). 
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Seizure control is essential, particularly in patients with POLG mutations as epilepsy is 
a key factor in patient mortality (Tzoulis et al. 2006). The use of benzodiazepine, 
phenytoin and levetiracetam have shown efficacy at controlling seizure occurrence in 
POLG patients. It has also been indicated that ketogenic diets may be a viable treatment 
for patients at risk of epileptic seizures; however the evidence for the effectiveness of 
this treatment is circumstantial. It has been postulated that the diet may up-regulate the 
production of antioxidants such as glutathione in mitochondria, potentially having a 
protective effect (Milder and Patel 2012).  
 
Some patients with mutations in POLG have shown Parkinsonian-like symptoms, 
predominately tremor, which is treatable with the use of Levodopa, which increases 
dopamine signalling in dopaminergic neurons. The use of L-arginine in MELAS has 
been shown to improve stroke like episodes (Koga et al. 2005), however the mechanism 
of the effect is unclear. It is likely that L-arginine increases the synthesis of nitric oxide 
(a potent vasodilator) which increases blood flow to affected areas (Koga et al. 2012). 
 
 Treatments for non-neurological symptoms in mitochondrial disease 1.8.1.2.
Several mitochondrial disorders exhibit skeletal muscle weakness as a symptom such as 
MELAS, MERRF, LHON and Alpers’ syndrome. Although it is often debilitating and 
can lead to breathing difficulties if respiratory muscles are involved, there is very little 
scope for treatment. Patients who suffer from breathing difficulties can use ventilators at 
night and in general patients are advised to avoid overexertion and remain hydrated in 
order to avoid kidney related complications (McFarland and Turnbull 2009).  
 
Cardiomyopathy is a common complication in MELAS and MERRF, progression of 
which may take place over a period of years. Rapid progression in MELAS can be 
managed by the use of β-blockers or ACE (angiotensin converting enzyme) inhibitors. 
Conduction defects may also require the use of a cardiac pacemaker (McFarland and 
Turnbull 2009). Patients with MIDD (maternally inherited diabetes and deafness) can 
have their condition managed by dietary controls or by the use of diabetes treatments 
such as insulin or metformin (Malecki et al. 2006). Deafness in MIDD patients can be 
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ameliorated with the use of hearing implants to limit the severity of hearing loss, 
improving patient well-being (Sinnathuray et al. 2003).  
 
 Surgical approaches 1.8.1.3.
Ptosis (drooping of the eye-lids caused by OXPHOS defects in ocular muscles) is one of 
the most common and obvious symptoms of mitochondrial disease. As ptosis becomes 
more severe it can lead to postural and neck problems, which arise as the patient 
compensates for the defect. This can be relieved using surgery to increase the degree of 
opening of the eye-lids (Horvath et al. 2008).  
Pearson’s syndrome is a paediatric form of mitochondrial disease caused by a single 
large scale deletion or duplication of mtDNA, which causes hypoblastic macrocytic 
anaemia, exocrine and endocrine deficiency and lactic acidosis (Smith et al. 1995). It is 
an incredibly debilitating disease and unfortunately death usually occurs in early 
infancy. The use of bone marrow transplants has been used to replace haematopoietic 
stem cells and cure the associated haematological symptoms. This was used in a 4 
month old child and was found to have completely removed deleted mtDNA species 
from her haematopoietic system (Faraci et al. 2007). While the patient unfortunately 
died due to other complications, this treatment may be used in other cases. Patients with 
MNGIE (mitochondrial neurogastrointestinal encephalomyopathy) may also show an 
improvement after bone marrow transplant. MNGIE is caused by mutations in TYMP 
gene (encoding thymidine phosphorylase), leading to high levels of circulating 
thymidine and deoxyuridine, which have been shown to cause mtDNA damage over 
time. The high levels of thymidine phosphorylase found in platelets means that bone 
marrow transplants from healthy individuals lead to an increase in the amount of 
functioning enzyme and therefore a decrease in the levels of thymidine and 
deoxyuridine (Garone et al. 2011; Halter et al. 2011). 
 
Patients with mitochondrial cardiomyopathy can be given heart transplants to correct 
the defect. Transplants are normally contraindicated in patients with multi-systemic 
disorders; however in patients with mitochondrial deficiency that has segregated to the 
heart, transplants have been shown to be successful at extending the life of affected 
children (Bonnet et al. 2001). 
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 Mitochondrially acting treatments 1.8.1.4.
Endogenous ubiquinone (coenzyme Q10) is an effective electron carrier from complex I 
or II to complex III (Crane 1977). Ubiquinol (reduced ubiquinone) can act as an 
efficient anti-oxidant by donating a hydrogen atom to lipid peroxyl radicals to form 
ubisemiquinone. Ubisemiquinone can then either deprotonate into ubiquinol or 
ubiquinone or it can react with oxygen to form a superoxide radical (which is detoxified 
by superoxide dismutase and peroxidases) and ubiquinone (Land and Swallow 1970). 
While many mitochondrial patients have been reported to take ubiquinone (possibly due 
to its beneficial anti-oxidant effects), and there is anecdotal evidence to suggest that 
their symptoms were relieved (Horvath et al. 2008), there is little clinical data to support 
the use of ubiquinone as a general therapy. In patients with mutations in genes encoding 
enzymes that function in the ubiquinone biosynthesis pathway, such as COQ2 and 
PDSS1, which have been shown to decrease the amount of CoQ10 and the length of 
CoQ10 prenyl chain respectively, there is evidence to suggest that OXPHOS improves 
with ubiquinone treatment (Horvath 2012).  
 
The bioavailability of ubiquinone is problematic as it is a highly lipophilic molecule. 
Recent attempts to create a mitochondrial targeted, bioavailable form of ubiquinone by 
conjugating it to TPP (triphenylphosphonium), a lipophilic cation, have led to the 
creation of MitoQ (Kelso et al. 2001). However, the ability of MitoQ to transport 
electrons from complex I was shown to be impaired by the addition of the TPP 
molecule, making it nonviable for use in ubiquinone replacement therapy (James et al. 
2007). The antioxidant properties were not impaired and uptake tests on mice have 
shown that MitoQ and similar molecules can accumulate into mitochondria in as little as 
5 minutes post intravenous injection (Ross et al. 2008). This speed of uptake is useful in 
applications such as modulation of reperfusion injury after cardiac ischemia. During 
ischemia OXPHOS is inhibited leading to an accumulation of lactic acid, phosphates 
and fatty acids. Once blood flow is restored, oxygen reacts with the damaged 
mitochondrial components causing a flood of ROS, which can have devastating 
downstream effects (Zweier et al. 1987). Exposure to MitoQ over a period of two weeks 
led to an accumulation of the antioxidant in the mitochondria of rats that subsequently 
protected their hearts from ischemia-reperfusion injury (Adlam et al. 2005). Although 
this is more relevant to ischemia than mitochondrial disease, the development of this 
drug highlights that it is possible to design mitochondrially acting pharmaceuticals.  
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Manipulation of mitochondrial biogenesis to increase proliferation also has the potential 
to alleviate the symptoms of mitochondrial disease (Dillon et al. 2012). Several drugs 
have been shown to modulate the signalling pathways that control mitochondrial 
biogenesis. As mentioned previously (section1.3.2) PGC-1α is the master regulator of 
mitochondrial biogenesis and as a consequence drugs that act either directly on PGC-1α 
or its regulators have been trialled as potential therapeutics. The pan PPAR agonist 
bezafibrate activates the PGC-1α/PPARγ pathway (Tenenbaum et al. 2005) and has 
been shown to improve the symptoms of mitochondrial dysfunction in “mutator” mouse 
models (Dillon et al. 2012). However, there was no apparent increase in the quantity of 
OXPHOS subunits. AMPK increases PGC-1α expression in response to exercise and 
caloric restriction. Pharmaceutical activation of AMPK by AICAR may also act to 
increase biogenesis. Incubation of AICAR with complex I deficient patient fibroblasts 
increased their O2 consumption and also caused a 20% increase in mitochondrial 
volume when compared to untreated cells (Golubitzky et al. 2011). Activation of SIRT1 
by resveratrol has been postulated to increase PGC-1α activity by increasing its 
deacetylation. Work in 2006 showed an increase in citrate synthase activity and a 
doubling of mitochondrial area in skeletal muscle in mice treated with resveratrol 
(Lagouge et al. 2006; Andreux et al. 2013). In the same study it was also found that 
there was an increase in the expression of genes associated with the control of 
mitochondrial biogenesis such as PGC-1α. Although the data is often not clear 
regarding drugs that increase biogenesis, it is apparent that there is a need to create 
compounds that can modulate the mitochondrial biogenesis pathways.  
 
 Exercise therapy 1.8.1.5.
Exercise therapy has been postulated to improve OXPHOS in mitochondrial myopathies 
caused by single large scale mtDNA deletions. In a study completed in 2006, it was 
found that endurance training improved the mobility and quality of life of mitochondrial 
disease patients without influencing levels of deletion heteroplasmy or copy number 
(Taivassalo et al. 2006). Resistance training has been shown to improve OXPHOS 
capacity of muscles and decrease the proportion of COX negative fibres in muscle 
biopsies. This effect was due to satellite cells (which have low levels of deletion 
heteroplasmy) replacing muscle cells damaged during training, thus improving the 
muscle phenotype (Murphy et al. 2008). 
Chapter One  Introduction 
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 1
.1
1
 -
 T
re
a
tm
en
ts
 f
o
r 
m
it
o
ch
o
n
d
ri
a
l 
d
is
ea
se
. 
 
T
h
e 
fi
g
u
re
 s
h
o
w
s 
v
ar
io
u
s 
tr
ea
tm
en
ts
 t
h
at
 a
ct
 d
ir
ec
tl
y
 o
n
 m
it
o
ch
o
n
d
ri
a 
to
 i
m
p
ro
v
e 
th
e 
d
is
ea
se
 p
h
en
o
ty
p
e.
 T
h
e 
o
u
tc
o
m
e 
o
f 
th
e 
tr
ea
tm
en
ts
 i
s 
sh
o
w
n
 b
y
 t
h
e 
g
re
e
n
 b
o
x
es
, 
re
d
 b
o
x
es
 t
o
 t
h
e 
le
ft
 o
f 
th
is
 r
ep
re
se
n
t 
c
u
rr
en
tl
y
 u
se
d
 t
h
er
ap
ie
s.
 O
ra
n
g
e 
b
o
x
es
 h
ig
h
li
g
h
t 
p
o
te
n
ti
al
 f
u
tu
re
 t
ar
g
et
s 
an
d
 t
h
er
ap
ie
s 
fo
r 
m
it
o
ch
o
n
d
ri
al
 d
y
sf
u
n
ct
io
n
. 
C
u
rr
en
tl
y
 t
re
at
ed
 s
y
m
p
to
m
s 
o
f 
m
it
o
ch
o
n
d
ri
al
 d
is
ea
se
 a
re
 h
ig
h
li
g
h
te
d
 i
n
 t
h
e 
b
lu
e 
b
o
x
es
. 
A
b
b
r:
 p
er
o
x
is
o
m
e 
p
ro
li
fe
ra
to
r 
ac
ti
v
at
in
g
 r
ec
ep
to
r 
(P
P
A
R
),
 
A
M
P
-a
c
ti
v
at
ed
 p
ro
te
in
 k
in
a
se
 (
A
M
P
K
),
 d
ea
ce
ty
la
se
 e
n
z
y
m
e
s 
(G
C
N
5
),
 t
ra
n
sc
ri
p
ti
o
n
 l
ik
e 
e
ff
ec
to
r 
n
u
c
le
as
es
 (
T
A
L
E
N
S
).
 
Chapter One  Introduction 
 
45 
 
1.8.2. Gene therapy  
The use of gene therapy with the aim of shifting heteroplasmy in favour of wild type in 
mtDNA disease has been postulated since the mechanism of the diseases was known. 
The following describes several approaches that have had varying degrees of success, 
despite this there are currently no effective gene therapies used in the treatment of 
mitochondrial disease. While some of the approaches listed below have shown efficacy 
in cell lines, the delivery of the gene therapies for use in multi-systemic diseases 
prevents their use in man.  
 
 Endonucleases  1.8.2.1.
Endonuclease restriction enzymes have the ability to specifically recognise sequences in 
DNA and induce double strand breaks. This makes them attractive in the treatment of 
mtDNA disease as there are two distinct populations of mtDNA, mutated and wild-type. 
By targeting an endonuclease with the ability to specifically recognise and cleave only 
mutant mtDNA, a proportionate increase of wild-type mtDNA levels could be achieved 
following degradation of digested molecules.  
 
Srivastava et al. attempted to use PstI endonuclease to specifically cleave mtDNA at 
either of the two PstI sites contained within human (m.6914 & 9024) and mouse 
mtDNA. Addition of a COX VIII targeting sequence to bacterial PstI enzyme caused 
effective colocalisation with mitochondria in transiently transfected HeLa cells 
(Srivastava and Moraes 2001). The authors created a hybrid cell line containing mouse 
mtDNA (which contained two PstI sites) and rat mtDNA (which contained none) to 
investigate the selective removal of PstI containing mtDNA. In hybrid cells which 
contained a ratio of 3:1 mouse to rat mtDNA and transfected with mitochondrial PstI, 
the heteroplasmy of mouse mtDNA fell from 75% to 38%, indicating that the mouse 
mtDNA was specifically degraded after digestion, whereas the rat mtDNA, which did 
not contain a PstI site, was unaffected.  
 
Although proven in principle, the usefulness of using endonuclease enzymes to treat 
mtDNA disease is fundamentally limited by the availability of a unique restriction site 
created by the disease causing mutation. The disease mutation m.8993T>G found in 
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neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP) and Leigh’s 
syndrome results in the creation of a unique SmaI restriction site in the mutated 
mtDNA, enabling the use of SmaI enzyme to remove mutated genomes (Tanaka et al. 
2002).  
 
To target SmaI to mitochondria Tanaka et al. made a mitochondrially targeted version 
of the enzyme by adding a COXIV presequence. After transfection into patient cell lines 
containing the m.8993T>G point mutation, the restriction enzyme eliminated all 
mutated mtDNA from the cells by digestion; however this required repeated 
transfections, something that is undesirable in patients (Tanaka et al. 2002). To improve 
the efficacy of this work Alexeyev and colleagues used the SmaI isoschizomer XmaI, 
modified for mitochondrial targeting by the addition of the COX VIII targeting 
sequence in an adenovirus transfection system (Alexeyev et al. 2008). As with the work 
done by Tanaka et al. mutant mtDNA was completely depleted.  
 
Although this approach to targeting mutated mitochondrial genomes is promising for 
NARP and Leigh’s syndrome, there are issues with the use of these strategies in 
patients, particularly the development of a reliable and safe cellular delivery method. 
 
 Zinc fingers 1.8.2.2.
Zinc finger peptides (ZFPs) are small protein motifs characterised by finger like 
protrusions that enable the specific binding of a target molecule. While they have the 
ability to bind various different molecules, one class in particular, Cys2His2, has had its 
ability to bind DNA in a sequence specific manner well characterised (Wolfe et al. 
2000; Persikov et al. 2009). Found in many mammalian transcription factors the 
Cys2His2 class has become particularly useful in the engineering of novel proteins that 
can bind specific regions of DNA enabling targeted modification and changes in 
expression. ZFPs readily localise to the nucleus where they interact and bind with DNA, 
a localisation that is so strong that it does not always require a nuclear localisation motif 
to be present on certain ZFPs (Minczuk et al. 2006).  
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Strong nuclear localisation presents a problem for using ZFPs to treat mitochondrial 
DNA disease, as to exhibit a therapeutic effect they need to efficiently localise to the 
mitochondrial matrix. It is also important that there is minimal nuclear localisation in 
order to prevent “off target” toxicity. To try and achieve this Minczuk et al conjugated 
either the N-terminal mitochondrial targeting sequence (MTS) of the F1β subunit of 
human ATP synthase or COX VIII subunit to three or four fingered ZFPs. While some 
of the peptides were translocated to mitochondria, none showed exclusive localisation 
(Minczuk et al. 2006). To try and prevent nuclear accumulation, the authors added a 
nuclear export sequence (NES), a small peptide that signals the ZFP for export from the 
nucleus, to the peptides. Immunofluorescent studies showed an exclusive localisation to 
mitochondria, something that was only achieved in ZFPs that had both the NES and 
MTS conjugated (Minczuk et al. 2006).  
 
Once in the mitochondria, ZFPs need to fold correctly and incorporate Zinc into their 
structure to become active. Minczuk and colleagues showed that a ZFP-methyalse can 
be specifically targeted to mitochondria where it folds correctly and methylates mtDNA 
(Minczuk et al. 2006). Subsequently this group have developed a ZFP-nuclease (ZFN) 
that can induce double strand breaks specifically in mtDNA with the m.8993T>G 
NARP mutation. This was achieved by joining two Fok1 nucleases with a flexible 
linker, which are then conjugated to a ZFP that has been previously shown to 
specifically bind mtDNA. This new ZFN had the ability to not only localise within 
mitochondria but also to specifically target and cut mutant mtDNA. This led to a stable 
decline in heteroplasmy in cells transfected with the ZFN which was maintained up to 
30 days after the initial depletion (Minczuk et al. 2008). Although this approach has 
shown some potential in the specific recognition and removal of mutated mtDNA, 
targeting to the mitochondria is hindered by the strong nuclear localisation of Zinc 
fingers.  
 
 TALENS 1.8.2.3.
TALENS (Transcription Activator-Like Effector Nucleases) are a family of proteins 
that can bind DNA in a sequence specific manner and induce a double strand break 
(Hockemeyer et al. 2011). Unlike ZFNs they do not possess a tendency to localise to the 
nucleus, which enables them to efficiently target mitochondria using protein import 
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sequences. Bacman et al. engineered TALENS with mitochondrial targeting sequences 
to bind and cleave the 4977bp “common deletion” breakpoint (m.8483_13459) in 
patient derived cell lines (Bacman et al. 2013). The authors used FokI nucleases that 
dimerise in order to cleave mtDNA, this required the use of two TALENS each 
designed to bind different regions of mtDNA, which when bound to species of mtDNA 
containing the deletion will be in close enough proximity for the nucleases to cleave 
DNA (Bacman et al. 2013). The authors showed a decrease in heteroplasmy from 70% 
to 30% in cell lines which contained both TALENS, without affecting the overall copy 
number of the cells, indicating a compensatory increase in mtDNA replication, which 
favoured an accumulation of wild type mtDNA as these were not removed by the 
TALENS. Although this technique showed excellent efficacy, the delivery of gene or 
protein therapies to patients limits its potential uses in man.  
 
 Mitochondrial Transfection 1.8.2.4.
Development of an effective nucleic acid delivery mechanism for mitochondria has so 
far proved elusive. While delivering oligomers into the cytoplasm has now become 
commonplace, the targeting and crossing of the charged mitochondrial double 
membrane is a technical challenge. Traditionally, liposomes have been used to facilitate 
the transport of oligomers across the cell membrane. However to use a liposomal 
approach to mitochondrial drug delivery, a mitochondrial targeting moiety will have to 
be employed to translocate the liposome to the mitochondrial membrane subsequent to 
cytoplasmic delivery. 
 
Initial successes were claimed in this area using cationic DQAsomes as a transfection 
agent. DQAsomes are formed by the sonication of dequalinium (Weissig et al. 1998), an 
anti-microbial drug that has been previously shown to accumulate in mitochondria 
(Weiss et al. 1987).  An overall cationic charge that is distributed across the molecule 
makes DQAsomes very attractive for targeting negatively charged mitochondria. 
D’Souza et al. created DQAsome-DNA complexes with plasmid DNA and then 
incubated these complexes with BT20 epithelial cells. The authors showed delivery of 
the plasmid into mitochondria by staining cells with the dsDNA stain SYBR green I, 
cells incubated with the DQAsome-DNA complex showed minimal SYBR green 
colocalisation to mitochondria (D'Souza et al. 2003). Subsequent work has claimed that 
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delivery of a green fluorescent protein (GFP) gene to mitochondria is also possible 
using a DQAsome delivery system (Lyrawati et al. 2011), however the results in this 
paper are far from conclusive. Although DQAsomes showed initial promise at 
delivering DNA to mitochondria, currently there are no published articles showing 
delivery of gene therapy agents to cells affected by mtDNA disease. 
 
Further advances in the design of mitochondria targeting liposomes have taken place 
since the discovery of DQAsomes. The conjugation of Rhodamine 123, a mitochondrial 
selective dye, to liposomes was used to deliver drugs to mitochondria and caused a 
significant increase in not only cellular internalisation of the liposome but also in 
mitochondrial localisation (Biswas et al. 2011). 
 
Recently, Yamada et al. have developed the dual function mito-porter consisting of an 
outer and inner liposome (Yamada et al. 2011). The complete mito-porter enters the 
cells via endocytosis after which the outer membrane fuses with the endosome releasing 
the drug containing inner liposome into the cytoplasm. The targeted inner liposome then 
fuses with mitochondria delivering the drug into the mitochondrial matrix.  
 
Mitochondrial targeting is achieved by modifying the liposomes with positively charged 
octaarginine (R8), enabling uptake into the cell via macropinocytosis and also forcing 
localisation to mitochondria via electrostatic interactions with the negatively charged 
mitochondrial membrane. The approach has the potential to deliver a wide range of 
bioactive molecules into the mitochondria including oligomers and peptides (Yamada et 
al. 2011). To test the concept of mitochondrial matrix delivery, Yamada encapsulated 
DNase I in the DF-mito-porter and tested the level of mtDNA depletion caused by the 
enzyme. The authors detected DNase I in mitochondria and also found that there was a 
decrease in mtDNA when measured using qPCR (Yamada and Harashima 2012). 
Although this result is promising, further work needs to be completed to assess the 
efficacy of their approach.  
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 Oligomer therapies 1.8.2.5.
The use of oligomer therapies in mtDNA disease could offer not only a treatment but 
also a cure for the diseases. While previous attempts such as endonuclease therapies 
have been centred on just one mutation in humans (Srivastava and Moraes 2001; 
Tanaka et al. 2002), oligomers have the potential to be designed to target any mutated 
region of mtDNA, thus enabling the treatment of all mtDNA disease.  
 
Heteroplasmic mtDNA mutations preserve a pool of wild-type mtDNA that could 
potentially rescue the mutant phenotype. By designing an oligomer that is 
complementary to the sense strand of an mtDNA mutation, be it a point mutation or a 
deletion, the oligomer has the potential to bind both the mutated mtDNA and also the 
mt-RNA that is transcribed from the mutated region. This strategy potentially offers a 
therapeutic effect against both mutated mtDNA and mutated mitochondrial mt-RNA or 
mt-tRNA. Experiments in vitro have shown that binding of an oligomer to mtDNA can 
halt the replication fork thus preventing replication of the mutated genome (Taylor et al. 
1997). If this were to happen in vivo then it is likely that the mtDNA molecules with a 
stalled replication fork would be degraded in order to prevent genome instability, or at 
the very least that it would lead to a preferential increase in the wild type genomes. As 
described previously, the level of wild type mtDNA drives the cellular phenotype, so a 
small increase in the proportion of wild type to mutated mtDNA could lead to a greater 
improvement in the biochemical defect of the mitochondria.  
 
Peptide nucleic acids (PNAs) showed early promise at inhibiting mtDNA replication in 
vitro. Developed to be both nuclease and DNase resistant, PNAs are formed by 
substituting the deoxyribose-phosphate backbone of DNA with aminoethyl-glycine 
groups to create a molecule that can also outcompete DNA:DNA interactions to 
preferentially bind complementary DNA sequences, due to the absence of a negatively 
charged phosphate group on the PNA backbone increasing the stability of PNA:DNA 
hybrids relative to DNA:DNA binding (Nielsen et al. 1991). As with all mitochondrial 
therapies, targeting PNAs to the mitochondrial matrix is challenging. Biotinylated 
PNAs complementary to the m.8344A>G MERRF mutation were conjugated to the 
mitochondrial targeting protein presequence of COX VIII to try and facilitate entry into 
the mitochondrial matrix (Chinnery et al. 1999). Although staining for biotin showed a 
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mitochondrial colocalisation, it was deemed that entry into the mitochondrial matrix 
was not occurring due to an absence of functional effect (Chinnery et al. 1999; 
Filipovska et al. 2004). 
 
Recent developments in this field have focused on improving the ability of PNAs to 
cross cell membranes. This has led to the emergence of a new class of oligomers termed 
cell membrane crossing oligomers (CMCOs) (Posch et al. 2012). Modifications on the 
backbone of CMCOs (phosphonic esters) enable them to enter the cell without the need 
for delivery mechanisms such as liposomal transfection. This ability to cross cell 
membranes and accumulate in the cytosol means that there is the potential to cause 
accumulation in the mitochondria if the CMCOs can be conjugated to a lipophilic cation 
such as TPP. On-going work to test the efficacy of such an approach forms a significant 
portion of this thesis (Chapters 3 and 4). 
 
 RNA import 1.8.2.6.
As mentioned previously, nuclear encoded RNAs are imported into the mitochondria 
and have important roles in both replication and the cleaving of mitochondrial tRNAs 
from RNA transcripts. It has also been shown that mitochondria have a conserved 
ability to import cytosolic tRNAs. S. cerevisiae yeast import the nuclear encoded 
tRNA
Lys 
(CUU) into mitochondria and although the mechanism is not clear, the 
requirement of an intact TOM/TIM set of proteins for successful import suggest that 
tRNA
Lys 
(CUU) is chaperoned with a protein, possibly an aminoacyl-tRNA synthetase 
(Tarassov et al. 2007). Overexpression of the nuclear-encoded tRNA
Lys 
(CUU) has been 
shown to rescue respiratory defects in MERRF immortalized cybrids cells however tests 
on patient fibroblasts with the MERRF mutation only demonstrated a partial rescue of 
mitochondrial function (Kolesnikova et al. 2004). Successful import of the tRNA
Lys
 has 
led to attempts to treat cells affected by the MELAS m.3243A>G tRNA
Leu(UUR)
 
mutation. By modifying the aminoacylation identity of tRNA
Lys 
(which has previously 
been shown to be imported by mitochondria (Tarassov et al. 2007)) from lysine to 
leucine a tRNA with the ability to correct m.3243A>G tRNA
Leu(UUR)
 mutations can be 
imported. The modified tRNA has been shown to increase the level of transcription of 
mitochondrial proteins in cybrids with the m.3243A>G mutation (Karicheva et al. 
2011).  
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Elucidation of the secondary structures needed to facilitate import of tRNA
Lys 
(CUU) 
and 5S rRNA into mitochondria have led to the creation of recombinant RNAs that can 
be imported into mitochondria, bind a specific region of mtDNA and prevent 
replication. In cells derived from Kearns Sayre syndrome patients with a single large 
scale 7075bp mtDNA deletion and a unique breakpoint, m.8363_15438, treatment with 
an oligomer complementary to the breakpoint caused a fall in heteroplasmy from 65% 
to 40% thus rescuing the mutant phenotype (Comte et al. 2013). 
 
Import of the RNA component of RNase P (H1 RNA) into mitochondria is modulated 
by PNPase, which recognises a 20bp stem-loop sequence present on the RNA, enabling 
its entry into the mitochondrial matrix (Wang et al. 2010). The nuclear encoded mRNA 
of human mitochondrial ribosomal protein S12 (MRPS12) has also been shown to 
contain regulatory sequences in its 3’UTR which are thought to cause localisation to the 
mitochondrial outer membrane (Russo et al. 2008). The addition of the 20bp stem-loop 
structure and 3’UTR regulatory sequence onto transfected wild-type mtRNAs could 
correct defects caused by mutations of mtDNA in vivo by driving import of the wild 
type tRNA into mitochondria.  
 
Targeted RNA import has been used to try and correct decreased translation rates in 
cybrids containing either the m.3243A>G MELAS or m.8344A>G MERRF mutations. 
Addition of the stem-loop targeting sequence onto wild-type tRNAs that are mutated in 
the MELAS (mt-tRNA
Leu(UUR)
) or MERRF (mt-tRNA
Lys(AAA)
) cybrids cell lines led to 
import into isolated mitochondria and a subsequent increase in peptide steady state 
levels (Wang et al. 2012). This approach has also been shown by these authors to work 
with the import of MTCO2 mRNA enabling correction of defects caused by mutations 
in mtDNA encoded proteins (Wang et al. 2012). Importantly the stem-loop structure is 
cleaved from the RNAs after importation enabling, in the case of tRNAs, allowing them 
to function correctly or, in the case of mRNAs, for them to be translated by the 
mitochondrial translation machinery. To achieve tRNA mediated rescue of respiration 
in whole cybrid cells, the import sequence was modified by the addition of the MRPS12 
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3’UTR targeting sequence, along with the PNPase realted stem-loop sequence to cause 
mitochondrial localisation (Wang et al. 2012). 
 
1.8.3. Prevention of mitochondrial disease 
Transmission of mtDNA disease through the germline can be prevented using pro-
nuclear transfer techniques, which involve removing the pro-nuclei from the fertilised 
oocyte of a mitochondrial disease affected mother and inserting it into the enucleated 
donor embryo of an unaffected individual (Craven et al. 2010). The use of the technique 
is currently being debated in the UK Houses of Parliament. Mitotic spindle transfer 
techniques in which the chromosomes from an unfertilised oocyte are transferred into an 
enucleated donor oocyte have been demonstrated in non-human primates. Although this 
has not been shown in humans, it offers another potential option for preventing 
transmission of the diseases (Tachibana et al. 2009). 
 
Alternatively, pre-implantation genetic diagnosis can be used to investigate the mutation 
load of blastocysts, selecting those that are at low risk of having high heteroplasmy of 
the disease mutation for implantation into the mother during IVF (Steffann et al. 2006).  
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1.9. AIMS 
Despite extensive research over the last 14 years into modulating heteroplasmy in 
mtDNA diseases, no practical treatments have been created. Over the same period there 
has been an absence of the development of mitochondrially acting pharmaceuticals. 
These two factors mean that treatment options for patients have not been greatly 
advanced, and as a consequence the prognosis for patients has not improved.  
 
To address these issues this project aimed to investigate potential therapies for 
mitochondrial disease. First, I investigated an anti-genomic approach using CMCOs, 
oligomers that have previously shown efficacy at inhibiting mtDNA replication in cell 
culture models, to selectively target mtDNA mutations, preventing the replication of 
mutated mtDNA and the translation of mutated mRNA. To achieve this, a strategy for 
targeting CMCOs to mitochondria was developed. Based on previous work in the field, 
which highlighted the difficulty of exploiting mitochondrial transport proteins to allow 
oligomer accumulation into the matrix, I exploited the mitochondrial membrane 
potential to drive accumulation of the oligomers into the matrix, after which their 
functional effects were investigated.  
 
The second part of the project focused on a large scale screen of compounds to 
investigate effects on mitochondrial mass. With work in the field indicating that 
mitochondrial biogenesis may improve mitochondrial myopathies (either through 
exercise or pharmacologically), it is important to discover compounds with better 
efficacy at increasing mitochondrial mass than currently available treatments. An assay 
was developed to screen for changes in mitochondrial mass in a quick and reproducible 
manner. This assay was then used to screen a library of compounds, after which any 
“hit” compounds were investigated further.  
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2 Materials and Methods 
2.1. MATERIALS 
2.1.1. Equipment 
ABI 3100 Genetic Analyser     Applied Biosystems. 
ABI Gene Amp 9700 Thermal Cycler   Applied Biosystems. 
ABI Prism 7000 sequence detection system   Applied Biosystems. 
Autoclave       Astell 
Automated fluorescent plate reader    BMG-Omega 
Automated plate reader EIx800    Bio-Tek 
Balance: Sartorius Basic     Sartorius 
Bench-top Microcentrifuge     Sigma 
Bench-top Centrifuge 3-15     Sigma 
Binder General Purpose Incubator    Philip Harris 
Dry Heat Block      Techne 
Electrophoresis power supply model 250EX   Life Technologies 
Fluorescent plate reader     Bmg labtech 
Geldoc system      BioRad 
Horizontal Agarose Gel Electrophoresis Systems  Amersham 
InCu SafeTM CO2 Incubator     Sanyo 
Liquid handling robot      Beckman Coulter 
Microflow Biological Safety Cabinet    Bioquell 
Nanodrop ND-1000 Spectrophotometer   Labtech International 
ND-1000 Software 
Nikon A1R point scanning confocal microscope  Nikon 
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Nikon Elements software 
3510 pH Meter      Jenway 
StepOne plus Real-time PCR     Applied Biosystems 
U.V hood       BioAir 
Zeiss Axiovert 200M fluorescence microscope  Zeiss 
 
2.1.2. Consumables 
0.2ml Thin-Walled PCR tubes    Starlabs 
0.5ml Thin-Walled PCR tubes    Starlabs 
1.5ml Eppendorf tubes     Starlabs 
2.0ml Eppendorf tubes      Starlabs 
Multi-well optical bottom plates    Greiner 
Aerosol resistant Pipette tips      Starlabs 
Coverslips (22x22mm)     Merck 
Cellstar
®
 Disposable Pipettes     Greiner 
 (5ml, 10ml, 25ml) 
Cellstar
®
 Tissue Culture flasks     Greiner  
(25cm
3
, 75cm
3
, 225cm
3
)  
Cryotubes       Nunc 
Falcon tubes (15ml and 50ml)    Starlabs 
Gilson Pipetteman (P2, P10, P20, P200, P1000)  Anachem 
Liquid handling tips      Beckman Coulter 
Western blotting equipment     BioRad 
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2.1.3. Solutions 
This list gives solutions not detailed in the methods section.  
DNA Loading buffer     0.25% (w/v) Bromophenol Blue 
       0.25% (w/v) Xylene Cyanol 
       30% (v/v) Glycerol 
 
Electrophoresis Buffer     100ml 10x TAE 
       900ml ddH2O 
       80µl ethidium bromide 
 
5% Milk solution in TTBS    5g Skimmed Milk powder 
       100ml TTBS 
 
4% Paraformaldehyde 20g paraformaldehyde in 250ml 
ddH2O 
                                                                                    250ml 0.2M phosphate buffer 
 
Phosphate Buffered Saline    Prepared from tablets; 1 Tablet in 
        100ml water  
 
Running Buffer (western) 5x        15g Trisma base 
72g Glycine 
5g SDS 
 
TTBS pH 7.6      2.42g Trisma base 
8g NaCl 
Made up to 1l with dH20 
0.1% Tween 20 (v/v) 
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2.2. METHODS 
 
2.2.1. Adherent cell-line culture 
Fibroblast or HeLa cells were cultured in either T75cm
2
 or T225cm
2
 vented Costar 
flasks in an appropriate amount of media specific to each cell line (Table 2.1) and 
incubated at 37
o
C in a humidified atmosphere with 5% CO2. Once cells reached 90% 
confluency, the cells were washed once in PBS and passaged using 0.5% Trypsin- 
EDTA. Trypsin was quenched by addition of complete media and cells transferred to a 
30ml universal prior to centrifugation at 160g for 4 minutes.  Cells were resuspended in 
their complete media and seeded in fresh flasks or dishes at an appropriate confluency.  
Cells to be frozen were placed in the complete media with 10% (v/v) DMSO, and frozen 
at -80
o
C for 24 hours in Cryotubes (Nunc), after which they were transferred to liquid 
nitrogen. HeLa cells were provided by Dr. Francesco Bruni (Newcastle University, 
UK), immortalised fibroblasts were provided by Ms. Marysia Wesolowska (Newcastle 
University, UK). 
Table 2.1 – Cell culture media  
 
 
2.2.2. Cell counts 
Prior to cell counting, 10µl cell suspension was mixed with 10µl Trypan blue. 10µl of 
the Trypan solution was then placed under the cover slip on a haemocytometer and cell 
number per ml calculated.  
 
 
 
 
 
Cell line Media Supplements 
HeLa 
EMEM with 
Earle’s salts 
10% FBS (v/v), 2mM L-glutamine, 1xNEAA 
Fibroblasts 
EMEM with 
Earle’s salts 
10% FBS (v/v), 2mM L-glutamine, 1xNEAA, 
1mM sodium pyruvate, 0.41µM Uridine 
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2.2.3. Live cell staining 
Mitochondrial network stains were diluted to the appropriate concentration in complete 
media for the cell line to be stained, unless otherwise stated the final concentrations of 
the dyes are stated in Table 2.2. Cells were incubated with the dye for 30 minutes at 
37
o
C in a humidified atmosphere of 95% air, 5% CO2. Dye containing media was 
aspirated and the cells washed in PBS three times, after which they were covered with 
complete media without Phenol Red. Cells were imaged using the appropriate excitation 
and emission profiles according to Table 2.2. Concentrations were determined using 
manufacturers guidelines, all stock solutions were made up in DMSO and stored at -
20
o
C. Final concentrations were diluted in media appropriate for the cell line.  
 
Table 2.2 – Concentration and properties of dyes used for live cell imaging.  
 
2.3. MICROSCOPY 
2.3.1. Wide-field microscopy 
Wide-field microscopy was carried out using an inverted Zeiss Axiovert 200M 
fluorescent microscope with the following filters: DAPI 359ex/461em, FITC 490/525, 
Texas Red 595/620. To image cells, an appropriate filter was chosen to capture signal 
from the fluorophores used for staining. To capture the image, Axiovision software was 
used to measure the signal emitted from the excited fluorophore and automatically 
determine the correct exposure time. Exposure time was manually adjusted to capture a 
minimal amount of background signal. Images were captured using a 60x oil immersion 
lens.  
Dye 
Wavelength 
Ex/Em (nm) 
Stock 
concentration 
Final 
concentration 
Atto 674N 644/669 5mM 1µM 
Calcein Blue 360/448 2.1mM 2.1µM 
Hoechst 33258 346/460 18mM 7.2µM 
Mitotracker Deep Red FM 644/655 1mM 50nM 
Mitotracker Green FM 490/516 1mM 50nM 
Picogreen  480/520 Unknown 1µl/ml 
TAMRA 553/576 10mM 250nM 
TMRM 549/573 5mM 15nM 
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2.3.2. Confocal microscopy 
Confocal microscopy was carried out using an inverted Nikon A1R point scanning 
confocal microscope equipped with 405nm, 457nm, 488nm, 514nm, 561nm and 647nm 
laser lines. Images were captured using photomultiplier (PMT) tubes and Nikon 
Elements software. Unless otherwise stated, images were captured using a 60x oil 
immersion objective (1.4 numerical aperture (NA)). Live cells were imaged in a bio-
chamber set at 37
o
C and 5% CO2 after an equilibration of 10 minutes to remove 
condensation. Appropriate laser lines were selected to image the cells based on the 
excitation wavelength of the fluorophores (Table 2.2).  
 
Imaging conditions were set up manually by adjusting laser power, PMT voltage and 
image offset to ensure the best possible image was obtained. Although there was 
variation between settings for each laser line and experiment, in general the laser power 
was set as low as possible to prevent fluorophore bleaching and photo-toxicity to the 
cells. PMT voltage was kept below 100V (1-150V range) where possible, to prevent 
introduction of noise into the image as this may lead to degradation in image quality. 
Image offset was adjusted to set the “black” level, for example this can be adjusted to 
remove background signal from samples. The confocal pinhole was set to the optimum 
diameter depending on the wavelength to be captured; this was set up automatically by 
the software.  
 
Prior to imaging, perfect focus system (PFS) was enabled to ensure that the focal plane 
did not drift during image capture. Images were captured by sequentially exciting the 
sample using an individual laser line, capturing emitted photons and repeating for each 
laser line in use. Depending on the quality of staining, line averaging was also used to 
remove noise from the image. This works by scanning the image a set number of times 
to determine if a signal is obtained from the same place each time. If the signal is not 
present on each scan then it is classed as noise and removed from the image, however 
the increase in scanning also increases exposure time and therefore bleaching and 
photo-toxicity.  
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For single plane imaging the cell to be imaged was scanned from top to bottom and the 
widest part of the cell was imaged. 3D images were obtained by capturing a series of 
images across a Z-stack. The top and bottom of the cell to be imaged was found by 
scanning through the cell and storing the locations in Nikon elements software. The 
number of slices to be imaged was then calculated based on the confocal aperture 
pinhole diameter, unless otherwise stated the image slice was 0.5µm. For general 
scanning of the sample, 512x512 pixels were imaged to decrease frame time, captured 
images had a 1024x1024 pixel resolution.  
 
2.3.3. High throughput imaging 
High throughput imaging was used to take bright field images of cells grown in 96 well 
plates as part of a drug screen; all images were obtained using a Nikon Eclipse wide 
field microscope with bio-chamber and automated stage, the microscope was controlled 
using Nikon Elements software with Nikon Jobs package Prior to imaging, HeLa cells 
were seeded in 96 well plates, left overnight and dosed with bacterial extracts according 
to section 6.3.2. The plate to be imaged was loaded onto the microscope stage and a 10x 
air (0.3 NA) objective selected.  
 
The following experimental workflow was set up using Nikon Jobs wizard. The 
appropriate 96 well plate was selected and the stage calibrated by moving the field of 
view to wells A1 and H12, enabling the software to map the layout of the plate. To 
compensate for focus drift as the plate moved around during imaging, an autofocus of 
100m was used. This adjusted the focus of the microscope over a range of 100m, 
after which the correct focal plane is selected automatically by measuring changes in the 
image contrast. An exposure time of 100ms and bulb voltage of 3V was selected before 
all wells were imaged in sequence.  
 
2.3.4. Colocalisation analysis 
Colocalisation of mitochondria with fluorescently tagged CMCOs was calculated using 
Volocity (Perkin Elmer) imaging software; all images were captured using a Nikon 
A1R point scanning confocal microscope. Volocity was used to determine the threshold 
of the fluorophores according to the method described by Costes and colleagues which 
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subtracts non-specific background fluorescence (Costes et al. 2004). This is essential to 
ensure that non-specific background staining is not classed as colocalised. The degree of 
colocalisation was calculated by Volocity and given as a Pearson’s correlation 
coefficient; therefore perfect colocalisation gives a value of 1 and no relationship 
between mitochondria and the fluorophore conjugated CMCO gives a value of 0.  
 
2.3.5. Mitochondrial volume analysis 
Investigation of active extracts after the drug screen was carried out using confocal 
microscopy. HeLa cells were seeded (1 x 10
4
 cells/well) in a class bottomed 24 well 
plate and placed in an incubator overnight. Active extracts were filter sterilised and 
added to the HeLa media at an appropriate concentration and incubated for 48 hours. 
HeLa cells were stained with 10nM TMRM and 2.1µM Calcein blue for 30 minutes, 
before washing in PBS and being placed in fresh, Phenol Red free media. Imaging was 
performed using a Nikon A1R microscope. All images were analysed using Imaris 
software (Bitplane AG), briefly each colour channel was detected by the software and a 
new image rendered. The volume of each stain was determined and the proportion of 
mitochondria per cell calculated.  
 
2.4. PROTEIN EXPRESSION 
2.4.1. Protein extraction 
Adherent cells were passaged according to section 2.2.1 and centrifuged at 160g for 4 
minutes to pellet the cells. Cell pellets were resuspended in PBS and centrifuged at 160g 
for 4 minutes after which PBS was removed. Pellets were resuspended in 50µl protein 
lysis buffer (0.05M Tris-HCl pH7.5, 0.13M NaCl, 2mM MgCl2, 2% Igepal CA-360, 1x 
protease inhibitors) and vortexed for 30secs. Samples were centrifuged at 560g for 2 
minutes to pellet nuclei and unbroken cells. Supernatant was removed and placed in a 
fresh 1.5ml tube and 50µl 10mM Tris HCl pH7.5 added. Protein lysates were aliquoted 
and flash frozen in liquid nitrogen.  
 
2.4.2. Bradford assay 
Protein concentration was determined using a BSA (bovine serum albumen) standard 
curve. A standard curve was produced using BSA concentrations of 0, 2, 5, 10, 20µg/µl 
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made in 800µl dH2O, 200µl Bradford reagent was then added to these. Samples were 
prepared by adding 1µl protein lysate to 800µl dH2O and 200µl Bradford reagent. 200µl 
of the standards and samples were added in duplicate to a 96 well plate and absorbance 
was read at 595nm using a BioTEK ELx895 plate reader. Sample protein concentration 
was extrapolated from the standard curve.  
 
2.4.3. Polyacrylamide gel electrophoresis 
Protein samples were separated by size using BioRad Mini-PROTEAN TGX Precast 
gels. Prior to gel loading, samples were diluted 1:1 with 2x Laemmli buffer (60 mM 
Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 100mM DTT, 0.01% bromophenol blue) and 
incubated at 37
o
C for 30 minutes. Gels were placed in an electrophoresis tank filled 
with an appropriate amount of running buffer (25mM Tris HCl, 192mM glycine, 
0.1%SDS, pH8.3). Samples were loaded on to the gel along with 5µl Spectra pre-
stained, broad range protein ladder (Thermo Fisher, USA) and run at 150V, 30mA for 
1hour or until separation of the ladder was complete.  
 
2.4.4. Protein Transfer 
For protein transfer on to PVDF membrane, BioRad Turbo blot kits were used 
according to the manufacturer’s instructions. Briefly, Turbo blot filter paper containing 
the PVDF membrane was placed membrane side up on the bottom of a Turbo blot 
transfer tray. The precast gel was then removed from the casket and placed on the 
PVDF membrane and rolled to ensure no air bubbles were present. The top section of 
filter paper was then laid on the gel and the lid attached to the running tray. Transfer 
was run at 2.5A, 25V for 4 minutes. Transferred proteins were stained by immersing the 
PVDF membrane in Ponceau S (0.1% Ponceau S (w/v) in 1% acetic acid (v/v)) for 10 
minutes before washing excess off using dH2O. Stained proteins were visualised by eye 
to determine if protein detection should be carried out. The transferred gel was stained 
with Coomassie brilliant blue ( 1% Coomassie Brilliant Blue, 500ml methanol, 100ml 
glacial acetic acid, 400ml dH2O) for 30 minutes at room temperature. Stain was 
removed and washed in dH2O before incubation with de-stain solution (500ml 
methanol, 400ml dH2O, 100ml glacial acetic acid) overnight at 4
o
C. Protein staining by 
Coomassie was assessed to determine efficacy of protein transfer.  
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2.4.5. Protein Detection 
PVDF membranes were blocked in 5% milk in TTBS for 1 hour at room temperature on 
a shaker to prevent non-specific antibody binding. Primary antibody was diluted in 5% 
milk in TTBS and incubated on the membrane overnight on a shaker at 4
o
C. After 
primary antibody incubation the membrane was washed 3 times in TTBS for 5 minutes 
and the appropriate secondary antibody conjugated to HRP diluted in 5% milk in TTBS 
incubated with the membrane on a shaker for 1 hour at room temperature. The 
membrane was then washed 3 times in TTBS for 5 minutes and placed on an acetate 
sheet, protein side up. Signal development was carried out using ECL Prime according 
to the manufacturer’s instructions and 1ml of the solution was used to cover the 
membrane for 5 minutes. A luminescent product was produced by reaction with the 
HRP conjugated bound 2
o
 antibody. This product was detected using a BioRad 
ChemiDOC MP CCD camera set at an appropriate exposure time. Antibody 
concentrations are shown in Table 2.3. 
 
 
                       Table 2.3 – List of antibodies used for western blotting 
 
 
 
 
2.5. MITOCHONDRIAL DNA ANALYSIS 
2.5.1. Adherent Cell DNA extraction 
Culture media was removed from the wells of cells grown in plates. Wells were washed 
in PBS before the addition of an appropriate volume of DNA lysis buffer (250µl 
1%Tween, 195µl ddH2O, 50µl Tris-HCl (pH 8.5) and 5µl Proteinase K). Plates were 
incubated at 55
o
C for 2 hours and lysis buffer transferred into fresh 200µl tubes. 
Proteinase K was denatured by incubating at 95
o
C for 10 minutes. DNA concentration 
and purity was analysed using a Nanodrop ND-1000 spectrophotometer and stored at     
-20
o
C. 
 
Antibody Stock concentration 
Dilution for 
protein detection 
Anti-COX I 1mg/ml 1:1000 
Anti-SDHA 1mg/ml 1:500 
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2.5.2. Real-time PCR copy number analysis 
Copy number of mtDNA was determined by comparing the relative expressions of the 
nuclear encoded B2M (β2 microglobulin) and the mitochondrial gene MTND1 using the 
primer sets described in Table 2.4. All reactions were prepared in a UV PCR hood to 
prevent contamination. For each sample to be investigated, a tenfold serial dilution was 
produced ranging from 1:10 to 1:100000, to enable the production of a standard curve. 
Relative expression of both genes for each sample was measured on the same plate; 
however the assays cannot be multiplexed (due to the high efficiency of the ND1 
reaction). For the ND1 assay 1µl of each sample was added to individual wells in 
triplicate to which 24µl real-time master mix was also added (12.5µl Taqman Universal 
master mix, 0.5µl ND1 VIC probe, 0.75µl 10µM forward and reverse primer, 9.0µl 
ddH2O). B2M assays were set up in the same way using B2M master mix (12.5µl 
Taqman Universal master mix, 0.5µl B2M FAM probe, 0.75µl 10µM reverse primer, 
0.08µl 10µM forward primer, 10.17µl ddH2O). A no template control was added to 
ensure no contamination from the master mix. After loading, 96 well plates were sealed 
with StarLab film and vortexed. Plates were briefly centrifuged to remove drops from 
the film. The plate was placed in a StepOnePlus real-time PCR machine (Applied 
Biosystems). Reaction conditions were an initial cycle of 2 minutes at 50
o
C, 10 minutes 
at 95
o
C followed by 40 cycles of 15secs at 95
o
C and 1min at 60
o
C. Copy number of 
MTND1 in relation to B2M was worked out using the CT (threshold cycle) value 
obtained.  
 
2.5.3. DNA Sequencing 
 Polymerase chain reaction 2.5.3.1.
PCR was used to amplify regions of the mitochondrial genome to provide enough DNA 
for sequencing. Extracted DNA was amplified using primer pairs designed to span the 
region of interest (Table 2.4), all primers were tagged with the M13 sequence (Forward 
- 5’-TGTAAAACGACGGCCAGT-3’, Reverse - 5’-CAGGAAACAGCTATGACC-3’) 
to facilitate sequencing, and were designed to anneal optimally at 58
o
C. PCR was 
carried out using a 25L mastermix of 16.87L ddH2O, 2.5L 10x PCR buffer, 2.5L 
10x dNTPs, 0.13L AmpliTaq Gold and 1µl extracted DNA. A no template control and 
positive control reaction was also amplified.  Reactions were placed in a thermal cycler 
under the following conditions: 95
o
C for 10 minutes then 30 cycles of 94.0
o
C for 45 
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seconds, 58
o
C for 45 seconds and 72
o
C for 1 minute. A final extension of 72
o
C for 8 
minutes was carried out. 
 
 Gel Electrophoresis 2.5.3.2.
Following PCR, 5L product was mixed with 1L loading buffer (0.25% (w/v) 
bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol) and loaded on to a 
1.5% agarose gel containing 0.4g/ml ethidium bromide to enable DNA visualization, 
along with PCRRanger 100bp ladder. Electrophoresis was carried out in 1X TAE buffer 
for 40 minutes at 70 volts. Subsequent to electrophoresis, PCR products were visualized 
in ultraviolet light using a BioRad ChemiDOC MP and a digital image obtained. Failed 
reactions or reactions that showed a positive signal in the negative control were 
repeated.  
 
 Cycle Sequencing 2.5.3.3.
After visualization, 5L of the product was placed in a 96 well sequencing plate to 
which 1.5L TSAP alkaline phosphatase (Promega) (containing exonuclease I and 
alkaline phosphatase) was added over ice to remove unreacted nucleotides and primers 
from the sample.  This was incubated in a thermal cycler for 15 minutes at 37
o
C to 
enable digestion and 15 minutes at 80
o
C to denature the enzymes. A 12L master mix 
containing 7L dH2O, 3L 5x Sequencing buffer, 1L Universal forward primer, 1L 
BigDye v3.1 was added to each sample after clean up. Samples were placed in a thermal 
cycler under the following conditions; 96
o
C for 1 minute then 25 cycles of 96
o
C for 10 
seconds, 50
o
C for 5 minutes and 60
o
C for 4 minutes. 
 
Prior to sequencing, PCR products were precipitated by the addition of 2l of 3M 
sodium acetate, 2μl of 125mM EDTA and 70μl of 100% Analar ethanol to each sample. 
This was mixed by inversion and left for 15 minutes prior to centrifuge at 2090g for 30 
minutes. The supernatant was discarded; 70L of 70% Analar ethanol was added to 
each sample and centrifuged at 1650g for 15 minutes. The supernatant was discarded 
and the samples allowed to air dry for 20 minutes in the dark. Before sequencing, 10L 
of HiDi formamide was added to each sample to facilitate the separation of DNA 
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strands and incubated for 2 minutes at 95
o
C. The plate was then placed in an ABI 3100 
Automated DNA sequencer for sequencing.  Sequenced fragments were analysed using 
SeqScape software by comparing sequences to the revised Cambridge Reference 
sequence (rCRS) (Andrews et al. 1999). 
 
 
 
 
 
 
 
2.6. CELL MEMBRANE CROSSING OLIGOMERS 
 
2.6.1. CMCO preparation 
CMCOs were delivered in a lyophilised form. All CMCOs were resuspended in a 
volume of PBS that should give a final CMCO concentration of 1mM according to the 
molecular weight and mass of the CMCO. Due to the manufacturing process, it is likely 
that the CMCOs are not pure and the concentration is likely to be lower than 1mM. 
After re-suspension, the concentration of CMCO was determined by measuring the 
optical density (OD) Absorbance at 260nm over a 1cm light path using a quartz cuvette. 
The following additive A260 EmM.cm
-1
 for PNA monomers was used: A=13.7, 
C=6.06, G=11.7, T=8.6. Following calculation of the final concentration, the CMCOs 
were aliquoted into appropriate volumes and frozen at -20
o
C. Fluorescently conjugated 
CMCOs were protected from light.  
 
2.6.2. Dosing 
Prior to dosing, HeLa cells were seeded at low density on a plate appropriate for the 
experiment to be completed. Biotinylated CMCO detection was carried out on cells 
grown on coverslips in 6-well plates, 
Table 2.4 – PCR primer sets.  
B2M F CCAGCAGAGAATGGAAAGTCAA
B2M R TCTCTCTCCATTCTTCAGTAAGTCAACT
ND1 F CCCTAAAACCCGCCACATCT
ND1 R GAGCGATGGTGAGAGCTAAGGT
B2M-FAM ATGTGTCTGGGTTTCATCCATCCGACA
ND1-VIC CCATCACCCTCTACATCACCGCCC
12 F CACTCAGCCATTTTACCTCAC
12 R ATGGCAGGGGGTTTTATATTG
Sequencing primers: 5875-6410
Real-time PCR primers
Real-time PCR probes
Chapter Two  Materials & Methods 
69 
 
 
2.6.3. Fixation & biotin detection 
After incubation with biotinylated CMCOs, HeLa cells grown on glass coverslips in 6-
well plates were washed three times in PBS and fixed in ice cold 70% ethanol for 30 
minutes. After incubation, ethanol was removed and the coverslip air-dried on ice for 10 
minutes. The coverslip was removed from the 6-well plate and 200µl blocking solution 
(10% FBS in PBST) added for 30 minutes. Streptavidin conjugated Alexa Fluor 488 
was diluted 1:500 in blocking solution. Blocking solution was then replaced with 
streptavidin solution and incubated in the dark at room temperature for 90 minutes. This 
solution was removed and coverslips washed three times in PBST for 5 minutes each 
followed by three washes in PBS for 5 minutes. Coverslips were mounted on slides 
using DAPI mount (Vectashield). Slides were stored at -20
o
C in the dark if not imaged 
immediately after staining. Images were captured using wide-field microscopy section 
2.3.1 and analysed using Volocity software.  
2.7. HIGH THROUGHPUT DRUG SCREEN 
 
2.7.1. Cell seeding 
HeLa cells were grown in T225cm
2
 flasks as described in section 2.2.1 until they 
reached 80% confluency. Cells were then dissociated and counted using a 
haemocytometer after which they were diluted to 5000 cells/150µl in complete HeLa 
cell growth media and placed in a Falcon tube. A total volume of 15ml was required per 
plate to be seeded. Cells were seeded onto HT 96 well plates using a Beckman Biomek 
FX Liquid Handling robot contained in a Class II cabinet. Beckman Coulter P250 sterile 
tips were loaded by the robot on to the 96 well arm and 150µl of the cell containing 
media loaded into each well on the plate. After seeding, plates were re-lidded and 
placed in a humidified incubator at 37
o
C and 95% air, 5% CO2. Plates were not stacked 
for the first hour of incubation to ensure even warming.  
 
2.7.2. Extract and control addition 
24 hours after initial seeding, cell containing plates were dosed with either bacterial 
extracts or control molecules. Prior to addition, a control plate was made by adding 
HeLa media with either 450µM Bezafibrate or 5µM FCCP to one third of a HT 96 well 
plate. The final third of the plate contained HeLa media only. Plates containing bacterial 
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extracts were centrifuged at 2000g for 30 minutes to pellet precipitates and prevent 
pipette tip blockage.  
 
Cell plates were loaded on to the robot, de-lidded and extracts were added to them to a 
final dilution of either 1 in 10 or 1 in 100. Each concentration of extract was added to 4 
cell plates creating 4 repeats of each dose. The final cell plate had its media removed 
and 150µl/well from the control plate added. Plates were re-lidded and placed in a 
humidified incubator at 37
o
C and 95% air, 5% CO2.  
 
2.7.3. Mitochondria detection 
Cells were incubated with either the extracts or control molecules for 48 hours after 
which their media was removed by the robot in the dark and replaced with HeLa media 
without Phenol red with 75nM TMRM. Plates were re-lidded and placed in a 
humidified incubator at 37
o
C and 95% air, 5% CO2 for 1 hour. After incubation the 
plates were placed on the robot and the TMRM containing media was removed. Plates 
were then washed 3 times with warm PBS before the addition of 100µl HeLa media 
without Phenol red. Plates were then placed in a BMG labtech omega plate reader and 
the signal emitted by TMRM after excitation at 561nm was measured. Each well was 
measured in 6 different areas and the average fluorescent signal recorded.  
 
2.7.4. Cell Fixation and Nuclei Counting 
After mitochondrial measurement the plates were fixed in 4% PFA using the robot. 
Briefly, media was removed and 100µl per well 4% PFA in PBS added and incubated 
for 10 minutes. PFA was removed and plates washed 3 times in PBS with the final wash 
being left on. At this stage plates can be left at 4
o
C before nuclei staining.  
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3 Development of a mitochondrial targeting system for anti-genomic 
mtDNA disease therapies 
3.1. INTRODUCTION 
Mitochondrial DNA (mtDNA) diseases are caused by an accumulation of inherited 
mutated mtDNA molecules and a subsequent reduction in the proportion of wild-type 
mtDNA. Although there are treatments for many of the symptoms of these disorders 
(for example insulin for the treatment of diabetes or surgical correction of ptosis), there 
are currently no therapeutics that target the cause of these diseases. To effectively treat 
these diseases, molecules that can interact with mutated mtDNA and prevent its 
negative downstream effects must be developed. Several mechanisms could be 
exploited to achieve this, including: prevention of mutated mtDNA replication, 
degradation of mutated mtDNA, increasing the replication of wild-type mtDNA, 
prevention of mutated mtDNA transcription or prevention of translation of 
mitochondrial mRNA (for a more in-depth assessment of the current work in this field 
please see section 1.8). 
 
Currently the most successful systems to selectively degrade mutated mtDNA, such as 
the use of mitochondrial targeted restriction enzymes (Tanaka et al. 2002) or the use of 
zinc finger nucleases and the use of TALENS (Minczuk et al. 2006; Minczuk et al. 
2008; Bacman et al. 2013), have not been developed to a point where they can be used 
in man. The use of RNA import mechanisms to deliver anti-sense molecules to the 
mitochondrial matrix have also been claimed to show efficacy in cell culture models 
(Comte et al. 2013). Although in theory these approaches could be used to treat mtDNA 
disease, in reality the delivery of these therapies to affected tissues in multi-systemic 
diseases currently prevents their use. However, there is the possibility of using anti-
genomic therapies in Leber’s hereditary optic atrophy as the ocular location of the 
disease makes delivery much easier.  
 
The use of anti-sense oligomers to treat mtDNA diseases has previously been attempted 
in this research group (Taylor et al. 1997; Chinnery et al. 1999). Peptide nucleic acids 
(PNAs), complementary to mtDNA disease mutations, were targeted to mitochondria 
using mitochondrial peptide targeting sequences conjugated to the PNA oligomer. 
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Although in vitro inhibition of mtDNA replication proved the concept of selective 
inhibition (Taylor et al. 1997), delivery of PNAs into the mitochondrial matrix proved 
elusive. Subcellular localisation studies showed that although the PNAs were delivered 
to the mitochondria; there was no appreciable effect on mtDNA expression (Chinnery et 
al. 1999). Based on imaging and molecular studies on mitochondrially localised PNAs, 
the authors of this work speculated that the PNAs had become embedded in the inner 
mitochondrial membrane, preventing their accumulation in the matrix and therefore 
binding to mtDNA. The use of anti-sense therapies still provides an attractive option for 
the treatment of mtDNA diseases. However, the efficacy of their delivery into the cell 
needs to be increased, as does the efficiency of mitochondrial targeting and in particular 
the problem of unequivocal access to the mitochondrial matrix needs to be resolved.  
 
3.1.1. Cell membrane crossing oligomers 
To improve the likelihood of accumulation within the mitochondrial matrix, a new class 
of PNA based oligomers has been developed by our industrial partner Ugichem GmbH 
(Innsbruck, Austria). They have modified the solubility of PNA monomers by adding 
phosphonic ester side chains, creating a new type of monomer - the Ugimer. The 
addition of phosphonic esters confers amphiphilic properties to the Ugimers, enabling 
them to be soluble in both water and lipids. By hybridising mixtures of PNA and 
Ugimer monomers, Ugichem have developed nucleobase oligomers that can cross 
plasma membranes and accumulate in the cytosol without the need for transfection – 
“cell membrane crossing oligomers” (CMCOs). The difference in structure between 
PNA oligomers and CMCOs is shown in figure 3.1. 
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The use of phosphonic ester side chains generates an uncharged molecule that has the 
ability to cross cell membranes, a so called “self-transfecting” oligomer (Posch et al. 
2012). Although the ability to cross cell membranes has not been fully investigated for 
CMCOs, Stein and colleagues recently reported that “locked nucleic acids” (RNA based 
anti-sense oligomers) can be modified to cross cell membranes without transfection 
agents (Stein et al. 2010). The phosphonic esters are protected from enzymatic 
degradation due the phosphorus atom being directly linked to the adjacent carbon atom, 
something that is not found in biological systems where an oxygen atom is usually 
required to join the two. Furthermore the CMCOs are designed to enable conjugation of 
other molecules at their termini, conferring properties that may enable subcellular 
localisation.  
 
Other approaches currently used to target RNA, DNA or proteins to mitochondria utilise 
one of the transport mechanisms found within mitochondria, such as the TOM/TIM 
protein import system. Although there have been some claims of success at exploiting 
these import mechanisms to drive accumulation of molecular therapies into 
mitochondria (Srivastava and Moraes 2001; Comte et al. 2013), the fact that 
transfection of the cell is required to deliver the treatment to mitochondria makes these 
Figure 3.1-The backbone structure of PNAs and CMCOs.  
The addition of phosphonic acid is highlighted by the blue boxes; the letter B denotes 
a DNA nucleobase (adenine, cytosine, guanine or thymine).   
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treatments un-practical. By using CMCOs we aimed to address these issues by 
designing a self-transfecting oligonucleotide that could specifically target and 
accumulate in the mitochondrial matrix. By exploiting the ability of the CMCOs to 
passively cross plasma membranes, it was decided to conjugate a targeting molecule to 
the CMCO to drive its accumulation specifically within the matrix. The targeting 
molecules were selected based on their ability to accumulate within mitochondria as a 
function of their charge, a process that has been shown previously using lipophilic 
cations (Blaikie et al. 2006; Ross et al. 2008; Finichiu et al. 2013). It has also been 
demonstrated that these molecules can be used to drive the mitochondrial accumulation 
of larger compounds such as vitamin E (Kelso et al. 2001; James et al. 2003; Adlam et 
al. 2005) and superoxide dismutase (Kelso et al. 2012). 
 
 CMCOs as mtDNA anti-genomic agents 3.1.1.1.
Prior to the initiation of this project, developmental work was carried out to determine 
the optimal backbone composition (the number of phosphonic ester side chains) and 
overall oligomer length to hybridise to complementary DNA in vitro (Kyriakouli 2007). 
A “minimal mtDNA replisome”- an in vitro technique that mimics mtDNA replication 
using human mitochondrial polγ was used to demonstrate the ability of the CMCOs to 
selectively bind and inhibit the replication of a mtDNA insert (Falkenberg et al. 2000; 
Korhonen et al. 2003; Kyriakouli 2007). Binding of the CMCO to the mtDNA template 
abolished the extension of the template, stalling replication at the CMCO binding site. It 
was also found that the optimal CMCO length for mtDNA binding and replication 
inhibition was a 16mer molecule with a backbone that contained 6 phosphonic ester 
groups spread evenly throughout the molecule.  
 
A CMCO, complementary to MTCO1 (nt.5979-5994), was manufactured to investigate 
the binding of mtDNA and mitochondrial mRNA in cultured cells. A sequence 
homologous to wild-type MTCO1 was chosen as it enabled, with relative ease, the 
investigation of both steady state levels of COXI protein and mtDNA copy number. The 
CMCO, which used 2,4 dinitrophenol as a targeting molecule, was found to cause a 
40% decrease in mtDNA copy number when compared to a random sequence control 
molecule. A significant 70% decrease in the steady state level of COXI protein was also 
shown following 9 days incubation with HeLa cells (Kyriakouli 2007). These results 
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indicated that the targeted CMCO was having an anti-genomic effect on wild-type 
mtDNA, which led to a decrease in protein expression, highlighting the potential use of 
CMCOs in the treatment of disorders caused by inherited mtDNA mutations.  
 
Although this work showed promise, subsequent work using CMCOs derived from a 
similar synthesis protocol has failed to replicate these results. It was therefore decided to 
attempt to improve this work by developing a more robust targeting method to reliably 
enable the detection of the subcellular localisation of the CMCOs. This chapter will 
discuss the development and testing of a system to target CMCOs to mitochondria using 
small, lipophilic cations.  
 
3.2. AIMS 
This chapter describes work to target specific CMCOs to mitochondria. To achieve this, 
I addressed the following aims: 
I. To investigate the efficacy of CMCO mitochondrial targeting using several 
“mitochondrial targeting” moieties. 
 
II. To develop methods to detect the subcellular localisation of targeted CMCOs. 
 
III. To develop a system to efficiently deliver CMCOs to mitochondria in live cells.  
 
3.3. METHODS 
CMCOs were produced by Ugichem GmbH using the automated process described by 
Koch and colleagues (Koch et al. 1997). All CMCOs were analysed using HPLC/MS 
(high performance liquid chromatography/ mass spectrometry) to assess the purity of 
the molecules and to ensure that there were no unused reagents present in the final 
product. CMCOs were delivered in lyophilised form. 
 
3.3.1. CMCO preparation 
Lyophilised CMCOs were stored at -20
o
C to ensure minimal degradation. Using the 
mass produced and molecular mass data provided by Ugichem, CMCOs were 
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resuspended in a volume of PBS to generate a final concentration of 1mM. CMCO 
solutions were heated to 90
o
C for 5 minutes to ensure that the molecules were fully 
dissolved, after which tubes were stored on ice and a 5µl aliquot was taken from each 
solution for further analysis. 
 
 CMCO concentration 3.3.1.1.
Although the 1mM CMCO solutions were produced using the mass information 
provided by Ugichem, it was decided to confirm the concentration by calculating the 
optical density at 260nm using a CARY 300 Bio UV-visible spectrophotometer (Agilent 
technologies, USA). Using the additive monomer absorbance values (A260 EmM.cm
-1
) 
for PNAs (A=13.7, C=6.06, G=11.7, T=8.6), the expected absorbance was calculated 
for each CMCO sequence. A 1 in 1000 dilution of the CMCO aliquots in PBS (1ml final 
volume) was added to a 1ml quartz cuvette and absorbance at 260nm measured. The 
expected and actual absorbance was used to determine the final CMCO concentration. 
All CMCOs were aliquoted in appropriate volumes according to the observed 
concentration and stored at -20
o
C. 
 
3.3.2. CMCO dosing 
HeLa cells (1 x 10
4
/well) were grown on glass bottomed dishes (WillCo Wells B.V., 
The Netherlands) for 24 hours prior to dosing. CMCOs were defrosted to room 
temperature and then briefly heated to 90
o
C for 2 minutes to ensure they were fully 
dissolved, after which they were placed on ice. Each CMCO was diluted to an 
appropriate concentration (depending on the experiment) in the required complete 
media without FBS - this was to ensure the CMCOs were not sequestered by the large 
proteins, such as albumin, found in FBS. Media was removed and the cells washed 
twice in PBS, the CMCO containing media was added and incubated with cells for 2 
hours. After the initial incubation, 10% (v/v) FBS was added and the cells returned to 
37
o
C in a humidified atmosphere of 5% CO2 for the required length of time. 
 
3.3.3. Biotin detection 
Initial experiments in this chapter describe the use of biotin conjugated CMCOs. After 
incubation with biotinylated CMCOs, media was removed and cells washed three times 
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in PBS, after which PBS was removed and the cells fixed in ice cold 70% ethanol for 10 
minutes. Ethanol was removed and the cells allowed to air dry. Cells were 
permeabilised 0.1% TBST for 30 minutes at room temperature, after which they were 
incubated with a 1 in 1000 dilution of streptavidin Alexa Fluor 488 (Invitrogen, Paisley 
UK) in 0.1% TBST for 30 minutes in the dark at room temperature. Following 
incubation, cells were washed three times in 0.1% TBST before a final wash in PBS. 
Cells were mounted using Vectashield hard mount with DAPI (Vector laboratories, 
USA) and a coverslip applied to seal the cells in the glass bottomed dishes.  
 
3.3.4. Microscopy 
Imaging of streptavidin conjugated biotin-CMCOs was carried out by wide-field 
microscopy using a Zeiss Axiovert 200M microscope. All images were captured using a 
20x air objective using appropriate filter sets (DAPI: 365/445-50 Em/Ex, FITC: 475-
40/530-50 Em/Ex). All other imaging was carried out using a Nikon A1R point 
scanning confocal microscope at 37
o
C / 5% CO2. Appropriate lasers were used for each 
dye (488nm, 561nm and 647nm for MitoTracker Green/FITC, TMRM/TAMRA and 
ATTO 647N respectively).  
3.3.5. Statistical analysis 
Volocity software (Perkin Elmer, USA) was used for quantitative analysis of captured 
images. Microsoft excel was used to collate data and Prism (GraphPad, USA) was used 
to generate graphs. Prior to statistical analysis, all data set were subjected to a normality 
test using Minitab 16 statistical software (Minitab Inc.). 
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3.4. RESULTS 
3.4.1. CMCO targeting molecules 
To drive accumulation of the CMCOs into mitochondria, several targeting molecules 
were selected to conjugate to the CMCOs. Previous work has shown that conjugation of 
TPP (triphenylphosphonium) with large molecules, such as vitamin E, can be used to 
force them to accumulate in mitochondria. TPP is a lipophilic cation that has the ability 
to cross the plasma membrane (Ross et al. 2008). However, once it enters the cytoplasm 
the positively charged TPP (figure 3.2) goes on to specifically accumulate in 
mitochondria in a membrane-potential dependent manner (Finichiu et al. 2013). This is 
unusual as charged molecules are generally too hydrophilic to cross plasma membranes, 
and would therefore not be able to enter the cell, preventing mitochondrial 
accumulation. TPP crosses membranes due to the delocalised positive charge generated 
by the phosphonium ion being distributed across the three phenyl groups. This 
maintains the lipophilic properties of the molecule while also enabling the positively 
charged ion to force accumulation down the charge gradient maintained across the inner 
mitochondrial membrane. These features make TPP an attractive option for use in 
driving the accumulation of CMCOs into mitochondria.  
 
2, 4-dinitrophenol (DN) (figure 3.2) has been shown to increase proton leak of the inner 
mitochondrial membrane, dissipating the membrane potential and lowering the 
efficiency of oxidative phosphorylation (Weinbach and Garbus 1965). It has been 
postulated that it could act as an anti-obesity treatment by increasing the oxidation of 
fatty acids to produce ATP in lieu of oxidative phosphorylation (Blaikie et al. 2006), 
however it is too toxic to be used for this purpose as it has a very narrow therapeutic 
window. Although it cannot be used to treat obesity, it does target mitochondria and can 
cross plasma membranes. Therefore it was decided to test the ability of DN to target 
CMCOs to mitochondria. It was hoped that binding DN to the CMCO would disrupt its 
ability to act as an uncoupling protonophore (reducing its toxicity), while maintaining 
its ability to accumulate in mitochondria.  
 
Due to the expense of manufacturing conjugated CMCOs, it was decided to investigate 
the effects of TPP and DN on mitochondrial localisation prior to testing other 
compounds. A CMCO conjugated to a phenyl group via a lysine molecule (Pac-K) was 
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also manufactured as a negative control to confirm that an uncharged phenyl group does 
not have the ability to cause mitochondrial accumulation. The phenyl moiety was not 
expected to cause mitochondrial accumulation as it lacks a positive charge and is unable 
to become deprotonated; therefore it acted as a negative control in these experiments. 
The structure of Pac-K is shown in figure 3.2. 
 
 
3.4.2. Biotinylated CMCOs 
Three 16mer CMCOs were designed, each with a different targeting molecule (table 
3.1). CMCOs were conjugated to the targeting molecule via a lysine residue at their N 
terminal. Apart from the difference in targeting molecule, all CMCOs were identical 
with a sequence complementary to MTCO1 (np.5979-5994) consisting of 6 phosphonic 
ester containing Ugimers at nucleobase: 2, 4, 6, 12, 14 & 16. Previously it was indicated 
that this CMCO could accumulate in mitochondria where it went on to have an anti-
genomic effect (Kyriakouli 2007). This was in comparison to several other CMCOs that 
targeted different regions of MTCO1 and had different backbone structures (ratio and 
location of PNA:Ugimers), none of which showed an anti-genomic effect on mtDNA or 
led to a depletion of COXI protein.  
 
 
 
Figure 3.2 - The chemical structures of triphenylphosphonium (TPP), 2,4 dinitrophenol (DN) and 
phenyl (Pac-K).  
The R denotes the CMCO attached via a lysine molecule 
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Red letters in the sequence information highlights Ugimer position, Black letters represent PNA 
monomers.  
 
 
Biotin was chosen as the detection molecule for the CMCOs as it is relatively inert, 
uncharged and is therefore unlikely to interfere with mitochondrial targeting of the 
CMCO, it is also easy to detect using fluorescent conjugates of streptavidin. However, 
during the purification of the CMCOs there is a risk that biotin may degrade and will 
therefore not be detected after incubation with cells. Although there is a risk that biotin 
may not survive, it was still used, as conjugation of other detection molecules such as 
fluorescent compounds may interfere with the subcellular localisation of the CMCO. 
This is because many fluorophores contain charged regions which may either prevent 
the CMCO from crossing cell membranes due to a change in lipophilicity, or cause 
accumulation in another cellular compartment.  
 
 Detection and quantification of biotin conjugated CMCO import 3.4.2.1.
The uptake of CMCOs into HeLa cells was investigated to deduce whether the targeting 
molecules preserved their ability to cross cell membranes, and which targeting molecule 
showed the best mitochondrial localisation. To determine if the CMCOs had entered the 
cells, changes in biotin levels were measured using streptavidin conjugated to the 
fluorophore; Alexa Fluor 488, in addition nuclei were stained with DAPI (section 
3.3.3). If the CMCO had accumulated in the cell, it would be expected that there would 
be an increase in the amount of fluorescence detected; due to increased binding of 
streptavidin Alexa Fluor 488 (strep 488), when compared to basal fluorescence levels 
(due to endogenous biotin) in no dose control samples. To carry out this experiment, 
three repeat doses of each of the three CMCOs were performed, along with three repeats 
of a no dose control. The CMCOs were incubated with HeLa cells according to the 
Table 3.1 - List of sequences and targeting molecules used for biotinylated CMCOs.  
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methods described in section 3.3.2 at a concentration of 10µM for 48 hours (Kyriakouli 
2007). Cells were fixed and stained using the methods outlined in section 3.3.3 and 
imaged at 20x magnification using an inverted Zeiss Axiovert 200M microscope. Four 
images were taken per dose (12 in total) using filter sets appropriate for the excitation 
and emission spectra of DAPI and Alexa Fluor 488. Analysis of fluorescence intensity 
was performed using Volocity image analysis software (Perkin Elmer, USA). Median 
pixel intensity was used as a measure of the amount of fluorescence emitted from strep 
488 for the entire image. As each image was captured using the same exposure times, 
changes in pixel intensity directly reflect the amount of strep 488 and therefore the 
amount of biotin in the sample. The median intensity values for each of the CMCOs 
were grouped according to targeting molecule and compared to the no dose control 
using a Mann-Whitney U test. It was found that there was no significant difference in 
the amount of biotin for any CMCO when compared to the no dose control (figure 3.3).
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Figure 3.3 - Quantification of biotin using streptavidin conjugated Alexa Fluor 488 after 
HeLa cells were incubated with 10µM CMCO.  
Three repeat cultures per dose were produced and 4 images captured per repeat. Panels A, B, C & 
D show sample images of cells that have been incubated with the relevant CMCO. A shows 
endogenous biotin levels in no dose control cells. B, C and D show biotin in cells incubated with 
DN, Pac-K and TPP conjugated CMCOs respectively. Panel E shows median pixel intensity for 
each captured image group according to CMCO (12 images per CMCO). Panel F shows median 
pixel intensities for each repeat dose (4 images per repeat). Nuclei are stained with DAPI (blue). 
Scale is 20µm. 
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 Analysis of biotinylated CMCO targeting 3.4.2.2.
Panels A-D (figure 3.3) show representative images of HeLa cells stained with 
streptavidin Alexa Fluor 488 either as a no dose control or after incubation with a 
CMCO. Analysis of median pixel intensity of the images was performed blinded to 
ensure that there was no bias of the results. There was no increase in the level of strep 
488 in CMCO treated cells when compared to no dose controls. This was confirmed 
using a Mann-Whitney U test for non-parametric data, which failed to find a significant 
change in the sample.  
 
The TPP conjugated CMCO showed the largest variation in median intensities. The 
reason for this variation is shown in panel F of figure 3.3 which shows that one repeat 
dose had a higher intensity than the other wells. Although this was a significant increase 
when compared to any of the no dose control repeats (p=0.0044 Mann-Whitney U test) 
it is unlikely to have been caused by increased levels of biotin. This is because when the 
outlying data is grouped with the other TPP CMCO repeats it is no longer significant, 
nor is there any reason for this dose to show higher levels of biotin as all repeats were 
dosed using the same source of CMCO which was prepared in  the same way for all 
repeats. Therefore it is likely that the higher levels of biotin indicated by this repeat are 
due to experimental error rather than because of the CMCO.  
 
Although the evidence suggests that there is no increase in biotin levels in CMCO 
treated cells relative to no dose controls, it does not necessarily mean that there was no 
import of the CMCOs. Several factors could lead to the biotinylated CMCOs not being 
detected, as discussed below.  
 
Biotin degradation 
As mentioned previously, there was a high probability that biotin may have degraded, 
either during the manufacturing process or during purification of the CMCOs. If biotin 
was no longer intact then it is unlikely that streptavidin would bind the CMCOs and 
therefore no increase in signal above endogenous levels would be detected.  
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Low levels of CMCO import may not be detected 
There is a relatively high level of biotin endogenously expressed by cells, in particular 
within the mitochondria, where it acts as a cofactor in enzymatic reactions (Tong 2013). 
If the amount of biotin on the CMCOs is low due to degradation or because the ratio of 
biotin to CMCO is less than 1:1, it is possible that the extra signal caused by the CMCO 
biotin is not detected above endogenous levels.  
 
CMCOs may not be retained in cells after fixation 
Cells were fixed in 70% ethanol prior to staining with streptavidin; however it may be 
that the CMCOs are too small to be fixed sufficiently. This is a possibility as their small 
molecular mass may prevent them from being held in place when the cell is fixed. This 
could lead to a situation where the CMCOs may “leak” out of the cell membrane upon 
subsequent washes, lowering the amount of signal detected when stained. PFA fixation 
may not improve this as it covalently crosslinks proteins (Shi et al. 2001), and as the 
CMCOs only contain one lysine residue, it is unlikely that this method will fix them.  
 
These factors, although possibly controllable, make biotin an unattractive option for use 
as a detection molecule and as a result of this experiment, it was decided to re-design 
the CMCOs and use a different targeting molecule. 
 
3.4.3. Fluorescently labelled CMCOs 
Due to the potential issues with fixation, it was decided to use a detection molecule that 
does not require additional labelling in order to measure its abundance and can therefore 
be detected in live cells. Fluorescent molecules are the best choice for this application as 
they emit light without the need for antibody or streptavidin based detection. They are 
also relatively bright when compared to background cellular auto-fluorescence which 
means that it should be easy to detect the presence of a molecule if it is within the cell. 
This will solve the issues experienced when trying to detect small increases in the level 
of biotin; however, several factors need to be considered when choosing a fluorophore, 
all of which are discussed below. 
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 Cellular autofluorescence 3.4.3.1.
It is important to choose a fluorescent molecule that emits light in a region of the 
spectrum distinct from the majority of cellular autofluorescence. This occurs primarily 
in the shorter wavelength regions of the spectrum (blue light) and gets progressively 
less common as wavelength increases (figure 3.4). NADH and FADH (two molecules 
that are abundant in the mitochondria) have been shown to auto-fluoresce in the blue 
and green region of the spectrum respectively (Andersson et al. 1998; Rodrigues et al. 
2011). Green and red fluorescence is also emitted by lipofuscin, lipid containing 
residues of lysosomal degradation (Schnell et al. 1999). 
 
 
Although most fluorophores are used at sufficient concentration to be detected above 
the background of cellular autofluorescence, if the conjugated CMCO shows poor 
accumulation within cells then it may be necessary to increase the exposure time in 
order to detect emitted light, thus increasing the likelihood of false positives caused by 
detection of autofluorescence. To minimise the likelihood of this occurring it was 
decided to use a fluorophore that emits light at a wavelength that is distinct from the 
auto-fluorescent regions of the spectrum, therefore a red or far red light emitting 
fluorophore was most appropriate.  
 
 Uptake of the fluorophore into live cells and subcellular localisation 3.4.3.2.
As the fluorophore will be conjugated to CMCOs, it is important that the ability to 
accumulate in live cells is not compromised by the addition of the fluorophore. 
Furthermore it is vital that the fluorophore does not alter the ability of the CMCOs to 
Figure 3.4 - A schematic showing the relationship between wavelength and cellular 
autofluorescence.  
The frequency of compounds which auto-fluoresce at a given wavelength decreases as wavelength 
increases, causing less cellular autofluorescence.  
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localise to mitochondria. The ideal fluorophore for this application therefore is a 
mitochondrial localising dye. 
Mitochondrial dyes are a group of fluorophores that specifically stain mitochondria in 
live cells, generally as a function of the mitochondrial membrane potential. A list of 
potential dyes is shown in table 3.2.  
 
 
 
 
Optimal concentrations were those given by the manufacturer or referred to in the literature (Scaduto 
and Grotyohann 1999). Proprietary dyes are still under patent protection and not available for use 
conjugation with other molecules. Toxicity is defined as the likelihood that respiration is inhibited by 
the dye when used at the optimal concentration. 
 
 
Proprietary fluorophores were not used as they are not produced in forms that enable 
efficient conjugation to the CMCOs. As a result of this, none of the MitoTracker dyes 
were used in this assay, despite them having low toxicity and, in the case of 
MitoTracker Red, the ability to be fixed within mitochondria. Of the three remaining 
dyes, Rhodamine 123 was not selected as it emits light in the green region of the 
spectrum, which may overlap with cellular autofluorescence and is highly toxic. TMRM 
and TAMRA are derivatives of rhodamine which both show membrane potential 
dependent mitochondrial localisation at low concentrations. While both dyes were 
suitable for marking the CMCOs, it was decided to use TAMRA as it is routinely 
conjugated to DNA oligonucleotides for use in quantitative PCR (Heid et al. 1996). 
TAMRA is freely available with chemical modifications which enable the labelling of 
the CMCOs without disrupting its fluorescent properties.   
 
 
Table 3.2 - Characteristics of commonly used live cell mitochondrial dyes. 
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3.4.4. Visualisation of mitochondrially targeted CMCOs using TAMRA 
TAMRA conjugated CMCOs were manufactured with the same sequence and 
Ugimer:PNA ratio as described in section 3.4.1, a list of which is shown in table 3.3. 
Each CMCO was conjugated to TAMRA and its relevant targeting molecule in a 1:1 
ratio.  
Red letters in sequence information highlights Ugimers, Black letters represent PNA monomers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 - List of sequences and targeting molecules used for TAMRA conjugated CMCOs.  
Figure 3.5 - The chemical structures of targeting molecules.  
Triphenylphosphonium (TPP), mononitrophenol (MN), phenyl 
(Pac-K) and acetyl (AC).R denotes the CMCO conjugated via a 
lysine molecule.  
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After consultation with Ugichem, it was decided to replace the targeting molecule DN 
with mononitrophenol (MN) due to the expense of manufacturing DN conjugated 
CMCOs. The ability of MN to target mitochondria is unclear; however it was decided to 
investigate it in lieu of DN. An acetyl (AC) conjugated CMCO was produced in order to 
test the ability of TAMRA to drive accumulation into mitochondria in the absence of a 
specific targeting molecule. The structures of the targeting molecules to be used in 
TAMRA CMCOs are shown in figure 3.5.   
 
HeLa cells were incubated with 10µM TAMRA CMCOs for 24 hours prior to imaging 
according to section 3.3.2. Prior to imaging, cells were incubated with 50nM 
MitoTracker green for 30 minutes and subsequently washed three times in PBS before 
the addition of Phenol Red free complete HeLa media. Phenol red was omitted as it 
auto-fluoresces in the green and red regions of the spectrum. Images were captured 
using a Nikon A1R point scanning confocal microscope (Nikon, Japan) using the 
excitation and emission settings shown in table 3.2. All images were captured at 37
o
C in 
a humidified atmosphere of 5% CO2. Subcellular localisation of TAMRA-CMCOs in 
relation to MitoTracker Green is shown in figure 3.6. 
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Figure 3.6 - Subcellular localisation of TAMRA conjugated CMCOs in relation to mitochondria 
stained with 50nM Mitotracker Green.  
HeLa cells were incubated with 10µM CMCO for 24 hours prior to staining with 50nM MitoTracker 
Green and imaged using a point scanning confocal microscope. The left hand column shows 
MitoTracker Green staining; the centre column shows signal obtained from TAMRA-CMCOs and the 
right hand column shows the merged imaged of CMCO (red) and Mitotracker Green (green) staining – 
colocalisation shows up as yellow regions. Cells in panels A-C were incubated with 
triphenylphosphonium targeted CMCOs, D-F mononitrophenol targeted CMCOs, G-I were incubated 
with phenyl targeted CMCOs and J-L were incubated with acetyl targeted CMCOs. Scale bar represents 
10µm.  
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Volocity software was used to generate a Pearson’s correlation coefficient in order to 
quantify the degree of colocalisation of MitoTracker Green and the CMCOs. Using the 
method described by Costes and colleagues, regions which showed staining for both 
dyes (MitoTracker and TAMRA) were classed as colocalised. The proportion of these 
regions in relation to non-colocalised regions was then calculated – a coefficient ranging 
from one to zero was determined by Pearson’s correlation analysis (one represents 
perfect colocalisation, zero represents no colocalisation).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 shows that the best colocalisation with mitochondria was achieved when 
using MN as a targeting molecule. Although TPP is regularly used to target small 
molecules to mitochondria, for this application the colocalisation achieved was lower 
than when using MN. This may have been due to the increased formation of CMCO 
aggregates which are visible as areas of puncta (dense white dots) seen in panel B figure 
3.6, possibly leading to the sequestration of the CMCO and preventing access to 
Figure 3.7 - Colocalisation coefficients of TAMRA conjugated 
CMCOs with MitoTracker Green.  
Error bars represent standard deviation of analysed cells (n=40). 
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mitochondria. As expected, the use of uncharged Pac-K did not lead to mitochondrial 
localisation, but led to severe aggregation of the CMCO (panel H, figure 3.6). The 
TAMRA-AC-CMCO did show some mitochondrial localisation, however this was 
much lower than the TPP or MN conjugated molecules. This shows that TAMRA may 
have had the ability to drive accumulation of the CMCOs into mitochondria (due to its 
ability to localise to mitochondria in its unconjugated form), the fact that there is an 
increase in colocalisation when using MN or TPP compared to the non-targeting AC 
CMCO, indicates that the targeting molecules are essential for the CMCOs to localise to 
mitochondria.  
 
 FITC conjugated CMCOs 3.4.4.1.
To understand the relationship between the fluorescent molecule and CMCO targeting, 
TAMRA was replaced with FITC (fluorescein isothiocyanate). This was to ascertain 
whether MN (the targeting molecule with the greatest mitochondrial accumulation) had 
the ability to drive mitochondrial localisation in the absence of TAMRA. The FITC 
CMCO was incubated with HeLa cells for 24 hours and imaged as described previously. 
As FITC emits green light (495/519nm Ex/Em), the use of MitoTracker Green to 
highlight mitochondria was not possible, therefore 100nM MitoTracker Deep Red 
(644/665nm Ex/Em) was used. To ensure mitochondrial autofluorescence was not 
mistaken for FITC fluorescence, a no dose control was imaged to determine the 
maximum possible laser power that could be used without detecting autofluorescence. 
These laser settings were used to image the FITC CMCO incubated cells (figure 3.8).  
 
Figure 3.8 shows that very little fluorescence was detected from the FITC CMCO when 
compared to MitoTracker Deep Red. This could be due to the fluorescent properties of 
FITC being compromised by conjugation to the CMCO (which could inhibit the 
fluorescent excitation of the molecule), leading potentially to lower detected 
fluorescence. It could also be due to FITC decreasing the ability of the CMCO to 
accumulate within the cell. In order to establish the localisation of the FITC CMCO, it 
was necessary to increase the laser power of the microscope to increase excitation of the 
fluorophore. However, this was not possible as mitochondrial autofluorescence (caused 
by FADH) prevents the detection of the fluorescence emitted by FITC. It was therefore 
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decided to replace FITC with a fluorophore that has a higher quantum yield (brightness) 
which will enable accurate detection at lower concentrations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.5. ATTO 647N conjugated CMCOs 
To address the issues experienced with the FITC-MN-CMCOs, ATTO 647N (ATTO-
TEC GmbH, Siegen) was used as a detection molecule as it has a high quantum yield, 
emits light in the far red region of the spectrum (644nm/669nm Ex/Em) and is available 
in forms conducive to CMCO conjugation. The use of ATTO Tec dyes was 
recommended by Ugichem. It was decided to manufacture ATTO conjugated CMCOs 
with TPP, MN or acetyl targeting groups in order to assess their targeting abilities in the 
absence of TAMRA (table 3.4). Pac-K was not chosen as a targeting molecule due to 
the poor localisation seen in figure 3.6. HeLa cells were incubated with the relevant 
CMCO for 24 hours prior to incubation with 50nM MitoTracker Green and imaged. 
Colocalisation was calculated as described previously. Captured images and 
colocalisation graphs are shown in figure 3.9 and figure 3.10 respectively. 
Figure 3.8 - Subcellular localisation 
of 10µM FITC conjugated CMCO 
in relation to 100nM MitoTracker 
Deep Red. 
 HeLa cells were incubated with 
10µM CMCO for 24 hours prior to the 
addition of 100nM MitoTracker Deep 
Red. A shows fluorescence emitted by 
FITC CMCO. B shows mitochondria 
stained with Mitotracker Deep Red. C 
shows the merged image – purple 
represents Mitotracker Deep Red, 
green represents FITC. Scale is 10µm.   
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Red letters in the sequence information highlights Ugimers, Black letters represent PNA monomers. 
 
Figure 3.9 - Subcellular localisation of ATTO 647N conjugated CMCOs in relation to 
mitochondria stained with 50nM Mitotracker Green.  
HeLa cells were incubated with 10µM CMCO for 24 hours prior to staining with 50nM MitoTracker 
green and imaged using a point scanning confocal microscope. The left hand column shows 
MitoTracker green staining; the centre column shows signal obtained from ATTO-CMCOs and the right 
hand column shows the merged imaged of CMCO (purple) and Mitotracker green (green) staining. 
Colocalisation is shown by regions of blue/light purple. Cells in panels A-C were incubated with 
triphenylphosphonium targeted CMCOs, D-F mononitrophenol targeted CMCOs, G-I were incubated 
with acetyl targeted CMCOs. Scale bar represents 10µm 
Table 3.4 - List of sequences and targeting molecules used for ATTO 647N conjugated 
CMCOs.  
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To determine if the ability of the CMCOs to colocalise with mitochondria was altered 
by the use of different detection dyes, colocalisation coefficients for both ATTO and 
TAMRA conjugated CMCOs were calculated by analysing 40 individual cells (figure 
3.10). The graph shows that the level of colocalisation with mitochondria is 
significantly higher (p<0.0001, Mann-Whitney U test) in all ATTO 647N CMCOs when 
compared to TAMRA CMCOs. As with TAMRA conjugated CMCOs, the greatest 
colocalisation was seen when MN was used as a targeting molecule (median coefficient 
of 0.8645). The fact that the non-targeted AC-CMCO shows an increase in 
colocalisation suggests that the ATTO dye may have the ability to drive mitochondrial 
localisation in the absence of a targeting molecule and therefore free ATTO 647N may 
stain mitochondria in live cells.  
 
 
Figure 3.10 - Colocalisation coefficients of ATTO 
647N conjugated CMCOs and TAMRA conjugated 
CMCOs with MitoTracker Green. 
Error bars represent standard deviation, n=40. A Mann-
Whitney U test was used to test significance, 
***=p<0.0001 
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 Un-conjugated ATTO 647N as a mitochondrial dye 3.4.5.1.
To investigate the ability of ATTO 647N to be used as a mitochondrial stain, 10µM of 
the dye was incubated with HeLa cells for 24 hours. Prior to imaging, mitochondria 
were labelled with 5nM TMRM, a live cell mitochondrial stain. Cells were imaged 
using a Nikon A1R confocal microscope and the colocalisation coefficient calculated as 
described previously. A sample image is shown in figure 3.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The colocalisation coefficient for the ATTO 647N and TMRM had a median value of 
0.8915, indicating almost perfect colocalisation between the two dyes. This finding 
highlights the fact that ATTO 647N has a tendency to strongly localise to mitochondria 
in live cells. Although the structure of the dye has not been published, the 
manufacturers state that it is a cationic molecule, which may enable it to specifically 
target mitochondria due to the relative negative charge of the organelle.  
Figure 3.11 - Colocalisation of 
ATTO 647N dye with the 
specific mitochondrial stain 
TMRM.  
HeLa cells were incubated with 
10µM ATTO 647N (purple) for 24 
hours before staining with 5nM 
TMRM (red). Images were 
captured using a Nikon A1R 
confocal microscope. 
Colocalisation is shown by regions 
of pink staining on the merged 
image. Scale bar represents 10µm.  
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To determine if ATTO 647N accumulates in mitochondria as a function of the 
membrane potential, the effect of FCCP on mitochondrial localisation was investigated. 
FCCP is an ionophore, which transports hydrogen ions from the intermembrane space to 
the matrix, destroying the proton gradient and uncoupling respiration (Benz and 
McLaughlin 1983). Therefore, upon addition of FCCP, the mitochondrial membrane 
potential will dissipate and any molecules that depend on the potential to accumulate in 
mitochondrial will diffuse into the cytosol.  
 
HeLa cells stained with 10µM ATTO 647N were imaged over a period of 14 seconds, 
after which 10µM FCCP was added and the cells imaged for a further 14 seconds 
(figure 3.12). 
 
The effect of FCCP addition is clearly visible as the pattern of ATTO 647N staining 
changes from a reticular form associated with mitochondrial staining to a more diffuse 
cytoplasmic pattern. This indicates that ATTO 647N localises to the mitochondria as a 
function of the membrane potential, and highlights its potential use as a mitochondrial 
stain. 
 
 
Figure 3.12 - The effect of 
10µM FCCP on the 
localisation of ATTO 647N.  
HeLa cells were incubated with 
10µM ATTO 647N for 24 hours 
prior to imaging. Frames were 
captured every 7 seconds. After 
14 seconds FCCP was added to 
a final concentration of 
10µM.Scale bar represents 
10µm.  
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3.4.6. mtDNA staining by ATTO 647N-MN-CMCOs 
In order for CMCO’s to have an anti-genomic effect on mtDNA, it is essential that they 
have access to the mitochondrial matrix. The results presented so far suggest that ATTO 
conjugated CMCOs are localising to mitochondria, however their location within 
mitochondrial is unclear. One way to see if the CMCOs have accessed the matrix is to 
see if they localise with mtDNA in live cells. A 1 in 1000 dilution of Picogreen 
(Invitrogen, Paisley UK), a fluorescent DNA intercalator which can accumulate in 
mitochondria as well as the nucleus, was used to stain mtDNA in fibroblasts incubated 
for 24 hours with ATTO 647N-MN-CMCO. Fibroblasts were chosen due to their flat 
morphology which leads to mitochondria having a planar distribution, in contrast to 
HeLa cells which are more ovoid in structure and therefore the mitochondria overlap in 
3D space, thus making it harder to accurately image mtDNA.  
 
Although it is possible to stain mtDNA, the fact that the ATTO CMCOs localise to the 
entire mitochondrial network means that it is impossible to detect specific localisation 
to mtDNA, due to the high levels of background network staining. It was decided to add 
10µM FCCP to the cells in order to equilibrate free CMCO between the network and 
cytosol (as it is likely to localise in a membrane potential dependent manner), thus any 
CMCO bound to mtDNA will remain and be expressed as regions colocalised with 
Picogreen staining. Prior to addition of FCCP, cells were also stained with 5nM TMRM 
to indicate when the membrane potential has dissipated. Images of one cell were 
captured every second for one minute, with FCCP added 21 seconds after the first frame 
was captured. Figure 3.13 shows sample images of the cell before FCCP addition and 
then 2 and 30 seconds post addition. A region of interest is highlighted by the white 
boxes; this will be investigated further in (figure 3.15). 
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The staining of TMRM and ATTO-MN-CMCO shows excellent colocalisation – as 
highlighted by the pink regions in the merged image – before the addition of FCCP. 
However, after FCCP is added the TMRM staining becomes more diffuse as the dye 
leaves the mitochondria and equilibrates with the cytosol (2 seconds post addition), this 
continues until a uniform distribution of the dye is seen 28 seconds later. Interestingly 
the same pattern of diffusion is not shown by the CMCO, which is contrary to what was 
seen with both TMRM and free ATTO 647N dye (figure 3.12). 30 seconds after FCCP 
addition there is still some CMCO localised to mitochondria, although the proportion of 
mitochondrial localised CMCO and the overall intensity of the signal has decreased due 
to cytosolic diffusion. The time taken for it to diffuse back into the cytosol highlights 
Figure 3.13 - The effect of 10M FCCP on a fibroblast cell stained with 10M ATTO-MN-
CMCO, 1 in 1000 Picogreen (Invitrogen, UK) and 5nM TMRM.  
Images show the localisation of individual dyes along with a merged image of all the dyes combined. 
Individual columns show the staining of the cell before the addition of FCCP, 2 seconds after the 
addition and 30 seconds after addition. White boxes highlight a region that will be investigated 
further in figure 3.15. Scale bar represents 10m.  
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the possibility that the ATTO-MN-CMCO may not be accumulating as a function of the 
membrane potential and that the MN could be driving accumulation by another means. 
This trend is quantified in figure 3.14, which shows the effect of FCCP addition on the 
intensity of TMRM and ATTO fluorescence. The sharp decline seen in the intensity of 
TMRM staining upon FCCP addition is due to the dye entering the cytosol and 
becoming less concentrated, thus decreasing in intensity. Although a decrease in the 
intensity of ATTO fluorescence is also seen, this is far less steep than the decline in 
TMRM intensity.  
 
Throughout the time course, picogreen staining has not decreased in response to FCCP 
addition, which will enable the analysis of the region of interest, highlighted by the 
white boxes shown in figure 3.13.  
 
The region of interest shown in figure 3.13 was investigated further to determine if there 
was colocalisation of the remaining ATTO-MN-CMCO with mtDNA stained with 
Figure 3.14 - Relative fluorescence intensity of 5nM TMRM and 10M ATTO-MN-CMCO in 
fibroblast cells. 
Intensity of the dye over a 60 second period was calculated using Volocity software and normalised. 
The addition of 10M FCCP is shown by the dotted line.  
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picogreen. The area was monitored 40 seconds after FCCP exposure to increase the 
chance that unbound ATTO-MN-CMCO had dispersed into the cytoplasm. Although 
some reticular CMCO remained, there was a danger that imaging would either cause 
bleaching or photo-toxicity, therefore mtDNA binding assessment 40 seconds after 
FCCP addition was chosen as a compromise.
 
Figure 3.15 - Time lapse images of colocalised mtDNA and ATTO 647N-MN-CMCO.  
Images were taken 40 seconds after FCCP exposure (figure 3.13) for 4 seconds. Individual rows show 
picogreen mtDNA staining, ATTO 647N-MN-CMCO, and the merge of the two stains. The arrow 
highlights the mtDNA nucleoid of interest. Scale bar represents 10m.  
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Still images of the magnified region of interest were captured over a period of 20 
seconds, a sample of these images, in which colocalisation of picogreen and 
ATTO647N-MN-CMCO is shown, are displayed in figure 3.15. The arrows highlight 
mtDNA stained with picogreen (probably in a nucleoid complex) and the corresponding 
region of ATTO 647N signal which colocalised. Although there are other regions of 
intense ATTO 647N staining on the images, these are not colocalised with picogreen 
and can therefore not be classed as definitely mitochondrially localised (they may be 
areas of aggregated CMCO). The fact that there is colocalised signal of the CMCO with 
picogreen could suggest that these particular molecules of mtDNA have bound CMCO 
and therefore prevented its diffusion from mitochondria after FCCP addition. If the 
CMCO has not bound mtDNA and the colocalisation is coincidental i.e. this particular 
region of the network has retained the CMCO and also contains mtDNA, it is still 
interesting as it shows CMCO retention in the mitochondrial network even after 
depolarisation. This provides more evidence that the CMCO does not accumulate in a 
membrane potential dependent manner, a potential mechanism for accumulation will be 
discussed in the next section. Although these results provide some evidence of CMCO 
binding mtDNA, at the image resolutions shown it is impossible to tell if the CMCO has 
accumulated in the matrix and has access to mtDNA. 
Chapter Three Targeting anti-genomic therapies to mitochondria 
103 
 
3.5. DISCUSSION 
 
3.5.1. Mitochondrial targeting of CMCOs 
This work shows that CMCOs have the ability to cross the cell membrane and, with the 
addition of a targeting molecule, they can also specifically localise to mitochondria. The 
addition of fluorescent molecules (which have a inate ability to accumulate in 
mitochondria) enables the visualisation of CMCOs in live cells without preventing 
mitochondrial targeting. I have shown that the use of different targeting molecules 
affects the degree of mitochondrial localisation and shown that CMCOs conjugated to 
MN have the greatest ability to localise to mitochondria. 
 
As the detection dyes had the ability to localise to mitochondria it was sensible to 
assume that the dyes may also play a role in driving the CMCO accumulation into 
mitochondria. This was shown to be the case as ATTO 647N conjugated CMCOs 
showed a much more efficient mitochondrial localisation than TAMRA conjugates. 
This was surprising as it had not yet been reported that free ATTO 647N localises to 
mitochondria in live cells. It is likely that ATTO 647N accumulates in mitochondria as 
a function of the membrane potential, as shown by the change in localisation of the dye 
after 10µM FCCP addition.  
 
The use of targeting molecules to drive the accumulation of anti-sense therapies into 
mitochondria is only possible when used in conjunction with oligomers that have the 
ability to diffuse across plasma membranes, such as CMCOs. Although previous work 
had demonstrated that CMCOs could be localised to mitochondria using targeting 
molecules (Kyriakouli 2007) attempts to repeat this using biotinylated CMCOs failed. 
Therefore the use of mitochondrial dyes to aid detection and possibly localisation led to 
progress in understanding the differential abilities of the targeting molecules to cause 
localisation with the following higher order now established: 
MN>TPP>AC>Pac-K 
In order to create an anti-sense therapy for mtDNA disease, accumulation in the matrix 
to access mtDNA has to be assured. Although this work has not proven matrix 
localisation, I have shown that ATTO 647N-MN-CMCOs are retained and some may 
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colocalise with mtDNA after the dissipation of membrane potential, and while it is 
impossible to determine the sub-mitochondrial localisation of the CMCOs using 
currently available microscopy techniques, the fact that some localisation was observed 
provides circumstantial evidence that this CMCO can access the matrix.  
 
The gold standard to assess the ability of the CMCOs to enter the matrix is to show that 
they have a functional effect on replication or translation. However, in the absence of 
activity it is important to show that the CMCOs are accessing the matrix (in order to 
understand an absence of functional effects), this will be discussed further in chapter 7.  
 
3.5.2. Mitochondrial accumulation of MN 
In this work CMCOs were targeted to mitochondria using MN, which was chosen as a 
replacement for dinitrophenol, due to the cost associated with using 2,4 DN as a 
targeting molecule. However, although there were no reports suggesting that MN could 
accumulate in mitochondria, this work has shown that there is an increased localisation 
to mitochondria when using MN in conjunction with either TAMRA or ATTO 647N 
detection systems, indicating that MN does have the ability to specifically accumulate 
within mitochondria.  
 
Unlike TPP, whose mitochondrial accumulation is well studied, MN does not contain a 
caged positive charge so it is unlikely that it will accumulate in mitochondria as a 
function of membrane potential. The fact that MN is a weak acid with a pKa 
(dissociation constant) of 7.23 in water may explain its mitochondrial accumulation 
(Schwarzenbach et al. 1988). This means that it has the ability to lose a hydrogen ion 
under certain conditions, which changes its ability to cross cell membranes as the 
molecule becomes ionised and less lipophilic.  
 
When in solutions around pH 7.4, the vast majority of MN is in a lipophilic, non-ionic 
form. As this is the approximately the same pH as the cytosol, MN is therefore free to 
cross plasma membranes including the mitochondrial membrane. However, under more 
alkaline conditions, such as in the matrix which has a pH of 7.8, the proportion of MN 
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molecules which have lost a H
+
 increases. These deprotonated forms of MN can no 
longer cross plasma membranes and become partitioned in the matrix (figure 3.16).  
 
Upon addition of FCCP the inner mitochondrial membrane becomes permeable to H
+
 
ions, which have been transported into the intermembrane space to create an 
electrochemical gradient to drive ATP synthesis. The influx of H
+
 ions into the matrix 
will lower its pH until it decreases to pH 7.4 in equilibrium with the cytosol. This is turn 
will cause the proportion of deprotonated MN to decrease, therefore increasing the 
proportion of MN that can diffuse across the mitochondrial membranes and re-enter the 
cytosol. However, there will still be a small amount of MN that is deprotonated and will 
still be retained in the matrix, which may explain why mitochondrial localisation or 
ATTO 647N-MN-CMCO was maintained (apart from mtDNA binding) even 
immediately after FCCP addition.  
 
 
 
Figure 3.16 - Schematic showing the proposed mechanism of MN accumulation into the matrix.  
Under cytosolic pH, the majority of MN can cross the mitochondrial membranes freely (green arrows). 
Once in the more alkaline conditions of the matrix the proportion of deprotonated MN increases due to 
its weakly acidic properties. This deprotonated form cannot cross the mitochondrial membranes (red 
arrow) and is therefore sequestered in the matrix. 
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3.6. CONCLUSIONS 
The use of fluorescent mitochondrial probes in conjunction with targeting molecules 
enabled real-time assessment of localisation of CMCOs within cells. Unfortunately, 
current live cell microscopy techniques do not offer the resolutions required to 
accurately assess the sub-mitochondrial localisation. Although super resolution 
microscopy techniques are offering insights into the fine structure of mitochondria, 
these currently require the cells of interest to be fixed and imaged in an oxygen 
scavenging environment, something that is not appropriate when using CMCOs. These 
techniques can also only be used in conjunction with fluorophores that can “blink” - a 
process by which the emitted fluorescence of the fluorophore can be repeatedly turned 
off and on again. This enables the location of the centre point of the fluorescent 
molecules to be pinpointed, offering resolutions as low as 10nm (Rust et al. 2006; 
Huang et al. 2008; Bates et al. 2013).  
 
Although this work has shown mitochondrial localisation of CMCOs, the only way to 
prove that they have access to mtDNA or mt-mRNA is to show that there is a functional 
effect on either replication or translation, leading to decreased production of COXI 
protein. This will be discussed in the following chapter.  
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4 Functional analysis of mitochondrially localised MTCO1 
complementary CMCOs     
 
4.1. INTRODUCTION 
The previous chapter described the development of targeted CMCOs and their 
localisation to mitochondria. Although mitochondrial targeting was achieved, sub-
mitochondrial localisation was impossible to determine using imaging techniques. It 
was therefore decided to investigate the anti-genomic effects of the MN-CMCOs (with 
or without fluorescent moieties) on mtDNA copy number and COXI expression. 
 
In order for the CMCOs to have an effect in man they must enter the cytoplasm and 
then specifically target and accumulate within the mitochondrial matrix before binding 
to mutated regions of mtDNA or mt-mRNA (figure 4.1). In order to prove the concept 
of CMCO anti-genomic therapies, CMCOs were designed to be complementary to wild 
type MTCO1 (np.5979-5994). This enabled the use of healthy cells with wild-type 
mtDNA, preventing the potential difficulties associated with using heteroplasmic 
mutant cell lines such as mutation loss over time. In work done previously, this 
sequence showed the greatest efficacy at causing an apparent decline in mtDNA copy 
number and COXI protein expression (Kyriakouli 2007). 
 
Previous in vitro work has shown that CMCO binding to mtDNA stalls replication by 
preventing the progress of Polγ (Kyriakouli 2007). Stalling of replication in vivo is 
likely to lead to the degradation of affected genomes, which in turn will lower copy 
number (Goffart et al. 2009) and as a result of this the steady state levels of all encoded 
proteins will decrease. If the CMCO hybridises mt-mRNA, translation is likely to be 
affected as the CMCO will prevent tRNA binding or ribosomal progression and 
therefore decrease the steady state levels of COXI without affecting mtDNA copy 
number. The outcomes of CMCO binding are summarised in figure 4.1. 
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This chapter focuses on the functional assessment of CMCOs targeted to mitochondria 
using mononitrophenol (MN) either on its own or in conjunction with a fluorophore. 
Any differences in the functional effect of the CMCOs will provide an insight into the 
most efficient method of targeting the matrix. It was also decided to test CMCOs with 
base substitutions to investigate their ability to bind mtDNA in vivo. This will primarily 
act as a control for CMCOs homologous to MTCO1; however it may also provide an 
insight into the ability of the CMCOs to specifically bind only one species of mtDNA 
and indicate the appropriateness of their use in targeting mtDNA with point mutations.  
 
The work carried out in this chapter was severely limited by the amount of CMCO 
available for experiments. Ideally several repeat doses should be carried out on large 
numbers of cells in order to provide enough material to analyse in a statistically robust 
manner. This was not possible due to financial and time constraints experienced by 
Ugichem during production of the CMCOs used in this chapter. This was unfortunate as 
the functional effect of the CMCOs could not be fully elucidated or validated. The 
results presented in this chapter indicate the preliminary investigations and highlight 
problems in cell and assay variability, as well as an inability to repeat key experiments.  
Figure 4.1- Schematic showing the downstream effects of CMCO 
binding to either mtDNA or mt-mRNA.  
Binding of the CMCO to mtDNA (panel A) will decrease mtDNA 
copy number, and therefore protein expression. CMCO binding to 
mitochondrial mRNA (panel B) will not affect mtDNA expression, but 
will decrease COX1 protein expression.  
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4.2. AIMS 
In order to expand the optimisation of mitochondrially targeted CMCOs, I investigated 
the effect of these molecules on mtDNA and protein: 
 
I. To investigate the effect of targeted CMCOs on COXI steady state levels and 
mtDNA copy number in HeLa cells. 
II. To determine which targeting and detection molecule combination has the 
greatest functional effect. 
 
4.3. METHODS 
 
4.3.1. CMCO dosing 
All CMCOs were prepared for incubation as described previously in section 2.6.1 and 
diluted to an appropriate concentration. HeLa cells were seeded in 24 well plates (1 x 
10
4
 cells/well) in complete media and allowed to grow overnight. Prior to CMCO 
addition, media was removed and the cells washed three times in PBS before the 
addition of FBS free HeLa media. A CMCO was added to each well to a final 
concentration of 10M (calculated using the method described in section 2.6.1) and the 
cells placed back in the incubator in standard conditions. After 2 hours incubation, 10% 
FBS (v/v) was replaced and the cells placed back in the incubator (a 2 hour period was 
chosen as uptake experiments have shown that CMCOs accumulate within cells after 2 
hours) (Kyriakouli 2007). Cells were allowed to grow until 90% confluent (roughly 4 
days) after which they were passaged and seeded in fresh plates at the same density as 
previously (1 x 10
4
 cells/well). Cells were allowed to settle and adhere to the plate for 6 
hours, before media removal and CMCO addition in FBS free media as described 
above. 10% FBS (v/v) was added to the media after 2 hours and the cells placed back in 
the incubator. This process was repeated for the duration of the experiment.  
 
4.3.2. Cell harvesting and lysate preparation 
At the experiment endpoint, HeLa cells were harvested as described in section 2.2.1. 
Cells were placed in a universal tube and centrifuged at 160g for 4 minutes. The 
supernatant was aspirated and the pellet re-suspended in 1ml PBS, after which 500l 
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was placed in a fresh universal. Both aliquots were centrifuged at 160g for 4 minutes. 
Whole cell protein lysate was prepared from one aliquot using the methods described in 
section 2.4.1. The concentration of the lysate was determined using the Bradford assay 
and diluted to an appropriate concentration of 0.5µg/µl in 10mM Tris-HCl, after which 
lysates were flash frozen in liquid nitrogen and stored at -80
o
C. DNA was extracted 
from the second aliquot using the method described in section 2.5.1. After extraction, 
the concentration of DNA was determined using a Nanodrop ND1000 and the DNA 
preparation aliquoted in appropriate volumes and stored at -20
o
C.  
 
4.3.3. Quantification of Western blots 
After signal detection by ECL Prime (GE Healthcare) and imaging, signal strength was 
analysed using ImageJ software. The intensity of signal for each band was calculated by 
using ImageJ to represent each band in graph form. This enable the measurement of 
area under the curve for each band, intense signal was represented by taller, wider peaks 
and therefore larger area under the curves. The ratio between the area under the curve 
for control proteins and test proteins was then calculated.  
 
4.3.4. Statistical analysis 
Microsoft excel was used to collate data and Prism (GraphPad, USA) was used to 
generate graphs. Prior to statistical analysis, all data set were subjected to a normality 
test using Minitab 16 statistical software (Minitab Inc.). 
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4.4. RESULTS 
The following section will focus on each class of CMCO (fluorescent and non-
fluorescent) and their functional effects separately.  
 
4.4.1. HeLa sequencing 
Prior to analysis of the CMCOs functional effects, it was decided to ensure that the 
region of MTCO1 the CMCOs were designed to bind (np.5979-5994) did not contain 
mutations, as these could affect CMCO hybridisation. Therefore MTCO1 in the HeLa 
cell line to be used for the functional analysis experiments was sequenced using the 
methods described in section 2.5.3. Total DNA was extracted from HeLa cells when 
they had reached 60% confluency in a T25cm
2
 flask. A 200bp product that contained 
the CMCO binding region was amplified by PCR and sequenced using an ABI genetic 
analyser. SeqScape software was used to align the sequence to the revised Cambridge 
reference sequence (Andrews et al. 1999) and it was found that the HeLa cell line did 
not contain any mutations in this region (figure 4.2). Therefore this cell line could be 
used in the functional analysis experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 - Sequence of mtDNA (np.5979-5994).  
HeLa cell mtDNA was sequenced and an electropherogram spanning the 
CMCO binding region was analysed for point mutations. The 
complementary CMCO sequence is also shown; red letters denote the 
position of phosphonic ester side chains. 
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4.4.2. Non-fluorescently conjugated CMCOs 
In collaboration with Ugichem, several CMCOs were designed that used MN as a 
targeting molecule, two CMCOs that had acetyl groups in lieu of a targeting molecule 
were also produced (to act as a non-targeted control). A similar fluorescent molecule 
was not conjugated in order to ascertain whether MN alone had the ability to drive 
accumulation of the CMCO into the mitochondrial matrix. This was necessary as the 
experiments in the previous chapter showed that MN increased targeting, however it 
was not possible to determine if MN can target CMCOs to mitochondria in the absence 
of a mitochondrial dye, as the localisation experiments relied on the presence of a 
fluorescent moiety. If MN alone can cause accumulation, which is sufficient to have a 
functional effect, it is very encouraging from a financial point of view as conjugation to 
fluorescent molecules (particularly ATTO 647N) is very expensive.  
 
Targeted CMCOs with different sequence homologies to np. 5979-5994 of mtDNA 
were designed in order to investigate specificity of binding. In order for CMCOs to treat 
mtDNA disease caused by point mutations the CMCOs must show differential binding 
to wild type and mutated mtDNA. Therefore the investigation of CMCOs with base 
mismatches to wild type mtDNA will indicate if they selectively bind only mtDNA to 
which they are 100% complementary. The various CMCOs and their sequence 
homologies are shown in table 4.1. 
 
 
 
 
 
 
 
 
 
Table 4.1 - Non-fluorescently conjugated CMCOs and their sequence homology to 
np.5979-5994 mtDNA.  
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 Effect of CMCOs on mtDNA copy number 4.4.2.1.
CMCO binding of mtDNA has been shown previously to inhibit the action of pol in 
vitro (Kyriakouli 2007), and if this occurs in vivo it is likely to cause a decrease in 
mtDNA copy number as the cells divide and cannot increase mtDNA, causing a relative 
fall in copy number per cell due to relaxed mtDNA replication. To determine relative 
copy number changes caused by CMCOs, it was decided to use quantitative PCR 
(qPCR) to ascertain the ratio of mtDNA to a nuclear marker gene.  
 
As the ability of MN-CMCOs to accumulate in mitochondria is not clear, it was decided 
to incubate HeLa cells with 10M CMCO for 30 days after which DNA and protein 
lysates were produced and analysed. Previous work indicated that this was long enough 
for any effect on copy number or COXI protein to be detected. mtDNA copy number 
was analysed by comparing the relative levels of the mitochondrial complex 1 gene 
MTND1 to nuclear gene B2M (2-microglobulin). The quantity of each gene was 
determined by comparing the Ct value to a standard curve produced from extracted 
HeLa DNA and diluted over a 6-log range. This is the most accurate way of determining 
copy number as the use of a standard curve on each reaction plate prevents variation in 
the MTND1 and B2M reactions from being interpreted as changes in copy number. To 
ensure there was no bias, the dosing was blinded.  
 
Due to the amount of CMCO available it was not possible to perform repeat doses, 
however if any CMCOs showed an effect these would be repeated at a later date with a 
new synthesis. The relative copy number of the CMCO treated HeLa cells was 
normalised to the average no dose control copy number (five no dose controls were set 
up in parallel to the CMCO incubation in a 24 well plate). This enabled relative copy 
number changes to be investigated, while also providing insight into the natural 
variation of mtDNA copy number within HeLa cells.  
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Figure 4.3 shows that there is variation in the copy number of control cell lines, both 
within the repeat real-time PCR measurements (the average standard deviation for all 
controls between real-time PCR runs was 0.17) and when compared to each other 
(standard deviation of 0.22). This high standard deviation indicates that there is an 
inherent margin of error when using real-time PCR. It also indicates that there is a large 
natural variation in the copy number of HeLa cells, even in the absence of CMCO 
treatment. Therefore repeat doses of CMCO treatment are necessary in order to 
compensate for this variation and to be certain of any CMCO effect on mtDNA copy 
number. 
 
Figure 4.3 indicates that the best performing CMCO was a MN conjugated molecule 
with a C>G substitution (Ugi 193) which decreased copy number by ~50%, whereas the 
homologous CMCO (Ugi 105) had no real effect on copy number. However, although 
this could suggest that the non-homologous CMCO has a greater ability to interrupt 
mtDNA replication, the fact that the two CMCOs that caused a similar decrease in copy 
number (Ugi 192 and Ugi 196) are a non-targeted and nonsense CMCO respectively 
suggests that the effect on copy number may be due to random variation rather than an 
effect of the CMCOs. It could also indicate a non-specific interaction with mtDNA 
causing depletion. Work in this lab has shown that real time PCR may vary by up to 
20% for copy number analysis, which could also contribute to the variation seen in 
these results (Dr. Julie Murphy, unpublished data). If the effect of these CMCOs is real, 
then it is likely that in cases where there is a fall in copy number, there will be a 
corresponding fall in COXI levels. 
 
 COXI expression 4.4.2.2.
After incubation with 10M CMCO for 30 days, cytolplasmic cell protein was extracted 
from treated HeLa cells, along with protein from 5 no dose control cell lines. The level 
of COXI in relation to non-mtDNA encoded SDHA was determined by western 
blotting. Changes in COXI could be due to either a fall in mtDNA copy number, or a 
fall in the translation of mt-mRNA, which could be caused by CMCO binding of 
mtDNA or mt- mRNA. It is possible that a CMCO could cause a fall in COXI by 
binding mt-mRNA without affecting mtDNA copy number. 
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Figure 4.4 shows western blotting data for HeLa cells treated with the CMCOs or no 
dose controls. Western blots were performed using 5g cytoplasmic cell lysate (this was 
limited by the number of cells available for protein extraction) and were probed using 
the antibody concentrations described in section 2.4. The quality of the western blots 
makes it difficult to infer what effect, if any, these CMCOs are having on the levels of 
COXI protein. This was due to the need to expose the blot for a long time in order to 
obtain signal from COXI, which caused overexposure of the SDHA signal, this was not 
suitable to easy analysis. 
 
As with the copy number data, there was a large variation in the levels of COXI in the 
control cell lines. The levels of COXI do not reflect the copy number of mtDNA as C1, 
which had the lowest copy number of all controls actually has the highest level of COXI 
protein. It is very difficult to understand what effect the CMCOs are having on COXI 
levels without having repeat doses as there is such a high variation between controls. 
 
The western blot did not suggest that there is a correlation between the CMCOs that 
caused the greatest fall in copy number and the CMCOs that indicated the largest 
decline in COXI. Ugi 105 – the MN targeted homologous CMCO caused the largest 
apparent decline in COXI – to 50% of average control levels, followed by Ugi 195 (3 
nucleotide change) and Ugi 193 (1 nucleotide change)- which also indicated the largest 
decline in copy number. However, although there was an apparent decline caused when 
compared to the average no dose control COXI/SDHA ratio, when compared to 
individual no dose controls C2 and C4 (which had the lowest COXI/SDHA ratios), 
there is no difference in COXI expression. 
 
 
 
 
 
 
Chapter Four  Functional analysis of targeted CMCOs 
118 
 
F
ig
u
re
 4
.4
 -
 W
es
te
rn
 b
lo
ts
 o
f 
C
O
X
I 
ex
p
re
ss
io
n
 
in
 H
eL
a
 c
e
ll
s 
a
ft
er
 t
re
a
tm
e
n
t 
w
it
h
 v
a
ri
o
u
s 
C
M
C
O
s.
  
H
eL
a 
ce
ll
s 
w
er
e 
in
c
u
b
at
ed
 w
it
h
 1
0

M
 C
M
C
O
s 
fo
r 
3
0
 d
ay
s 
p
ri
o
r 
to
 w
h
o
le
 c
el
l 
p
ro
te
in
 e
x
tr
ac
ti
o
n
. 
5

g
 p
ro
te
in
 w
a
s 
lo
ad
ed
. 
P
ro
b
in
g
 w
a
s 
ca
rr
ie
d
 o
u
t 
u
si
n
g
 1
 i
n
 1
0
0
0
0
 d
il
u
ti
o
n
 o
f 
a
n
ti
-S
D
H
A
 a
n
d
 1
 i
n
 
1
0
0
0
 d
il
u
ti
o
n
 o
f 
a
n
ti
-C
O
X
I 
an
ti
b
o
d
ie
s.
 C
O
X
I 
le
v
el
s 
w
er
e 
n
o
rm
al
is
ed
 t
o
 S
D
H
A
 p
ri
o
r 
to
 
n
o
rm
la
is
at
io
n
 t
o
 a
v
er
a
g
e 
C
O
X
I/
S
D
H
A
 r
at
io
s 
 f
o
r 
n
o
 d
o
se
 c
o
n
tr
o
l 
ce
ll
s.
 T
h
e 
g
ra
p
h
 s
h
o
w
s 
th
e
se
 
ra
ti
o
s.
 T
h
e 
b
la
ck
 b
ar
 r
ep
re
se
n
ts
 a
ll
 n
o
 d
o
se
 
co
n
tr
o
ls
, 
re
d
 r
ep
re
se
n
ts
 M
N
 t
ar
g
et
ed
 C
M
C
O
S
, 
b
lu
e 
re
p
re
se
n
ts
 A
c 
ta
rg
et
ed
 C
M
C
O
s 
a
n
d
 w
h
it
e 
b
ar
s 
re
p
re
se
n
t 
n
o
 d
o
se
 c
o
n
tr
o
ls
. 
C
ro
ss
-h
a
tc
h
in
g
s 
re
p
re
se
n
t 
n
o
n
-h
o
m
o
lo
g
o
u
s 
C
M
C
O
S
. 
D
en
is
to
m
et
ry
 w
as
 c
al
c
u
la
te
d
 u
si
n
g
 I
m
a
g
eJ
 .
 
Chapter Four  Functional analysis of targeted CMCOs 
119 
 
The data presented does not indicate that these CMCOs had a functional effect on 
mtDNA or COXI expression. It is therefore impossible to draw a firm conclusion due to 
the difficulty in analysing the western blots and the absence of repeat experiments. 
Logically the best performing CMCO should have been Ugi 105 as this was targeted 
using MN – the best targeting molecule (Chapter 3, figure 3.10), and also had 100% 
sequence homology to the targeted region. The fact that this showed the greatest 
decrease in COXI when compared to all no dose controls suggests that the CMCO may 
have bound, however further experiments are needed to fully understand any effect. 
These results will be discussed further in section 4.5. 
 
4.4.3. Fluorescently conjugated MN-CMCOs 
The previous chapter (chapter 3, figure 3.10) showed that the CMCO with the greatest 
mitochondrial colocalisation were MN targeted and conjugated to ATTO 647N. It was 
therefore decided to investigate the functional effect of these along with TAMRA 
conjugated CMCOs. As it is clear that fluorescently tagged MN-CMCOs colocalise to 
mitochondria to a certain degree, it was decided to repeat the previous dosing 
experiment (section 4.4.2) but for 14 days instead of 30. This change in incubation 
period was due to the fact that the CMCOs colocalised relatively rapidly to 
mitochondria and were therefore more likely to be present in higher concentration 
within the matrix (if they could access it), enabling a greater inhibition of mtDNA 
replication and COXI expression. This decision was also influenced by the obvious 
need to carry out repeats. Ideally it would have been more robust to dose for 30 days, 
however this was limited by CMCO availability. The concentration (10M) remained 
the same and protein and DNA samples were extracted for each CMCO, however for 
these experiments there were two repeats for each CMCO. Four no-dose controls were 
set up in parallel to the CMCO incubations. As with the previous experiments, the 
dosing was blinded. Details of the CMCOs to be investigated are shown in table 4.2. 
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All CMCOs are homologous to MTCO1 (np. 5979-5994) and contain 6 phosphonic ester side chains. 
Ugi 199 and Ugi 200 contain a new proprietary side chain in lieu of the previously used phosphonic 
ester side chain, in order to investigate its functional effects. Red letters denote the position of 
phosphonic ester side chains, or the new side chain for Ugi 199 and 200. 
 
It was shown in the previous chapter that mitochondrial localisation was achieved by 
fluorescent CMCOs in the absence of MN. Therefore it was decided to investigate the 
functional effects of both MN and Ac (non-targeted) CMCOs in conjunction with either 
TAMRA or ATTO 647N. All CMCOs contained the same ratio of phosphonic esters (6 
in total) as used in the colocalisation experiments. Ugi 199 and Ugi 200 replaced the 
previously used side chains with a new proprietary side chain that has not been 
previously tested in this application – it was likely to alter the lipophilic properties and 
strength of DNA binding. These CMCOs were provided by Ugichem as they have 
shown efficacy in binding DNA in other areas of their research. Due to the proprietary 
nature of this side chain I am currently unable to provide details on its structure or 
proposed function. 
 
 Effect of fluorescently conjugated CMCOs on mtDNA copy number 4.4.3.1.
Using the method described previously (section 2.5.2), the ratio of MTND1 to B2M was 
used to determine the relative mtDNA copy number for each CMCO treated cell line 
using the standard curve method. Copy number ratios were also determined for no dose 
control cell lines, the average of which was used to normalise the CMCO data. 
Table 4.2 - Details of fluorescently tagged CMCOs. 
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Figure 4.5 shows changes in mtDNA copy number in response to treatment with 10M 
of the various fluorescent CMCOs. In this experiment, there was a much smaller 
variation in the copy number of real-time PCR repeats in control cells (mean standard 
deviation of 0.10 for all controls, compared to 0.17 in the previous experiment), 
Figure 4.5 - The effect of 10M fluorescently conjugated CMCOs on mtDNA copy number after 
incubation for 14 days. 
Data is normalised to the mean of no dose controls (grey bar). Red bars denote TAMRA conjugated 
CMCOs, Blue bars denote ATTO647N conjugates CMCOs. White bars show individual no dose 
controls. Cross-hatchings denoted new side chain. The table shows relative mtDNA copy number 
normalised to controls (ND1/B2M ratio). No significance decrease in mtDNA copy number was 
detected (Mann-Whitney U test). Error bars represent standard deviation of dosing repeats (calculated 
from average of triplicate real time PCR values).  
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although the deviation between controls was 0.19 (relative ND1/B2M ratio), which is 
comparable to the previous experiment’s control standard deviation. The fact that the 
deviation is similar indicates that the natural variation in mtDNA copy number of HeLa 
cells is relatively well conserved across experiments.  
 
The data for each CMCO represents both repeat experiments and indicates that there 
was no evidence of decreased mtDNA copy number in treated cells. There was much 
less variation of copy number in all treated samples when compared to the previous 
experiment (figure 4.3), which could be due to the presence of repeats, therefore this 
data indicates that there was no inhibition of mtDNA replication. 
 
 Effect of fluorescently conjugated CMCOs on COXI expression 4.4.3.2.
In spite of the absence of evidence of mtDNA depletion, the CMCOs may have the 
ability to bind COXI transcripts and prevent their translation. This was investigated by 
western blotting; the levels of COX in relation to SDHA in 5g cytoplasmic protein 
lysate were analysed for each CMCO and normalised to the no dose control average. 
 
Figure 4.6 shows western blots for individual repeats, along with a graph showing the 
relative COXI levels for each CMCO in relation to the average for the no dose controls. 
Although the signal obtained from the western blot is relatively diffuse, there is an 
obvious variation in the control levels of COXI, particularly C4 which indicated 80% 
lower COXI than the average controls. No CMCOs indicated an effect on COXI 
expression, with the possible exception of Ugi 200. This ATTO 647N-CMCO is 
targeted to mitochondria using MN and also contains the new, modified side chain. 
Although the C4 no dose control also indicated a lower level of COXI, the fact that both 
repeats of the Ugi 200 dose showed a decrease indicates that there could be a functional 
effect. This will require further investigation and more repeat doses, however after 
consultation with Ugichem, it is clear that this particular side-chain has led to functional 
effects in other areas of their research particularly in anti-viral anti-genomic therapies 
and as a consequence this new design is in the process of being patented.  
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The error bars on the graph shown in figure 4.6 represent the two repeat doses. It is 
clear that there was a large variation between repeats, indicating that further 
experiments are needed to fully investigate any effect. It is also unlikely that Ugi 96 and 
100 caused an increase in COXI protein; this was probably caused by variation 
introduced into the quantification of the western by the low level of signal obtained 
during detection. 
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4.5. DISCUSSION 
The data presented in this chapter suggests that the non-fluorescently conjugated 
CMCOs tended to not have a functional effect on either replication of mtDNA or 
expression of COXI protein, however, there is not enough data to conclusively argue 
that they were completely ineffective. An absence of functional effect could be due to 
the CMCOs not localising to the mitochondrial matrix, and therefore not having access 
to mtDNA, or it could be that the CMCOs could not bind mtDNA and inhibit 
replication. Compounds which do cause mtDNA depletion, such as ethidium bromide, 
can be expected to lower copy number by several orders of magnitude when compared 
to control molecules. This was not seen in any of the experiments carried out in this 
chapter by any of the CMCOs, although such a large effect may be beyond their 
capabilities.  
 
4.5.1. Non fluorescently tagged CMCOs 
The previous chapter indicated that MN had the ability to localise CMCOs to 
mitochondria when used in conjunction with a fluorescent mitochondrial marker. The 
mtDNA depletion results indicated that the CMCO which tended to cause a fall in copy 
number in these experiments had a one base difference to np.5979-5994 (Ugi 193), or 
were completely non-homologous to mtDNA (Ugi 196), whereas the homologous 
CMCO (Ugi 105) had no effect on mtDNA copy number, although there was not 
enough data to fully investigate this. Ugichem experience similar effects in other areas 
of CMCO research where non-homologous CMCOs show a greater effect than 
completely homologous oligomers although the reason for this is unclear. However, the 
fact that the completely random Ugi 196 also indicated a fall in copy number, suggests 
that the results are more likely to be due to random variation rather than an actual effect 
on mtDNA replication. It could also be possible that the nonsense CMCO may have a 
nonspecific interaction with a part of the replication machinery which causes a general 
decrease in replication. However, with the current data this is difficult to comment on 
further and may require further investigation.  
 
The relationship between CMCO dosing and COXI expression is unclear. Detection of 
decreased COXI levels by western blotting relies on there being a large decrease, as 
quantification is difficult due to the variation seen when using the technique. Therefore 
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in order to reliably confirm a COXI decline, the quantity of COXI detected by western 
blotting needs to be substantially lower than all control cell lines. This was not the case 
in this experiment, and it is therefore not possible to confirm an effect on the expression 
of COXI by any of the non-fluorescently tagged CMCOs. The westerns presented are 
difficult to analyse as the signal from SDHA is substantially stronger when compared to 
COXI, therefore a small variation in COXI will cause a large change in the ratio of the 
two proteins. The reason for this is unknown as it was only experienced in this 
experiment, however it could be due to experimental error as unfortunately there was 
not sufficient protein lysate to repeat these experiments.  
 
As discussed in the previous chapter, further investigations are needed to determine if 
MN-CMCOs do have the ability to accumulate within the mitochondrial matrix. If it 
becomes clear that MN-CMCOs can accumulate within the matrix but do not have a 
reproducible effect on mtDNA or protein expression, then different CMCO structures 
can be trialled (discussed in chapter 7). 
 
4.5.2. Fluorescently tagged CMCOs 
Neither the TAMRA nor ATTO 647N conjugated CMCOs showed any effect on 
mtDNA copy number after 14 day 10µM incubation in the two experiments completed. 
Although it is clear that the ATTO 647N-CMCOs localise to mitochondria, it is 
unknown if they accumulate within the matrix, therefore the absence of any functional 
effect could be due to the CMCOs not accessing the matrix, or not being able to 
sufficiently bind and inhibit mtDNA replication, however more experiments are needed 
to fully understand the activity of these CMCOs.  
 
Western blot data also indicates that the CMCOs did not cause a decline in COXI 
expression in the two repeats carried out, with the possible exception of Ugi 200. 
Although the western blot quality is limited by the quantity of protein loaded, there is a 
decrease in the quantity of COXI for both repeat Ugi 200 incubations when compared to 
the average COXI/SDHA ratio for the no dose controls. This work will need to be 
repeated in order to confirm a depletion of COXI. As mentioned previously, for a COXI 
depletion to be confirmed, it is essential that the quantity of detected COXI is lower 
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than all no dose controls rather than just the average. In this case, no dose control 4 also 
indicates a relatively low level of COXI expression, lower in fact that seen in Ugi 200 
treated cells. The lower level of COXI in no dose 4 could be due to a natural variation 
of endogenous protein, or it could be due to the small quantity of protein loaded 
increasing the variation when detecting COXI and SDHA. 
 
The fact that both Ugi 200 repeats indicated a depletion of COXI is interesting and will 
require further repeat experiments to confirm any effect. The combination of MN-
ATTO 647N was the most efficient at targeting mitochondria, so it was expected that if 
any CMCO had a functional effect on COXI levels it would be these ones. As Ugi 100, 
which is also MN-ATTO 647N conjugated, had no effect it is possible that the new side 
chain plays a role in increasing the ability of the CMCOs to bind mRNA. If this is the 
case, it would explain why Ugi 100 did not have an effect on COXI expression whereas 
Ugi 200 may have. Consultation with Ugichem has confirmed that CMCOs with the 
new side chain have shown efficacy in inhibiting nuclear encoded genes and viral genes 
and as a result of this the company no longer manufactures CMCOs with the original 
phosphonic ester side chain. Therefore all future experiments will be carried out using 
CMCOs with the new side chain. 
 
Future work investigating the functional effects of CMCOs will require a larger quantity 
of oligomers to complete adequate repeats, something that was not possible in this work 
due to technical and financial constraints. The sensitivity of the techniques used in this 
chapter may prevent their use in future investigations. On-going work in this lab has 
highlighted the need for multiple experimental and technical repeats when using real-
time PCR in order to ensure the obtained data is statistically robust. Using more repeats 
also enables the accurate quantification of small changes (>20%) in mtDNA copy 
number. This work will be applied in future investigations using CMCOs. The greater 
variation of copy number in cells cultured for 30 days when compared to 14 days may 
warrant incubating HeLa cells for less time in order to lessen the chance of inducing 
such a large variation.  
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The sensitivity of western blotting is also an issue; therefore I intend to re-optimise the 
technique for future work. The detection of small changes in protein using western blots 
is not possible; therefore the use of a different technique may be warranted. This is 
something that I will fully investigate prior to commencing further work; however it 
may be possible to use an immunocytochemical based technique to directly assess 
protein levels in vivo. 
 
4.6. CONCLUSIONS 
Although the effect of CMCOs on mtDNA replication and COXI expression is unclear, 
CMCOs are still an attractive option for treating mtDNA diseases, as they do not require 
a specific delivery mechanism to enter the cell. The variation of copy number and 
protein expression could be due to the genetic instability of the HeLa cells or a 
differential growth rate. If some of the cells did reach a slightly higher confluency than 
others before harvesting, the expression of mitochondrial proteins and mtDNA 
replication is likely to fall as the cells may enter a G0 stage of growth, and no longer 
require as much energy (Martínez-Diez et al. 2006).  
 
As there was some indication of a functional effect of Ugi 200 (MN-ATTO 647N 
targeted with the new side chain), it is important to repeat the mtDNA and COXI 
depletion experiments. However, prior to investigating this CMCO, I will analyse the 
variation of mtDNA copy number and COXI expression in other cell types, particularly 
cells that grow at a slower rate, as the risk of confluency related mtDNA depletions is 
smaller. In conjunction with Ugichem, I will design more targeted CMCOs with the 
new, active side chain in order to see if there is an effect on mtDNA copy number. I 
believe it is important to understand where and why the CMCOs localise within 
mitochondria, as until this question is answered it is difficult to analyse the functional 
effects of the CMCOs in vivo. 
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5 Design and optimisation of a high throughput assay to detect changes 
in mitochondrial mass 
 
5.1. INTRODUCTION 
Mitochondrial dysfunction is primarily associated with mitochondrial diseases, however 
deficits in mitochondrial function have also been shown to be a contributing factor in 
numerous neurological diseases including Parkinson’s (Abou-Sleiman et al. 2006) and 
Alzheimer’s diseases (Reddy and Beal 2005; Reddy and Reddy 2011). Although the 
involvement of mitochondrial dysfunction in these diseases has been known for a 
number of years, there are currently no routinely used pharmaceuticals that target 
mitochondria in these diseases. Consequently there is a need to discover novel 
compounds that can act on mitochondria to improve their function in tissues affected by 
such diseases.  
 
Although there are several interventions that could lead to an improvement in 
mitochondrial function in these diseases, such as causing an increase in ATP 
production, decreasing free radical production or increasing removal of damaged 
mitochondria through autophagy, it was decided to create an assay to detect changes in 
mitochondrial mass with the aim of detecting a compound that causes an increase in 
mitochondrial biogenesis. Increased mitochondrial mass was chosen as an endpoint as it 
is logical to assume that increases in mitochondrial biogenesis may lead to an 
improvement in cellular function. Recent work by Dillon and colleagues also supports 
this conclusion (Dillon et al. 2012). There are several ways to detect this, including; 
detection of increases in mitochondrial proteins by western blotting, detecting up 
regulation of genes driving mitochondrial biogenesis by RT PCR and network 
quantification using microscopy. Although these methods have all been shown to have 
the ability to detect changes in mitochondrial biogenesis (Medeiros 2008), none of them 
can be used to screen large numbers of compounds as they require too much time and 
resources to process each sample.  
 
Development of an assay that is both high throughput and reproducible is essential for 
the screening of large numbers of compounds. Therefore an assay to detect changes in 
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mitochondrial biogenesis which can be applied to 96 well plates was developed. The 
use of fluorescent mitochondrial probes in the detection of changes in mitochondrial 
volume has been well characterised when used in conjunction with microscopy or 
fluorescently activated cell sorting (FACS) (Karbowski et al. 2001; Dingley et al. 2012)  
by determining the quantity of mitochondrial staining per cell, however their ability to 
highlight volume changes in a 96 well plate format has not been tested. This chapter 
focuses on the development of the assay to enable the detection of changes in 
mitochondrial volume in cells grown in 96 well plates using a fluorescent probe. The 
assay will then be used to screen compounds to see if they cause a change in cellular 
mitochondrial volume. 
 
5.2. AIMS 
The development of this assay involved the fulfilment of four aims:  
I. To develop a 96 well plate based assay to screen compounds for effects on 
mitochondrial density. 
II. To determine if mitochondrial dyes can be used to quantify changes in 
mitochondrial density. 
III. To develop a plate reader based system to determine cell number per well. 
IV. Investigate the benefits of automation of liquid handling and determine its 
suitability for the high throughput assay.  
 
5.3. METHODS 
As this chapter describes the development of a methodical approach for the 
mitochondrial mass detection assay and various aspects of its optimisation, the 
following is a brief description of the general techniques used.  
 
5.3.1. Cell growth 
All HeLa cells used were grown according to the protocol listed in section 2.2.1. Prior 
to seeding in clear 96 well plates they were harvested from culture flasks and counted as 
described in section 2.2.2. Once seeded in a plate cells were grown in appropriate media 
in the presence of 50 units/ml penicillin and 50µg/ml streptomycin (pen/strep). All 
HeLa cell cultures were incubated at 37
o
C in a humidified atmosphere of 5% CO2.  
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5.3.2. Cell staining and fixation 
Mitochondrial dyes were diluted in complete media without Phenol Red to an 
appropriate concentration depending on experiment. Dye containing media was used to 
replace the media in each well and cells were incubated with the dye for 30 minutes at 
37
o
C. Prior to reading on a plate reader, dye media was removed and wells washed 3 
times in PBS and appropriate media without Phenol Red (to prevent high background 
signal during imaging) added to each well. Immediately after imaging, cells were fixed 
in 4% PFA in their wells and washed in PBS. Plates were either stored at 4
o
C or stained 
with an appropriate concentration of Hoechst 33258 and imaged.  
 
5.3.3. Statistical analysis 
Microsoft excel was used to collate data and Prism (GraphPad, USA) was used to 
generate graphs. Prior to statistical analysis, all data set were subjected to a normality 
test using Minitab 16 statistical software (Minitab Inc.).
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5.4. RESULTS 
5.4.1. Optimisation of cell seeding density 
The human adenocarcinoma cell line; HeLa, was used in this assay to screen 
mitochondrially acting compounds. This cell line was chosen based on its short 
doubling time (18–24 hours) and on experience from previous chapters which shows the 
cells are relatively flat and have a reticular mitochondrial network that is conducive to 
imaging studies.  
 
To ensure that cells did not become too confluent, it was essential to determine a 
seeding density that enabled sustained growth for as long as possible before confluency 
was reached, but also created an even layer of cells in the well. Therefore a 1:1 serial 
dilution of cells was performed across a 96 well plate (ranging from 1x10
4
 to 78 
cells/well approximately). These cells were allowed to grow for 72 hours before the 
spread of the cells across the well was determined by eye using microscopy. It was 
found that at seeding densities below 5x10
3
 cells/well, cells were distributed unevenly 
across the well, whereas a 5x10
3
 cells/well seeding density led to an even distribution of 
around 90% confluency which equated to 8x10
4
 cells/well following 72 hours growth. 
To maximise the incubation length with compounds, it was decided that assayed cells 
will be allowed to grow for 72 hours, as any longer and the cells became over confluent.  
 
5.4.2. Cell number normalisation 
To ensure that the mitochondrial signal could be normalised to cell number, determining 
the number of cells per well following treatment was essential. It was decided that 
removing the cells from each well using trypsin and counting them manually would be 
too time consuming to make the assay viable and potentially not all cells would be 
removed, skewing the cell number data. Therefore a method to read the number of cells 
whilst they were still attached to the plate was developed. 
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Nuclear staining and counting is a technique routinely used in several assays to 
determine cell number for normalisation of other parameters (Chen et al. 2005; Zhou et 
al. 2012). However, most of these techniques require the physical counting of individual 
nuclei, rather than a measure of the overall fluorescent signal emitted by their staining. 
To stain nuclei, the DNA stain Hoechst 33258 was chosen as it has an emission and 
excitation spectra distinct from most live cell mitochondrial dyes (figure 5.1). It also 
exhibits a larger Stokes shift than other DNA stains in this emission range, meaning that 
it has distinct excitation and emission peaks. It is likely to have minimal background 
staining as the intensity of its emitted fluorescence increases 1000 fold upon 
intercalation into dsDNA. 
 
To investigate the relationship between cell number per well and whole well 
fluorescence emitted by a nuclear stain, a 1:1 serial dilution of HeLa cells was seeded 
across a 96 well plate, ranging from 0 to 8 x10
4
 cells/well in octuplet. Cells were 
allowed to adhere to the plates overnight before fixation and staining with 100µl 
Hoechst 33258 (4µg/ml in ddH2O) for 30 minutes. This concentration was chosen as it 
is recommended by the manufacturers (Sigma-Aldrich, St. Louis, USA) for staining the 
nuclei of fixed cells. A fluorescence plate reader using the appropriate excitation and 
emission filters (see materials and methods, table 2.2) was then used to measure relative 
Figure 5.1 - Excitation and emission spectra of Hoechst 33258, Mitotracker Green, Mitotracker 
Red and TMRM. 
Dotted lines represent excitation spectra, solid lines represent emission spectra. Labelled arrows denote 
emission peaks. 
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fluorescence per well and the relationship between cell number and fluorescence 
plotted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 shows the relationship between the number of cells seeded per well and 
fluorescence obtained after staining with Hoechst 33258. A trendline was generated by 
linear regression (r
2
=0.989), demonstrating a linear relationship between Hoechst 
fluorescence and cell number for the cell number range investigated here. Therefore 
emitted Hoechst fluorescence can be used to estimate relative cell number per well.  
 
5.4.3. Measurement of mitochondrial density 
As with cell number counting, measurement of mitochondrial mass has to be achieved 
using a technique that is both reproducible and high-throughput i.e. can be achieved in a 
Figure 5.2 - HeLa cell number plotted against mean fluorescence 
emitted per well by Hoechst dye /RFU (Relative fluorescent units). 
Trendline shows linear regression (r
2
=0.989). Error bars represent 
standard error of the mean for the octuplet. Cells fixed 6 hours after 
seeding.  
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relatively short amount of time and be carried out on a 96 well plate. Techniques used 
routinely in our lab include quantification of mitochondrial mass using anti-Porin 
antibodies as a marker with either fluorescent or chromogen visualisation. This requires 
the cells to be fixed and then permeablized prior to incubation with a primary and 
suitable secondary antibody. Samples are then imaged using microscopy and levels of 
staining quantified using densitometry. Although this method has been validated within 
the lab, it is not appropriate for this assay, primarily because of the number of steps 
involved and the amount of antibody required for staining a whole plate, but also the 
requirement of glass bottomed plates to enable accurate microscopy. These factors make 
the technique prohibitively expensive. Measurement of mitochondrial mass in live cells 
is achieved by staining mitochondria using a specific dye and analysing the total volume 
of the stained regions compared to a cytoplasmic stain for example Calcein Blue, 
enabling calculation of total mitochondrial mass per cell. Again, this method requires 
microscopy to be used to image the mitochondria and is therefore not appropriate for 
this assay. However, the use of a mitochondrial specific stain may enable the 
quantification of changes in mitochondrial mass using a plate reader. 
 
 Optimisation of mitochondrial dye concentrations 5.4.3.1.
To investigate this, first the relationship between dye concentration and fluorescence 
was determined. Two dyes were examined, MitoTracker
TM
 Red and TMRM, both of 
which accumulate in mitochondria in a membrane potential dependent manner. 
Although MitoTracker Green also has these properties, this dye was not chosen as its 
excitation spectra overlaps with Hoechst (figure 5.1). A concentration gradient was 
prepared by diluting the dyes in PBS to create an appropriate concentration range from 
300nM to 25nM decreasing in 25nM steps. This concentration range was chosen to 
ensure sufficient signal was picked up by the plate reader. Each concentration was set 
up in quadruplicate on a 96 well plate and emitted fluorescence read using a plate reader 
with the appropriate filter set 520nm/ 560nm (Ex/Em).  
 
The relationship between TMRM and concentration is shown in figure 5.3. An 
exponential growth trendline (dashed line) has been used to illustrated the non-linear 
relationship across the entire concentration range, (r
2
=0.9858) when compared to a 
linear regression trendline (solid line) with an r
2 
value of 0.904. However, when 
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analysed it was found that for concentrations below 125nM, the interaction between 
TMRM concentration and fluorescence changes from a non-linear to a strongly linear 
relationship, as shown in figure 5.3 B, r
2
= 0.9902, indicating that across this 
concentration range TMRM fluorescence increases in a predictable ratio against TMRM 
concentration. 
 
The relationship between MitoTracker Red concentration and fluorescence is shown in 
figure 5.4. Unlike TMRM, the interaction between concentration and fluorescence was 
linear across the entire range of concentrations, r
2
=0.9731. Although the linear 
relationship extends across a wider range of concentrations than TMRM, the difference 
in r values for MitoTracker Red and TMRM (25nM to 125nM) suggests that over this 
concentration range, the interaction between TMRM concentration and fluorescence is 
more predictable.  
 
Figure 5.3 - TMRM concentration plotted against fluorescence. 
A shows the relationship of fluorescence over a concentration range of TMRM from 25n-300nM. The 
dotted trendline is an exponential growth line (r
2
=0.9858), the solid trendline a linear regression 
(r
2
=0.9051). B shows the relationship between fluorescence and TMRM concentration over a range of 
25-125nM, the trendline is a linear regression (r
2
=0.9902). Error bars represent standard error of the 
mean (n=8). 
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The intensity of emitted fluorescence of TMRM is greater than Mitotracker Red, on 
average TMRM emits 2.25 times more relative fluorescence over a concentration range 
of 25nM to 125nM. This enables a reduction in sensitivity of the plate reader (a 
reduction in gain) which decreases the chance of picking up fluorescent signal that can 
be attributed to noise; in turn this increases the reproducibility of the assay. The stronger 
linear relationship of TMRM than MitoTracker Red across this concentration range also 
makes TMRM more attractive for this assay. This is because the ability to determine 
mitochondrial density from fluorescence is essential and TMRM behaves in a more 
predictable way than MitoTracker Red. Therefore TMRM was chosen for use in the 
assay. 
 
Figure 5.4 - Changes in fluorescence with increasing concentration of 
MitoTracker Red.  
The trendline represents linear regression (r
2
=0.97311). Error bars represent 
standard error of the mean for the octuplet. 
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The median value of the linear range of concentrations was chosen for the assay and 
therefore a TMRM concentration of 75nM was used for the rest of the optimization 
steps. This value was chosen as it enables the maximum possible changes in 
fluorescence over the linear range. For example, if the number of mitochondria 
increases, which is likely to lead to a relative increase in fluorescence, by choosing an 
initial TMRM concentration of 75nM this increase will be detected over this predictable 
range. However, if the starting concentration was 125nM, any increases in relative 
fluorescence would be detected outside the linear range, leading to increased variability 
when interpreting the results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TMRM as a marker of mitochondrial mass 5.4.3.2.
To investigate the interaction between increasing cell number and detected fluorescence 
emitted from 75nM TMRM, a 1:1 serial dilution of HeLa cells was prepared on a 96 
well plate ranging from 8x10
4
 cells per well to 625 cells per well. Each concentration of 
cells was prepared in octuplets. Cells were allowed to adhere to the plate over night 
Figure 5.5 - Cell number per well plotted against fluorescence. 
 Measured by a plate reader after incubation with 75nM TMRM for 40 minutes. 
Trendline represents linear regression (r
2
=0.980). Error bars represent standard 
error of the mean for the octuplet.  
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before staining with 100µl 75nM TMRM for 40 minutes prior to washing 3 times in 
PBS and emitted fluorescence measured using a plate reader. Figure 5.5 shows the 
relationship cell number and TMRM fluorescence. The trendline (r
2
=0.980) shows the 
linear relationship between the two factors, indicating that as cell number and therefore 
the number of mitochondria per well increases, so does fluorescence in a predictable 
manner. It should be noted that the level of fluorescence detected was markedly lower 
in this experiment than in the previous dye only experiment, however, this is likely to be 
because the uptake of TMRM is limited and therefore excess dye is removed during the 
washing stages which in turn means less fluorescence is detected. Although this is 
unlikely to affect the assay as the strong, linear relationship is maintained. 
 
5.4.4. Relationship of Hoechst and TMRM 
The interaction between Hoechst and TMRM was investigated. This was carried out to 
determine if as cell number increased, and therefore emitted fluorescence from Hoechst, 
the increase in TMRM fluorescence could be reliably predicted, i.e. is the relationship 
between Hoechst and TMRM fluorescence linear?  
 
As with the previous experiments, a 1:1 serial dilution of HeLa cells was prepared 
ranging from 8x10
4
 to 625 cells/well in octuplet across a 96 well plate. This was then 
stained with 75nM TMRM as described previously. After reading, the cells were fixed 
in 4% PFA and stained with Hoechst prior to washes in PBS and fluorescence measured 
by a plate reader. The relationship between these two dyes is shown in figure 5.6. The 
relationship has a strongly linear characteristic, represented by a trendline of r
2
=0.991. 
This shows that as Hoechst fluorescence increases in proportion to cell number, so does 
TMRM fluorescence. The predictable nature of this relationship means that if TMRM 
fluorescence changes due to an increase in mitochondrial mass, it would be detected as 
the normal relationship is so well defined.  
 
This relationship shows that the dye choice of TMRM and Hoechst for mitochondria 
detection and cell number normalisation are excellent as together they enable the 
assessment of changes in TMRM fluorescence or cell number relative to controls. 
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5.4.5. Control molecules 
Although I have shown that the assay can detect increases in mitochondrial load per 
well, appropriate controls are needed to show that the assay can detect both increases 
and decreases in mitochondrial mass per cell when compared to untreated cells. 
Therefore the characterisation of a positive control, which will increase mitochondria 
per cell, and a negative control, which will decrease mitochondria per cell will be 
discussed in this section.  
 Negative control 5.4.5.1.
Treatment with 10µM FCCP has been shown to cause membrane depolarisation which 
in turn leads to the degradation of mitochondria through autophagy (Saita et al. 2013). 
TMRM accumulation into the mitochondria will also be prevented by this loss of 
Figure 5.6 - Hoechst fluorescence plotted against TMRM fluorescence across a cell 
number concentration series.  
A linear regression trendline is shown (r
2
=0.991). Error bars represent the standard error of the 
mean for the octuplet.  
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membrane potential as the dye localises to the mitochondrial matrix in a membrane 
potential dependant manner. To allow TMRM to accumulate, the membrane potential 
has to be restored by removing FCCP and allowing the proton gradient to recover. This 
is essential as it will ensure that any fall in detected TMRM fluorescence has not been 
caused by decreased dye accumulation.  
 
To develop a protocol for FCCP removal and restoration of Δψm, HeLa cells were 
grown in glass bottomed wells in the presence of 10µM FCCP for 24 hours, a no dose 
control was also prepared. After incubation, one well was washed three times in PBS 
and placed in FCCP free media. This was then left for 1 hour at 37
o
C in an atmosphere 
of 5% CO2, before washing three times in FCCP free media. After this, all wells were 
incubated with 10nM TMRM as described in section 2.3.1, and imaged using a Zeiss 
Axiovert 200M fluorescent microscope. Images are shown in figure 5.7. Cells not 
treated with 10µM FCCP (figure 5.7 A) show normal mitochondrial TMRM staining. 
This is contrasted by FCCP treated cells which do not exhibit a reticular network (figure 
5.7 B & C). However, in cells treated with FCCP but washed prior to staining (figure 
5.7 B) there is a punctate pattern of staining not seen in the treated and unwashed cells. 
 
Punctate staining in figure 5.7 B is likely to be the remaining mitochondria that have not 
degraded by autophagy. The unwashed cells show no discernible pattern of TMRM 
staining, it should be noted that the cell outline is visible in these cells due to the high 
exposure time of 1.6 seconds needed to pick up a signal in the TMRM emission range. 
The lack of staining was due to FCCP preventing the restoration of a normal 
mitochondrial membrane potential, thus inhibiting TMRM accumulation within 
mitochondria. 
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Once it was established that staining of the mitochondrial network is possible after 
removal of FCCP, the effect of the negative control on TMRM fluorescence was 
assayed using a plate reader. 5x10
3
 cells per well were seeded on a 96 well plate and 
allowed to grow for 48 hours. The media of 50% of the 96 wells was replaced with 
complete media supplemented with 10µM FCCP and then left to incubate for 22 hours. 
After incubation, all cells were washed to remove FCCP. The level of TMRM and 
Hoechst fluorescence was measured as described previously. The level of TMRM 
fluorescence was normalised to cell number by dividing TMRM by Hoechst 
fluorescence. Normalised values for non-treated and FCCP treated cells were analysed 
using an unpaired Student’s t-test which found a significant difference between the two 
populations (p<0.0001). A boxplot of the data is shown in figure 5.8; this shows the 
significant decrease in mitochondrial mass when cells are treated with 10µM FCCP for 
24 hours.  
 
No FCCP FCCP - Washed 
FCCP –Not Washed 
Figure 5.7 - HeLa cells stained with 10nM 
TMRM after incubation with 10µM FCCP 
for 24 hours.  
A- non FCCP treated cells, B-FCCP treated, 
washed with PBS three times and media three 
times prior to TMRM incubation. C- FCCP 
treated, not washed.  
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 Positive control 5.4.5.2.
A literature search was performed to highlight any compounds that have been shown to 
increase mitochondrial density that could act as a positive control for the assay. Two 
compounds were found; paclitaxel and bezafibrate, both of which are currently used as 
pharmaceutical agents and both of which have been shown to increase the density of 
mitochondria (Karbowski et al. 2001; Wang and Moraes 2011). The first of these, the 
anti-mitotic drug paclitaxel, has been shown to stabilize microtubule assembly, 
preventing their breakdown. Although this drug is primarily used pharmaceutically to 
inhibit cell division, Karbowski and colleagues have shown that stabilisation of 
microtubules during interphase can cause an accumulation of mitochondria in HeLa 
cells (Karbowski et al. 2001). Although the authors determined mitochondrial density 
per cell using Mitotracker Orange dye to stain mitochondria and then quantifying the 
Figure 5.8 - Effect of FCCP on mitochondrial mass.  
Boxplot of no dose control and 10µM FCCP treated HeLa cells against 
TMRM fluorescence normalised to Hoechst fluorescence. Error bars show 
maximum and minimum values. Significance was determined by 
Student’s t-test (***=p<0.0001). 
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amount of dye per cell using FACS, this assay should be able to detect the change as it 
too quantifies mitochondria based on the amount of a mitochondrial dye per cell.   
 
To test this, HeLa cells were synchronised in G1/S phase of the cell cycle by double 
hydroxyurea block to deplete deoxyribonucleotides (Karbowski et al. 2001). Briefly, 
cells were cultured for 48 hours in a T75cm
2
 flask before the addition of 0.1M 
hydroxyurea. Cells were left for 24 hours before washing in fresh media and cultured in 
the absence of hydroxyurea for 8 hours. After 8 hours, 0.1M hydroxyurea was added to 
the cells and incubated for 16 hours. The now synchronised cells were passaged and 
seeded on a 96 well plate (5x10
3
 cells/well) and allowed to grow for 24 hours. Media 
was removed from 8 wells on the plate and replaced with media containing 2.5µM 
paclitaxel as described by (Karbowski et al. 2001) and left for 24 hours. A further 8 
wells were incubated with 2.5µM paclitaxel for 22 hours. This was carried out on the 
remaining wells every two hours, 8 wells were left free of paclitaxel to act as no dose 
controls. The effect of incubation length with paclitaxel was investigated to determine 
the correct time to dose the cells as the effect of the drug is cell cycle dependant. 
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Figure 5.9 shows the effect of paclitaxel incubation length on cell number and 
mitochondria per well. Incubation times of longer than 14 hours limit the number of 
cells per well (figure 5.9 A). This is likely to be caused by either cell death induced by 
longer incubations with paclitaxel, or because paclitaxel has inhibited the division of 
cells which may have occurred 16 hours after the start of the experiment, thus limiting 
their number at the end of the assay. The interaction of paclitaxel with mitochondria 
shows that incubations shorter than 24 hours actually causes a decrease in mitochondria 
both per well shown by total TMRM fluorescence (figure 5.9 B) and per cell (figure 5.9 
C). This is possibly because periods shorter than 24 hours limit the time available for 
mitochondria to accumulate during interphase. The reason that mitochondria do not 
increase with cell number for the shorter (<14hour) incubations could be due to 
paclitaxel induced toxicity during cell division preventing the biogenesis of new 
mitochondria.  
 
Figure 5.9 - Effect of 2.5µM paclitaxel on cell 
number and mitochondrial density. 
 A shows the effect of incubation period on cell 
number per well. B shows the effect of 
incubation period on total mitochondria per 
well. C shows the effect of incubation time on 
mitochondrial density per cell 
(TMRM/Hoechst), the y-axis has been 
truncated. Panel A and B error bars show 
maximum and minimum values, C error bars 
show standard error of the mean (n=8).   
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Figure 5.9 C shows that there is an increase in the density of mitochondria per cell in 
cells incubated with paclitaxel for 24 hours. A Student’s t test was performed to 
determine the significance of this increase, however it was found that this was not 
significant (p=0.229) compared to no dose controls.  
 
Due to the lack of significance with this result, it was decided to investigate a second 
positive control compound; the PPAR pan agonist bezafibrate. Work by Wang and 
Moraes has shown that a 72 hour treatment with 400µM bezafibrate leads to an increase 
in mitochondrial biogenesis in HeLa cells (Wang and Moraes 2011). More recently it 
has been shown that bezafibrate can improve the so called “ageing” phenotype in a 
mtDNA mutator mouse model (Dillon et al. 2012). Both of these effects are believed to 
be caused by bezafibrate activating PPARs (Tenenbaum et al. 2005), which regulate 
transcription of genes involved in mitochondrial biogenesis (Puigserver and Spiegelman 
2003). Based on this evidence it was decided to trial bezafibrate as a potential positive 
control.  
 
An initial experiment was carried out to assess the optimal concentration to dose HeLa 
cells. Although Wang and Moraes showed a 400µM concentration caused mitochondrial 
biogenesis, they stated that this concentration was selected from work based on 
fibroblast cell lines. Therefore HeLa cells were incubated with a concentration range of 
500µM to 50µM bezafibrate for 72 hours, after which their mitochondrial density and 
cell number was measured. This data was used to normalise the density of mitochondria 
to cell number which is shown in figure 5.10. A Mann-Whitney U test was performed to 
assess significance in changes of mitochondrial density. It was found that a 
concentration of 450µM gives a greater increase in mitochondrial density when 
compared to no dose controls (p<0.001). Interestingly, all concentrations of bezafibrate 
led to a lower cell number when compared to no dose controls, this correlates with data 
shown by Wang and Moraes that indicates slowed growth of HeLa cells in glucose 
media when exposed to bezafibrate (Wang and Moraes 2011).  
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Due to the significant increase in mitochondrial density, it was decided that bezafibrate 
should be used as a positive control for the assay. 
 
5.4.6. Automation 
To increase the throughput of the assay, it was important to develop methods to 
automate part of or the entire assay. Due to the large number of media changes and 
washes, it was decided to use a Beckman Coulter liquid handling robot equipped with a 
96 well liquid handler in place of manual pipetting. Over the course of the assay this 
decreased the time it took to process one plate from 20 minutes to 5 minutes. Using the 
Figure 5.10 - The effect of bezafibrate concentration on 
mitochondrial density.  
HeLa cells were incubated with various concentrations of bezafibrate 
for 72 hours prior to the density of mitochondria per cell being assessed 
using the plate reader assay. Error bars show maximum and minimum 
values. *=p<0.05, **=p<0.01, ***=p<0.001, one way ANOVA test.  
 Bezafibrate concentration (µM) 
*** 
* 
* 
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robot not only increased the speed of carrying out the various steps but it also enabled 
the control of liquid velocity as the liquid is moved into and out of the well. This was 
essential as it prevents the loss of cells, which may be aspirated off the bottom of the 
well by over-zealous pipetting.  
 
A comparison of manual and robotic pipetting was carried out by determining the cell 
number of six plates, three of which were processed manually, three by robot. 
Incubation times and assay length were the same for all plates and all plates were 
seeded using cells from the same culture. Two measures of cell number standard 
deviation (SD) were calculated, inter-plate SD comparing whole plates processed by 
robot or manually and intra-plate SD comparing deviation of 8 well columns on all 
plates. Graphs of this are shown in Figure 5.11. 
 
 
Figure 5.11 A shows that there is smaller deviation of Hoechst fluorescence in plates set 
up robotically than manually. The smaller error bars also indicate that there is less 
variation between plates set up robotically than manually. This is also the case in figure 
Figure 5.11 - Standard deviation of Hoechst fluorescence of 96 well plates when processed either 
manually or robotically. 
A shows standard deviation of Hoechst fluorescence calculated from whole plates; n=3. B shows 
standard deviation of 8 well columns; n=36. Error bars show standard error of the mean.  
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5.11 B which shows that the variation of Hoechst fluorescence is lower across 
individual plates when processed using the robot. This means that using the robot will 
lead to less variation between plates and also between individual wells on plates and 
will therefore be used to carry out all liquid handling procedures for this assay.  
 
5.5. DISCUSSION 
This chapter aimed to develop a plate reader based assay that uses fluorescent markers 
to detected changes in mitochondrial density in cells after treatment with test 
compounds. The methods in this chapter were developed to screen a large number of 
compounds for effects on mitochondrial density. Screening of compounds is essential 
for the effort to discover new drugs that can improve symptoms in diseases with 
mitochondrial pathologies.  
 
Development of this assay has shown that it is possible to detect changes in 
mitochondrial density by detecting emitted fluorescence from mitochondria stained with 
TMRM and then normalising to cell number. Use of the robot has enabled the accuracy 
of the assay to increase while also decreasing the time taken to perform each step. 
Although methods exist that have been shown to be sufficient for mitochondrial density 
quantification, development of a higher throughput system is essential for drug 
screening as it enables investigation of more compounds and therefore increases the 
chances of discovering an active agent. The assay developed during this chapter is 
summarised in the schematic below (figure 5.12). The final assay protocol is shown in 
materials and methods section 2.7.  
 
It should be noted that as this assay uses 75nM TMRM, a quenching effect is likely to 
be seen. This phenomenon occurs when high concentrations of TMRM are used and 
causes a decrease in the intensity of emitted fluorescence. In situations where the 
membrane potential dissipates and TMRM leaves mitochondria, the concentration of the 
dye decreases and the quench is resolved, briefly increasing the intensity of the emitted 
fluorescence (Scaduto and Grotyohann 1999). This will not be an issue for this assay as 
the membrane potential will remain stable during imaging. However, if any of the 
extracts cause a fall in membrane potential, it is possible that the TMRM will not 
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accumulate to the same concentration as other samples, and if this concentration is low 
enough to not be in “quench mode” then it is possible that the emitted fluorescence is 
more intense than other samples, creating a false positive. If this does occur, the use of 
microscopy to determine changes in mitochondrial mass will highlight the false positive 
and the extract will be removed from the investigation.
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6 A high throughput screen to detect changes in mitochondrial mass 
caused by a library of bacterial extracts 
 
6.1. INTRODUCTION 
 
As discussed in the previous chapter (section 5.1), there is an essential need to develop 
pharmaceuticals that can improve the function of mitochondria. With recent work 
showing that increased mitochondrial biogenesis can lead to an improved phenotype in 
models of mitochondrial dysfunction (Dillon et al. 2012; Dillon et al. 2012), it was 
decided to use the assay developed in chapter 5 to screen a library of compounds for 
effects on mitochondrial mass.  
 
6.1.1. The Library 
A library of compounds secreted from actinomycetes bacteria, a major component of 
the phylum Actinobacteria, has been collated by our industrial partner Demuris Ltd. 
Actinomycetes are Gram-positive bacteria which are found in almost every 
environmental niche on Earth, ranging from marine environments to deserts (Takizawa 
et al. 1993; Jensen et al. 2005; Pathom-Aree et al. 2006; Montero-Calasanz Mdel et al. 
2013). This success at colonising diverse habitats has been facilitated by their ability to 
produce and secrete a range of natural products, many of which have the ability to 
inhibit competing organisms such as other bacteria and fungi. The ability of 
actinomycetes to secrete a wide range of bioactive compounds has been exploited in the 
production of antibiotics, for example the widely used anti-mycobacterial Streptomycin 
is secreted by Streptomyces griseus, an actinobacterium (Waksman et al. 1946).  
 
Although the majority of the library has not yet been properly characterised, their uses 
as anti-microbial agents are of primary interest to Demuris; however some compounds 
secreted by the bacteria have been shown to act on mitochondrial targets. One such 
example is chloramphenicol, a broad-spectrum antibiotic derived from the bacterium 
Streptomyces venezueluae, which decreases production of mitochondrially encoded 
proteins by preventing translation via reversible binding to the 55S ribosomal subunit 
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and inhibition of peptidyl transferase (Kuntzel 1969; Denslow and O'Brien 1974). An 
interaction of this type highlight the potential that other secreted compounds could also 
interact with mitochondria, some of which may have positive effects such as increasing 
mitochondrial biogenesis. It is likely that extracts will contain numerous compounds 
that have been secreted by the bacteria. In the event that an increase in mitochondrial 
mass is highlighted during the screen, the responsible extract will have to be 
fractionated to determine the active compound. However, prior to fractionation of any 
interesting extracts, further investigations using microscopy will be carried out to verify 
any changes in mitochondrial mass highlighted during the screen.  
 
This chapter will focus on the screening of extracts using the methods described 
previously in chapter 5.  
 
6.2. AIMS 
In order to facilitate the discovery of compounds that affected mitochondrial biogenesis, 
this chapter fulfilled the following aims: 
I. To screen and characterise changes in mitochondrial mass caused by 864 
individual extracts secreted by actinomycetes bacteria.  
 
II. Identify extracts that show a greater effect on mitochondrial mass than 
bezafibrate. 
 
III. To verify increases in mitochondrial mass using microscopy techniques. 
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6.3. METHODS 
The assay will be performed using the protocols developed in chapter 5 and detailed in 
materials and methods section 2.7.  
 
6.3.1. Extract preparation 
To generate the library, 864 individual actinomycetes species were grown on agar for an 
appropriate length of time, after which agars were crushed using sterile syringes and 
placed in 1.5ml tubes prior to overnight storage at -20
o
C to further degrade the agar. 
Freezing of the bacteria may also lyse their cell membrane, however this is likely to be 
minimal and the majority of cells are likely to be intact. Tubes were thawed and 
centrifuged to pellet the agar; the supernatant containing aqueous and organic extracts 
was then taken and arrayed into 96 well plates. This generated a library of 864 unique 
extracts.  
 
6.3.2. Extract dosing 
Arrayed extracts were delivered by Demuris Ltd in 96 well plates, with each well 
containing a unique extract containing molecules secreted by one species of bacteria. 
Plates were stored at -80
o
C to limit degradation of compounds that make up the extracts. 
Prior to screening, plates were defrosted on ice and allowed to reach room temperature. 
The extracts are not produced in an aseptic environment; therefore there is a chance of 
bacterial or fungal contamination. To minimise the chance of infection and to pellet 
precipitates, plates were centrifuged at 2000g for 30 minutes to pellet remaining 
bacteria, and fungal spores. 
 
All pipetting steps were carried out using a Beckman Coulter liquid handling robot. 3µl 
of each extract was added to individual wells on a 96 well plate containing HeLa cells 
that were seeded 24 hours previously (original density was 5 x 10
3
 cells/well). Each 
well contained 147µl complete media, creating a 1 in 50 dilution of extracts (the 
rationale for this dilution is discussed in section 6.4.1). The supernatant of each extract 
was added to 1 well of HeLa cells - on four separate plates - generating four repeats. 
The repeats were set up in this way to enable the use of the 96 well robotic liquid 
handler. Once dosed, plates were incubated at 37
o
C in a humidified atmosphere of 5% 
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CO2 for 48 hours. Plates containing no dose controls, FCCP (negative) controls and 
bezafibrate (positive) controls were also prepared in accordance with the protocols 
described in section 2.7.2.  
 
6.3.3. Excitation and emission analysis 
Extracts that indicated increases in mitochondrial mass had their fluorescence emission 
at 561nm measured using the plate reader. A 1 in 50 dilution in H2O of each active 
extract was arrayed on a 96 well plate in triplicate (100µl/well). The plate was excited 
using a 520/30nm filter and emission at 561nm measured.  
 
6.3.4. Microscopy analysis 
To verify “hit” extracts, HeLa cells were seeded in 24 well glass bottomed plates- 5x103 
cells per well. After 24 hours “hit” extracts were added to the wells to a final dilution of 
1 in 50 and incubated for 48 hours. Cells were stained with 10nM TMRM and Calcein 
Blue (20µM final concentration) for 30 minutes, after which they were washed 3 times 
in complete media without Phenol Red. Z-stack images were captured using a Nikon 
A1R confocal microscope using appropriate excitation and emission settings. The 
volume of mitochondrial staining (TMRM) was calculated and normalised to cell 
volume (Calcein blue: 360/449nm Ex/Em) using Imaris software (Bitplane, AG), to 
give mitochondrial mass.  
 
6.3.5. Statistical analysis 
All statistical analysis for the screen was performed using the statistical package R 
(version 2.15.2). Graphs were also produced using this package and GraphPad Prism. 
Microscopy analysis was quantified using Excel (Microsoft). Normality tests were 
performed on all data sets using Minitab 16 statistical software (Minitab, Inc.). 
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6.4. RESULTS 
Using the assay developed in chapter 5, a library of 864 unique bacterial extracts was 
screened for changes in the mitochondrial mass of HeLa cells.  
 
6.4.1. Concentration determination 
Prior to screening the entire library, a sample plate of extracts was chosen at random to 
trial the assay. Information from this trial was used to determine an appropriate dosing 
concentration and likely infection rates. The extracts to be screened are likely to be 
heterogeneous in concentration and potency, with a range of activities and toxicity 
therefore likely to be seen on one plate of extracts. Due to this, choosing a concentration 
that represented the best range for testing for every extract in the screen was very 
difficult. It was decided to choose a concentration that caused the least toxicity, while 
maintaining the bioactivity of the extracts. It is unlikely that a change in mitochondrial 
mass would be found from screening just one plate of extracts, therefore bioactivity had 
to be determined using another marker. 
 
One plate of extracts was chosen at random and added to HeLa cells over a range of 
dilutions (1 in 10, 1 in 50 and 1 in 100). Cells were incubated for 24 hours before being 
imaged using the protocol in section 2.7, after which they were incubated for a further 
24 hours at 37
o
C to monitor for cell death. Morphological changes in treated HeLa cells 
were used as a marker for bioactivity of the extracts. This was chosen as it is easy to 
determine and could indicate potential effects such as interactions with the cytoskeleton 
(Sumiya et al. 2011; Brandhagen et al. 2013), highlighting bioactivity of the extracts. A 
morphological change was defined as any difference in the shape of the cells that could 
be recognised by eye when compared to controls. All plates were examined by 
microscopy and it was found that one extract led to morphological changes that 
occurred in samples diluted 1 in 10 and 1 in 50 (figure 6.1 A & B). However this 
change was not observed in cells treated with a 1 in 100 dilution of the extract (figure 
6.1 C). Cells were examined 24 hours after imaging and it was found that the 1 in 10 
dilution had killed the cells, it was therefore decided to use a 1 in 50 dilution when 
dosing with the remaining extracts. Although this is a crude way of determining dosing 
concentration, it was decided to use this dilution initially to look for hits and in the 
event that no hits were found, or the toxicity was too high to try another dilution.  
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Figure 6.1 - Morphological changes induced by one extract over a dilution series.  
A shows changes caused by a 1 in 10 dilution. B shows changes caused by a 1 in 50 dilution. C shows 
changes caused by a 1 in 100 dilution. D shows HeLa cells that have not been treated. Morphological 
changes were classed as a change in shape of the cells when compared to the no dose control.  
Scale bars -100µm. 
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6.4.2. The high throughput screen 
Due to the quantity of plates to be analysed (41, 96 well plates in total), it was not 
possible to complete all the live cell procedures at the same time, therefore the extract 
plates were screened in two groups, separated by one day (table 6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Five plates of extracts were seeded in group one, four plates in group two totalling 864 
individual extracts. Each extract was diluted 1 in 50 and incubated with HeLa cells for 
48 hours in quadruplicate. No dose controls totalled 96 individual repeats per group, 
10µM and 5µM FCCP totalled 32 wells each per group, 450µM bezafibrate control 
consisted of 96 individual repeats. A 5µM FCCP control was added to the assay to 
investigate any difference in the degradation of mitochondria when compared to 10µM 
FCCP. In total 3872 wells were dosed with either an extract or control and stained with 
both dyes (TMRM and Hoechst), generating 7744 individual data points for the entire 
screen. The data generated from the entire screen is discussed in the remainder of this 
chapter. 
Table 6.1 - Timings of the extract screen 
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6.4.3. Plate diagnostics 
Prior to analysis of changes in mitochondrial mass, the data was analysed to ensure that 
there was no difference in cell growth due to edge effects, which are a known issue 
when using a high throughput assay (Lundholt et al. 2003). They are caused by 
differential growth of cells based on where they are on the plate, but in general it is 
thought that cells seeded on the outside rows (1&8) and columns (1&12) are prone to 
variation in cell number (Lundholt et al. 2003). This is due to differences in evaporation 
rates, CO2 exposure and temperature, in wells on the edge of the plate, with gas 
diffusion and exchange occurring more readily in these wells.  
 
 No dose controls  6.4.3.1.
To check for edge effects, boxplots of Hoechst fluorescence for individual columns and 
rows were produced, first for no dose control plates, and then for the data set as a whole.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 - Boxplot of Hoechst fluorescence plotted against column number 
for no dose controls.  
Boxplot shows the interquartile range and median value, whiskers show maximum 
and minimum values.  
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Figure 6.2 shows a boxplot of Hoechst fluorescence per column for the no dose control 
plates. There is little variation in the median value between columns; however the 
interquartile range and maximum and minimum values is greater for columns on the 
edge of the plate (1, 2 & 11, 12), therefore a Mann-Whitney U test was performed to 
compare the values for the edge columns against the other columns. It was found that 
there was no significant difference between the two (p=0.21), indicating no edge effect 
associated with column number. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 shows Hoechst fluorescence plotted against row number for the same no 
dose control data set as represented in figure 6.2. There is less variation of Hoechst 
fluorescence between rows than was seen when the data was grouped according to 
column number, however this could be due to an increase in the number of data points 
represented (12) when the data is grouped in rows rather than columns (8 data points). It 
could also indicate that the wells with the highest variation are found in columns 1 and 
12, an effect which is disguised when data is grouped by row. A Mann-Whitney U test 
Figure 6.3 - Boxplot of Hoechst fluorescence plotted against row number for 
no dose controls. 
Boxplot shows the interquartile range and median value, whiskers show maximum 
and minimum values. 
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was performed to test for significant differences between the fluorescence of inside 
rows when compared to the two edge rows. As with the column data, no significant 
difference was found between the medians of Hoechst fluorescence (p=0.37), indicating 
no edge effects.  
 
 Whole screen  6.4.3.2.
To ensure the relationship between row, column and Hoechst fluorescence was the same 
across the whole screen as it was for the no dose control plates, boxplots were 
constructed. The Hoechst fluorescence data for all plates was collated and plotted 
against either row number or column number, these are shown below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 - Boxplot of Hoechst fluorescence plotted against column number for all 
screened plates.  
Boxplot shows the interquartile range and median value, whiskers show maximum and 
minimum values (excluding outliers); outliers are represented by circles (values 1.5 
times bigger or smaller than the quartiles).  
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Figure 6.4 represents collated data for the entire screen plotted against column number. 
The boxplot shows a uniform distribution of Hoechst fluorescence across all columns, 
indicating that there is not a significant difference between the edge columns and inner 
columns, this was confirmed using a Mann-Whitney U test (p=0.31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 shows the collated data for all screened extracts plotted against row number. 
As with the previous boxplot, there is no obvious difference in the variation of the data 
between row numbers, again a Mann-Whitney U test showed there was no significant 
difference between fluorescence detected in the wells of the edge rows when compared 
to the inner rows (p=0.11). 
 
Figure 6.5 - Boxplot of Hoechst fluorescence plotted against row number for all 
screened plates.  
Boxplot shows the interquartile range and median value, whiskers show maximum and 
minimum values (excluding outliers); outliers are represented by circles (values 1.5 
times bigger or smaller than the quartiles). 
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Although edge effects are common in plate based assays, the degree of any effect is 
dependent on the volume of liquid in the well, as this determines evaporation rates and 
heat retention. As this assay uses 96 well plates with 150µl of liquid per well, it is likely 
that this volume is sufficient prevent a severe edge effect being exhibited, whereas it is 
common for screens using 384 well plates to ignore the outermost wells as these are 
badly affected by edge effects due to the use of much smaller volumes (Lundholt et al. 
2003). 
 
6.4.4. Normalisation 
Due to the different seeding times discussed in section 6.4.2 and shown in table 6.1, it 
was not possible to use cells from the same flask to seed all plates. Therefore prior to 
cell seeding, a culture was split into two T225cm
2
 flasks to provide two batches of cells, 
one for each group of plates both with the same passage number.  
 
The difference in seeding times and cultures may lead to different growth rates between 
the groups of cells, causing lower Hoechst fluorescence to be detected at the endpoint of 
the assay and consequently lower TMRM fluorescence. The Hoechst and TMRM 
fluorescence for the two no dose control plates – seeded on separate days- was analysed 
to see if there was a significant difference using a Mann-Whitney U test. The median 
values for both fluorophores and the significant difference between each plate are 
shown in Table 6.2.  
 
Table 6.2 - Table showing the median values of Hoechst and TMRM fluorescence for day one and 
day two no dose control plates.  
 
Significant differences of day two plate from day one plate are shown, as calculated by a Mann-Whitney 
U test.  
 
Plate 
Hoechst median 
value 
Significance 
(Mann-Whitney 
U test) 
TMRM median 
value 
Significance 
(Mann-Whitney 
U test) 
Day one- ND 
control 
508 NA 8209 NA 
Day two- ND 
control 
408.5 P<0.0001 6458 P<0.0001 
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Due to the significant difference between the Hoechst and TMRM fluorescence for the 
control plates, it was necessary to normalise the two halves of the screen. The difference 
in cell number between the two plates is likely to be a constant across the entire screen, 
with the day one seeded plates showing a higher cell number than the day two plates 
after 72 hours growth. However, due to the effect the extracts may have on cell number, 
it is difficult to analyse the differences attributed to seeding time on an individual 
extract basis. Therefore a general normalisation factor was applied across the screen 
based on the behaviour of the no dose control plates. This factor was worked out by 
dividing the median value of plate one by the corresponding median of plate two to 
generate a factor for each dye: 
Hoechst normalisation factor = 1.24 
TMRM normalisation factor = 1.27 
The fluorescent values obtained for all plates seeded on day two were multiplied by the 
appropriate factor. Due to the difference between the normalisation factors, the ratios of 
TMRM/Hoechst fluorescence were investigated to ensure that there was no significant 
difference between them after normalisation. This was important to ensure that the 
relationship between mitochondria and cell number was equivalent between the two 
seeding times, and that any changes in the level of TMRM/Hoechst are attributed to the 
extracts rather than being caused by normalisation.  
 
Figure 6.6 shows the distribution of fluorescence measured from the two control plates, 
and the subsequent normalised fluorescence. The ratio of TMRM/Hoechst for each plate 
before and after normalisation is also shown. A significant difference between the day 
one and day two TMRM/Hoechst ratios was discovered, however this difference 
became non-significant after normalisation of the day 2 values (p=0.204) (figure 6.6 C). 
It is likely that this difference was due to pipetting error when preparing TMRM (due to 
the large volumes required to stain all plates) which could have caused an unintentional 
difference in concentration of the dye; this would also explain the need for a larger 
normalisation factor for the TMRM values. It is unlikely that there was variation in the 
concentration of Hoechst as all plates were stained with the dye on the same day and the 
same stock was used.  
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Boxplots of fluorescence measured for individual wells were generated for each dye and 
arranged according to plate. Data is shown for both raw fluorescence and normalised 
fluorescence for Hoechst (figure 6.7) and TMRM (figure 6.8), plates contained in the 
boxes were subject to normalisation.  
Figure 6.6 - Boxplots of measured 
fluorescent signal from no dose 
(ND) control plates seeded on 
separate days and their subsequent 
normalisation. 
A-Measured Hoechst fluorescence 
for day 1 and day 2 control plates. 
Normalised values for day 2 are also 
shown. B-Measured TMRM 
fluorescence for day 1 and day 2 
control plates. Normalised values for 
day 2 are also shown. C-
TMRM/Hoechst ratios for day 1 and 
day 2 control plates. The ratios 
generated from the day 2 normalised 
values are also shown. Statistical 
analyses was performed using a 
Mann-Whitney U test, 
***=p<0.0001.  
Chapter Six  Mitochondrial mass drug screen 
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hoechst fluorescence (RFU) 
Hoechst fluorescence (RFU) 
F
ig
u
re
 6
.7
 -
 B
o
x
p
lo
ts
 o
f 
H
o
ec
h
st
 f
lu
o
re
sc
e
n
ce
 f
o
r 
in
d
iv
id
u
a
l 
p
la
te
s.
  
T
h
e 
b
lu
e 
b
o
x
 d
en
o
te
s 
p
la
te
s 
se
ed
ed
 o
n
 t
h
e 
se
co
n
d
 d
a
y
 o
f 
th
e 
sc
re
en
. 
A
 s
h
o
w
s 
p
re
-n
o
rm
al
is
at
io
n
 v
al
u
es
. 
B
 s
h
o
w
s 
n
o
rm
al
is
ed
 v
al
u
e
s.
 E
rr
o
r 
b
ar
s 
sh
o
w
 
m
ax
im
u
m
 a
n
d
 m
in
im
u
m
 v
al
u
es
. 
Chapter Six  Mitochondrial mass drug screen 
168 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TMRM fluorescence (RFU) 
TMRM fluorescence (RFU) 
F
ig
u
re
 6
.8
 -
 B
o
x
p
lo
ts
 o
f 
T
M
R
M
 f
lu
o
re
sc
e
n
ce
 f
o
r 
in
d
iv
id
u
a
l 
p
la
te
s.
  
T
h
e 
b
lu
e 
b
o
x
 d
en
o
te
s 
p
la
te
s 
se
ed
ed
 o
n
 t
h
e 
se
co
n
d
 d
a
y
 o
f 
th
e 
sc
re
en
. 
A
 s
h
o
w
s 
p
re
-n
o
rm
al
is
at
io
n
 v
al
u
es
. 
B
 s
h
o
w
s 
n
o
rm
al
is
ed
 v
al
u
e
s.
 C
o
n
tr
o
l 
p
la
te
 1
(C
o
n
 
1
) 
co
n
ta
in
s 
F
C
C
P
 n
o
 d
o
se
 c
o
n
tr
o
ls
, 
co
n
tr
o
l 
p
la
te
 2
 (
C
o
n
 2
) 
co
n
ta
in
s 
b
ez
a
fi
b
ra
te
 c
o
n
tr
o
ls
. 
E
rr
o
r 
b
ar
s 
sh
o
w
 m
a
x
im
u
m
 a
n
d
 m
in
im
u
m
 v
al
u
e
s 
 
Chapter Six  Mitochondrial mass drug screen 
169 
 
6.4.5. Mitochondrial mass analysis 
Following normalisation, data was analysed to assess changes in mitochondrial mass in 
HeLa cells. Data obtained from the plate reader was inputted into the statistical 
computing programme R which collated data and generated a data table containing 
information relevant for analysis using a code written by Dr Peter Banks (High 
throughput screening facility, Newcastle University) and optimised for this assay by 
myself. A mean RFU value for each fluorescent marker was produced for each 
compound screened; this included the three controls (FCCP, bezafibrate and no dose). 
Mean Hoechst values were plotted against mean TMRM values to investigate the 
relationship of mitochondrial mass to cell number for the entire screen (figure 6.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 - Mean Hoechst fluorescence plotted against mean TMRM fluorescence for each 
compound.  
Points are labelled with compound name. A trendline (black) was generated by calculating linear 
regression for all data points (r
2
=0.571). The 99% prediction (red) and confidence (blue) intervals 
are also shown.  
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The r
2 
value for the linear relationship was 0.571, which suggests that the relationship 
between mitochondrial mass and cell number isn’t as strong as the relationship seen 
during assay development, where the linear relationship between the two was r
2
=0.991. 
This difference could be due to a number of outliers that had relatively high Hoechst 
fluorescence; this could be caused by microbial infection- something that was 
monitored throughout the screen. Images were captured of cells after 24 hours 
incubation with the extracts during the screen. Each of these images was analysed to 
check for infection, in particular the wells affected by high Hoechst fluorescence. It was 
found that all of the wells in this outlier region had signs of bacterial contamination. 
Several wells showed signs of fungal infection, interestingly this type of infection 
caused higher TMRM fluorescence, images of two example wells are shown in (figure 
6.10). 
 
 
 
All wells that were deemed to have been infected were removed from the analysis as the 
effect of the infection altered the fluorescent readings. In total 5.5% of extracts led to 
either a bacterial (in spite of the presence of penicillin and streptomycin in the media) or 
fungal infection. 
 
Figure 6.10 - Examples of infected wells. 
A shows characteristic filament like fungal infection. B shows a punctate bacterial infection. Both 
images are labelled with the extract they were dosed with. Images were captured 24 hours after 
dosing. Scale 100µm.  
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The data was reanalysed and mean Hoechst fluorescence plotted against TMRM once 
again, this time with the infected extracts excluded (figure 6.11). The outliers have been 
removed and linear regression calculated from all data points. This is shown by the 
black trendline along with the 99% confidence (blue lines) and prediction (red lines) 
prediction intervals.
 
Hoechst and TMRM fluorescence show a linear relationship (r
2
=0.8431), indicating that 
as cell number increases so does mitochondrial mass. However, the relationship is not 
as strong as seen previously with different numbers of no dose control cells; however 
Figure 6.11 - Mean Hoechst fluorescence plotted against mean TMRM fluorescence for each 
compound. 
Points are labelled with compound name. A trendline (black) was generated by calculating linear 
regression for all data points (r
2
=0.8431). The 99% prediction (red) and confidence (blue) intervals 
are also shown. 
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this is likely to be because of the effect of the extracts causing a deviation from the 
normal relationship.  
 Control molecules 6.4.5.1.
To understand graphically the distribution of the control molecules within the data 
obtained from extract treated wells, a graph was produced which labelled the control 
molecules only. The data from the extracts is shown as purple points, the control 
molecules; bezafibrate, no dose control, 10µM FCCP and 5µM FCCP are labelled as 
BEZ, EMPTY, 10uM FCCP and 5uM FCCP respectively figure 6.12. The same 
trendline, confidence and prediction intervals are shown as in figure 6.11. 
 
 
Figure 6.12 - Mean Hoechst fluorescence plotted against mean TMRM fluorescence for 
each compound.  
Control molecules are represented by black circles and labelled accordingly. Purple points 
represent extract treated cells. A trendline (black) was generated by calculating linear 
regression for all data points (r
2
=0.8431). The 99% prediction (red) and confidence (blue) 
intervals are also shown. 
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Bezafibrate and no dose controls are found in the region of the graph with the highest 
levels of TMRM fluorescence, with bezafibrate showing a greater level of TMRM 
fluorescence than the no dose control, for approximately the same cell number 
indicating an increase in mitochondrial mass. The FCCP controls show a relatively low 
amount of TMRM fluorescence for their cell number, indicating a decrease in 
mitochondrial mass. In general there was a lower level of TMRM fluorescence detected 
in cells treated with the extracts than in the no dose controls. This could be due a toxic 
effect caused by the extracts which leads to a lower level of TMRM fluorescence, 
however to investigate this fully will require further experimentation. 
 
To verify that the positive and negative control molecules increased or decreased 
mitochondrial mass when compared to the no dose control, the TMRM/Hoechst ratio 
was calculated for individual wells treated with the control molecules (figure 6.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 - TMRM/Hoechst ratios of HeLa cells treated 
with controls as part of a high throughput screen.  
450µM bezafibrate was incubated with the cells for 48 hours. 
FCCP controls were incubated for 22 hours prior to medium 
changes. Significance was determined using a Mann-
Whitney U test. ***=p<0.0001 
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There was a significant increase in mitochondrial mass caused by 450µM bezafibrate 
when compared to the no dose controls (p<0.0001, Mann-Whitney U test). A significant 
decrease in mitochondrial mass was found in cells treated with either the 5µM FCCP 
(p<0.0001) or 10µM FCCP (p<0.0001) negative controls when compared to the no dose 
control. Interestingly there was no significant difference in mitochondrial mass between 
the two FCCP controls, indicating that there was a similar effect of both concentrations 
on the removal of mitochondria through autophagy (Saita et al. 2013).  
 
 Statistical analysis of changes in mitochondrial mass 6.4.5.2.
In order to determine which extracts generated the greatest increase in mitochondrial 
mass, a mixed model was used to investigate the effect of Hoechst fluorescence on 
TMRM fluorescence. A no intercept mixed model was chosen as preliminary analysis 
of the data indicated that the relationship between Hoechst and TMRM fluorescence 
was linear. This model enabled the integration of a random effect, in this case the 
extract or controls incubated with the cells, and its effect on the relationship between the 
fixed effects - Hoechst and the variable dependent -TMRM fluorescence (McLean et al. 
1991). This will enable the identification of extracts that have the highest TMRM 
fluorescence in relation to Hoechst fluorescence, and therefore have caused an increase 
in mitochondrial mass.  
 
The fixed part of the mixed model consisted of a single parameter, the gradient, defining 
the average relationship between Hoechst and TMRM fluorescence. The random part of 
the model identified the deviation for each extract or control molecule from the average 
gradient, allowing the identification of those extracts which had the greatest effect on 
the TMRM/Hoechst relationship. The residuals of this model were analysed and 
verified as normally distributed to validate the model. 
 
Table 6.3 shows a list of extracts that led to an increase in mitochondrial mass, 
according to the mixed model, when compared to the no dose controls. The data is 
sorted according to the gradient value (the larger gradients indicate increases in 
mitochondrial mass); the mean and standard deviations for each fluorophore along with 
the TMRM/Hoechst ratios are also shown. Data is also shown for the FCCP controls; 
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which predictably led to the two largest decreases in mitochondrial mass for the entire 
screen. For a comprehensive list of the effects of every extract please see appendix A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The data is sorted by gradient size, largest to smallest. Gradients were generated using a mixed model 
and indicate the quantity of TMRM fluorescence in relation to Hoechst. Mean values and standard 
deviations for both fluorophores are also shown. Only extracts that increased mitochondrial mass in 
relation to the no dose control are shown. The FCCP controls are also shown.  
 
 
 
 
 
Table 6.3 - List of extracts that have increased mitochondrial mass in relation to control 
molecules.  
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6.4.6. Selection of active extracts 
A set of criteria were developed to determine which extracts to investigate further. This 
was necessary as it was important to ensure that the effect of the extracts on 
mitochondrial mass was significant in order to prevent the investigation of false 
positives. The criteria were as follows: 
 A gradient greater than that of bezafibrate. 
 A TMRM/Hoechst ratio that was significantly higher (Mann-Whitney U test) 
than that of bezafibrate. 
 A standard deviation of TMRM fluorescence smaller than 5% of the mean 
TMRM RFU value. 
Only extracts that caused a greater increase in mitochondrial mass than the positive 
control, bezafibrate, were selected for continued investigation as the aim of the screen is 
to discover a compound that has higher efficacy than bezafibrate. It was also essential 
that TMRM/Hoechst ratios of treated cells were significantly increased in comparison to 
bezafibrate controls. Significance was calculated using ratios generated from the 
repeated doses. Extracts with standard deviations smaller than 5% of the total TMRM 
fluorescence were chosen. It was important to only pick extracts with the smallest 
standard deviations to ensure that the effect they had on mitochondrial mass was similar 
for all repeats and not just due to experimental error or a random effect on one well. 
Extract RP8_F2 was not taken forward as it caused excessive cell death (Hoechst value 
of 114). The extracts that met these criteria- “hit” extracts- are shown in table 6.4. 
 
 
 
 
 
TMRM/ Hoechst ratio, gradients (generated from a mixed model) and standard deviation (SD) as a 
percentage of mean TMRM fluorescence are shown. P values were calculated using a Mann-Whitney U 
test to compare the TMRM/Hoechst ratios of extracts to bezafibrate.  
 
 
Table 6.4 - List of extracts that meet the criteria set out in section 6.4.6.  
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The relationship between of mitochondrial mass per cell for each of the “hit” extracts is 
shown in figure 6.14; significance was calculated using a Mann-Whitney U test. The 
graph shows that extract BP2_G4 caused the largest increase in mitochondrial mass of 
any compound used in the screen, including bezafibrate (p<0.0001). Extract BP2_D1 
also caused a significant increase in mitochondrial mass when compared to bezafibrate 
(p<0.0001). There was a large amount of variation of the TMRM/Hoechst ratios, as 
shown by the large spread of data in figure 6.14, even though the standard deviation of 
the mean met the criteria developed earlier. The variation is caused by the fact that the 
repeat with the lowest detected TMRM fluorescence had the highest cell number; 
therefore a lower TMRM/Hoechst ratio was generated. The final two selected extracts; 
BP6_F4 and JB10_F11 also showed a significant increase in mitochondrial mass when 
compared to bezafibrate.  
Figure 6.14 - Boxplots of TMRM/Hoechst ratios of bezafibrate and 
“hit” extracts.  
Statistical significance was calculated using a one way ANOVA test, 
***=p<0.0001, *=p<0.05. 
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Prior to further analysis, the fluorescent properties of the extracts were investigated to 
ensure that the increase in TMRM signal was not due to the extracts emitting 561nm 
light. The amount of emitted 561nm light was measured for a 1 in 50 dilution in ddH2O 
of each extract (3 repeats of each extract) using the plate reader. A 75nM TMRM 
control and H2O control was also measured (figure 6.15). None of the extracts emitted 
any fluorescence in the 561nm region of the spectra and it was therefore decided to 
confirm changes in mitochondrial mass using microscopy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.15 - 561nm fluorescence emitted by individual 
extracts, 75nM TMRM and H2O.  
Emitted fluorescence from a 1 in 50 dilution of each extract 
was measured in triplicate using a plate reader along with 
TMRM and H2O controls. Error bars represent standard error 
of the mean (n=3).  
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6.4.7. Mitochondrial mass quantification using microscopy 
HeLa cells were seeded on glass bottomed 96 well plates (1 x 10
5
cells/well) in 
antibiotic containing HeLa media. Each extract was diluted 1 in 10 in media prior to 
sterilisation through a 0.22µm filter, after which a volume of extract was added to the 
first well to create a 1 in 50 dilution of the original extract concentration. A 1 in 4 serial 
dilution was then performed across 3 wells generating 1 in 40, 1 in 160 and 1 in 640 
dilutions of the original extract. The starting dilution was chosen to ensure continuity 
with the drug screen. Cells were dosed with the same batch of extract that was used in 
the screen along with a fresh batch of extracts produced from a new bacterial culture, to 
ensure that any effect is reproducible and does not rely on extract batch.  
 
After 48 hours incubation, culture cells were stained with 10nM TMRM and 2µM 
Calcein Blue for 45 minutes before washing in Phenol red free HeLa media and 
imaging using a Nikon A1R confocal microscope (60x magnification). Imaris software 
was used to define the area covered by each stain, TMRM stained mitochondria (Figure 
6.16 panel B), Calcein Blue stained cytoplasm (Figure 6.16 panel C), and then to work 
out the proportion of mitochondria (TMRM) to cell volume (Calcein), a sample image 
is shown in figure 6.16, with the rendered computer generated image of the two stains 
shown in panel D. Four images per concentration were captured, each containing 5 
cells; the proportion of mitochondria was calculated for each image and the data 
grouped together (figure 6.17). It should be noted that this experiment was blinded until 
after analysis of the data to prevent bias at any stage.  
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Figure 6.17 shows changes in mitochondrial mass after treatment with various 
concentrations of the selected extracts. The graph in figure 6.17 shows that only one 
extract, BP2_G4 had an effect on mitochondrial mass with the most concentrated dose 
for each batch showing a doubling in mitochondrial mass per cell. The original batch of 
this extract caused a dose dependent increase in mitochondrial mass, with the lowest 
dose (1 in 640 dilution) showing no effect. The new batch of extract showed a similar 
increase when used at 1 in 40, however the 1 in 160 dilution led to a greater increase in 
mitochondrial mass than any other. The reason for the difference in potency between 
batches could be due to the fact that it is impossible to know the concentration of the 
extract, so although the dilutions are the same, the concentration of the active compound 
is likely to vary between batches. Therefore the concentration range used provides an 
insight into the active concentration range for use in further experiments.  
 
Figure 6.16 - HeLa cells stained with 10nM TMRM and 2µM Calcein 
Blue and the quantification of their respective areas . 
Imaris software was used to detect and calculate the areas stained by each 
dye . The raw image is shown in panel A. Panel B shows a rendered 
image highlighting the TMRM staining only, C shows a rendered image 
of Calcein Blue cytoplasm staining only, D shows the reconstructed 
image which was used to calculate the proportion of mitochondria per cell 
area. 
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6.5. DISCUSSION 
High throughout screens are an essential tool in drug discovery, enabling thousands of 
compounds to be investigated in a relatively short period time. The screen used in this 
chapter was designed to highlight compounds which increase mitochondrial mass in 
HeLa cells; an ability that was verified both in this chapter and the previous chapter 
through the use of control compounds.  
 
By working in collaboration with our partner Demuris Ltd. it was possible to investigate 
a range of diverse compounds that have previously never been investigated for changes 
in mitochondrial mass. Many of the strains that produce the extracts are unique to this 
library and although 864 extracts were analysed in the final screen, the extracts are by 
no means homogenous with each one containing hundreds of different compounds. 
Therefore the screen is actually investigating potentially tens of thousands of 
compounds.  
 
6.5.1. Active extracts 
The screen was carried out with the aim of finding a compound that could increase 
mitochondrial mass to a greater extent than bezafibrate – a compound that has shown 
efficacy at improving mitochondrial function in animal models (Dillon et al. 2012). 
Although the screen indicated that 12 extracts achieved this (table 6.3), it was decided to 
exclude extracts that caused non-significant increases in mitochondrial mass or large 
standard deviations in cell number (this indicated that the extract was not affecting all 
repeats in the same manner and may not be reproducible). It was also decided to exclude 
extracts that exhibited high levels of toxicity (Hoechst fluorescence <200 RFU). 
 
The remaining four extracts were investigated further by microscopy and one extract; 
BP2_G4, was found to cause an increase in mitochondrial mass. No increase was found 
in cells treated with other extracts even though the screen indicated that they had caused 
significant increases. This discrepancy could be due to the extracts causing an increase 
in mitochondrial membrane potential which in turn would enable more TMRM to 
accumulate in mitochondria and therefore emit a greater amount of fluorescence, 
indicating an increase in mitochondrial mass. Conversely the increase in TMRM 
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fluorescence could be due to a lower membrane potential caused by the extracts. As 
75nM TMRM is likely to be in “quench mode”, a decreased membrane potential may 
prevent the quench and cause a larger signal as the fluorescence from TMRM increases. 
However this is likely to require a large fall in membrane potential and both scenarios 
will require further investigation. 
 
6.5.2. BP2_G4 causes an increase in mitochondrial mass 
Extract BP2_G4 caused a significant increase in mitochondrial mass (p<0.0001 Mann-
Whitney U test) when compared to no dose controls. Data from the original screen 
showed that there were fewer cells at the end of the assay than in no dose controls. This 
could indicate toxicity from either the active compound or another compound in the 
extract. The lower cell number could also be due to the fact that mitochondrial mass 
increased from ~20% to over 40% of total cell volume. This increase may cause a 
diversion of cellular resources from other areas to the growth and maintenance of 
mitochondria, which in turn may cause damage to accumulate in the cell, which may 
eventually become unviable. It is unlikely that the extract inhibits cell division as the 
Hoechst fluorescence was 315 RFU at the endpoint, which according to data obtained 
during development of the assay equates to ~2.5 x 10
4
 cells/well. This number of cells 
indicates that at least 2 divisions have occurred since seeding (5 x 10
3
 cells/well) and as 
HeLa cells double every 18-24 hours a division must have occurred ~24 hours after 
dosing with the extract. 
 
The effect of the extract in other cell-lines also needs to be investigated in order to see if 
extract induced changes in mitochondrial mass is specific to HeLa cells. These 
experiments will be carried out using the microscopy techniques described previously 
and also western blots to semi-quantify changes in mitochondrial markers. If changes in 
mitochondrial mass are seen in other cell-lines then the extract will be fractionated in 
order to identify the active compound. This will enable investigation into the 
mechanism of mitochondrial mass increase and will also enable the creation of dose-
response curves which will show the concentration range over which the compound is 
biologically active. The effect of the active compound on OXPHOS will also be 
investigated and analysed using a Seahorse XF analyser to measure oxygen 
consumption of OXPHOS deficient patient cell lines.  
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Although extensive further work is necessary, the discovery of BP2_G4 highlights the 
fact that there are naturally occurring compounds that have the potential to increase 
mitochondrial mass and possibly act to increase ATP production in patients with 
mitochondrial disease.  
 
6.6. CONCLUSIONS 
The need to discovery mitochondrially acting drugs is essential if mitochondrial 
diseases are ever going to be treated effectively. This work has shown that it is possible 
to develop a relatively simple screen to detect changes in mitochondrial mass. By 
discovering the hit extract I have shown that natural products may have the ability to act 
on mitochondrial biogenesis. Although the screen was relatively small compared to 
industrial sized screens, the use of the Demuris library, which contained mixtures of 
compounds within one extract, may be beneficial as it may contain synergistic 
compounds, the effect of which would have been missed if screening single compounds. 
This may also be a hindrance as the action of one compound within an extract may be 
inhibited by another, preventing a pharmacological action that would otherwise have 
been discovered if screening individual compounds. However, it is clear from this work 
that although the extracts are not pure, they still have the ability to have a biological 
effect. With future work focussing on the isolation of the active compound, it may be 
possible to develop a drug with the ability to improve mitochondrial function. 
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7 Final Discussion 
 
The development of treatments for mitochondrial disease is vital for improving the 
prognosis of patients affected by these disorders. Currently there are no effective 
treatments for mitochondrial dysfunction and, as a result of this deficit, clinicians can 
only modulate the symptoms of the disorders; it is therefore inevitable that patient’s 
conditions progress. This project aimed to address this by investigating novel treatment 
options through the development of two different paradigms; a targeted, mutation 
specific approach using anti-genomic CMCOs, and a broad drug screen aimed at 
discovering compounds to increase mitochondrial mass.  
 
7.1. CMCO DEVELOPMENT 
Targeting therapeutics to mitochondria is a complex issue as the trafficking of 
molecules into and out of the matrix is a tightly regulated process. Therefore delivery of 
proteins or small molecules across the inner mitochondrial membrane is facilitated by 
specific carrier proteins which, in the case of peptide transport require specific 
recognition factors to be present on the substrate. Delivery of an anti-genomic 
compound to the matrix will therefore rely on manipulating one of these transport 
systems in order to cross the inner membrane.  
 
Current leaders in this field utilise the TOM/TIM peptide transport system to deliver 
enzymes that can specifically recognise and induce a double strand break in mutated 
mtDNA genomes, leading to mtDNA degradation (Srivastava and Moraes 2001; Tanaka 
et al. 2002; Bacman et al. 2013). The use of TALENS is an approach that has shown 
excellent efficacy in cell models, however, delivery to the cells of a patient is difficult 
as it requires an efficient transfection mechanism that is currently unachievable for 
delivery to affected tissues in man (Bacman et al. 2013). Therefore I attempted to 
specifically target anti-sense oligomers – which do not require specific transfection for 
cellular delivery - to the mitochondrial matrix, where they would be able to recognise 
and hybridise to mutated mtDNA genomes, preventing their replication in vivo. 
Although the inner membrane is generally impermeable to charged molecules, 
lipophilic cations have been shown to accumulate within the matrix after diffusing 
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across the inner membrane. To exploit the ability of this class of molecules to diffuse 
across the inner membrane, I used CMCOs, a class of oligomers with this ability (Posch 
et al. 2012). 
 
Conjugation of mitochondrial specific stains (TAMRA and ATTO 647N), along with 
2,4-mononitrophenol to the CMCOs enabled the specific localisation to mitochondria, 
with ATTO 647N-CMCOs showing the strongest localisation (chapter 3). The sub-
mitochondrial localisation of the CMCOs is unclear however as current microscopy 
techniques cannot resolve the fine structure of mitochondria. Super resolution 
techniques could be used, however these currently require fixation prior to imaging, 
which in the case of CMCOs is not possible as they are not retained within 
mitochondria after membrane depolarisation The “gold standard” test to prove matrix 
localisation is to detect a functional effect on the mtDNA or the levels of COXI protein, 
however no such effect was conclusively proven during this project (chapter 4).  
 
Although more repeats are needed to fully understand the functionality of CMCOs, an 
absence of activity could be due to numerous factors, such as lack of matrix localisation 
or an inability of the CMCO to bind mtDNA or mt-mRNA in vivo. It could also be 
possible that the CMCOs are in fact binding a minority of MTCOI mRNA and 
preventing its translation, but other populations of MTCOI mRNA could be disguising a 
CMCO related inhibition. However, the experiments used in this project mean that it is 
impossible to resolve the reason for this, as it is still unclear if the CMCO has access to 
mtDNA (chapter 3). Therefore it is difficult to draw firm conclusions about the 
effectiveness of CMCOs at selectively binding mtDNA in vivo, except that it was not 
obviously occurring during the experimentation described within this thesis (i.e. there 
was not a dramatic shift in mtDNA copy number). After consultation with our partners, 
Ugichem, who are keen to support the project, it has been decided to redesign the panel 
of experiments carried out on the CMCOs.  
 
As it is difficult to infer the reasons for a lack of functional effect without knowing the 
sub-mitochondrial localisation of the oligomers, future experiments will focus on 
ascertaining this. A new batch of CMCOs, all with the new proprietary side chain, will 
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be produced by Ugichem, which will be incubated with cells or isolated mitochondria. 
After incubation, the mitochondria will be centrifuged through oil (in the case of whole 
cells, mitochondria will first be extracted) in order to remove any unbound CMCO from 
the outer mitochondrial membrane. The mitochondria will then be lysed and the 
contents used in a gel shift assay in order to detect the presence of the CMCOs after 
hybridisation with a complementary probe. This will answer the first question – are 
CMCOs capable of entering mitochondria, both in vivo and in vitro.  
 
If the CMCOs are not shown to enter mitochondria, the project will be abandoned. If 
they are capable of entering mitochondria, the sub-mitochondrial localisation will be 
determined. This could be achieved by repeating the oil centrifugation experiment, after 
which the mitochondrial outer membrane can be shaved off and the contents of the 
intermembrane space removed. If CMCOs are detected in the inner membrane/matrix 
fraction then it is likely that the CMCO has accessed the matrix, or become sequestered 
in the inner membrane. Experience from using this technique to determine the sub-
mitochondrial localisation of proteins has shown that it requires numerous repeats in 
order to be certain of the localisation as fractionation of mitochondria does not always 
yield 100% pure fractions, therefore CMCOs may be detected in the incorrect fraction. 
However, this technique will be optimised to minimise the chance of this occurring and 
substantial repeats will also be used.  
 
Once the sub-mitochondrial localisation has been confirmed it will be possible to 
investigate the functional effects of the CMCOs. As it is clear that the CMCOs can bind 
and inhibit mtDNA in vitro (Kyriakouli 2007) and can also selectively bind nDNA 
targets (Unpublished data, Ugichem, GmbH) optimisation of CMCO mtDNA binding in 
vivo should also be possible. However, optimisation may require the production of 
CMCOs with different thermal melt temperatures by modifying the length and 
backbone. CMCOs designed to bind different areas of the mitochondrial genome will 
also be investigated in order to determine if the secondary structure of mtDNA may 
play a role in CMCO binding by preventing access to the mtDNA.  
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Although this project has not been wholly successful at decreasing the production of 
COXI protein via interactions with mtDNA or mt-mRNA, the creation of an anti-
genomic treatment remains a viable way of treating the mtDNA disease. The use of 
small molecules, such as CMCOs, is attractive as they are far more likely to enter cells 
within a patient than large plasmid DNA (discussed in introduction, section 1.9.2). This 
project may have been unduly influenced by past data which affected the experimental 
strategies used in this work, however the completion of further investigations mentioned 
previously, along with set goals and endpoints will answer the question of the whether 
CMCOs have potential in this field.  
 
7.2. HIGH THROUGHPUT DRUG SCREEN 
Recently, evidence has pointed to improvements in mitochondrial function caused by 
biogenesis of the organelle. This has been caused both pharmacologically, using the 
PPAR pan agonist bezafibrate, and by exercise. This work is interesting, particularly in 
the case of mtDNA diseases where heteroplasmy has not been shown to increase, 
highlighting the safety of the techniques in patients. Although there is evidence to show 
that pharmacological intervention can improve the disease phenotype by acting on 
biogenesis pathways (Dillon et al. 2012; Dillon et al. 2012), the efficacies of the drugs 
that achieve this are relatively poor. Therefore I set out to develop a simple screen to 
discover compounds that can increase mitochondrial mass – a marker of biogenesis.  
 
The screen was developed using the fluorescent markers TMRM and Hoechst, which 
stain mitochondria and nuclei respectively. The relationship between cell number 
(Hoechst intensity) and mitochondria (TMRM intensity) was shown to be linear. This 
enabled deviations in the proportion of mitochondria per cell to be determined using a 
plate reader to measure the intensity of the two fluorescent markers. Control molecules 
(FCCP and bezafibrate) were used to cause decreases and increases in the proportion of 
mitochondria per cell respectively. 
 
Screening of hundreds of thousands of compounds was not practical as I did not have 
easy access to a large library of single molecules, nor is there appropriate equipment to 
enable a screen of this many compounds within Newcastle University. Therefore I 
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decided to screen 846 extracts from discrete strains of bacteria within the 
Actinomycetes family. This library, which was compiled by Demuris Ltd (Newcastle, 
UK), contains rare species of bacteria of diverse origins, enabling the screening of 
compounds that may not be present elsewhere in nature or other molecule libraries. The 
number of compounds in each extract is likely to number in the hundreds or thousands, 
therefore the screen of molecules is actually several orders of magnitude larger than the 
846 extracts suggests. 
 
Using the screen I was able to identify an extract (BP2_G4) which caused the volume of 
mitochondria per cell to increase from 20% to 40% after 48 hours incubation. Although 
this is promising, there are many factors that could be causing this such as an inhibition 
of mitophagy, inhibition of fission or increased fusion. There is also evidence to suggest 
that preventing the breakdown of microtubules can also increase mitochondrial volume 
(Karbowski et al. 2001), although to date I have not found an article discussing a 
pharmaceutical that can increase the volume of mitochondria to this degree.  
 
The effect of the active extract on mitochondrial volume will be investigated in other 
cell lines (fibroblasts and sarcoma cells – both of which are conducive to imaging 
studies) to see if there is an increase detected using microscopy and also to see if there 
is an increase in the proportion of mitochondrial markers (matrix, inner and outer 
membrane proteins) when compared to a cell based control protein. If these results 
confirm an increase, the extract will be fractionated in order to determine the active 
compound. As the extract will be separated into multiple fractions, it is likely that the 
designed high-throughput assay will be used to assess their activities as this is the most 
practical method. Upon fractionation, the mechanism of the increase will be 
investigated by determining changes in the level of biogenesis and mitophagy 
associated transcripts. The toxicity of the compound in relation to fission and fusion 
changes will also be investigated. Changes in OXPHOS will also be investigated in 
control and patient cell lines to quantify changes in relation to mitochondrial mass. This 
will also highlight the potential benefits of the compound for improving the function of 
OXPHOS complexes in patient cell lines.  
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7.3. FINAL CONCLUSIONS 
It is clear that there is a need to invest in the discovery of mitochondrially acting 
pharmaceuticals if there is ever going to be a viable treatment for mitochondrial 
dysfunction. Although there is the will to do this in academia, the facilities and funds 
available do not necessarily make it possible. Therefore a focused approach or a screen 
of completely novel compounds like those used in this project, are the only options 
viable for academia when working alone. The use of two approaches is necessary as 
targeted therapies such as CMCOs are only applicable for treating mtDNA diseases, 
whereas improving the function of mitochondria can be used to treat mitochondrial 
diseases caused by mutations in both nDNA and mtDNA. It could be argued that the 
focus should be on developing treatments for all mitochondrial diseases; however the 
fact that targeted treatments, which remove mutated mtDNA molecules, can offer a cure 
in affected patients means that apart from the academic and patient benefits of 
developing such a treatment, there is an economic incentive to do so as well.  
 
The capacity of mitochondrial research in industry has been traditionally focused on 
mitochondrial toxicology; however, in collaboration with Novartis (Basel, Switzerland), 
this lab is developing assays in order to screen for mitochondrially acting therapeutics. 
This collaboration is ideal as it combines the resources of a large pharmaceutical 
company with the specialist knowledge that an academic lab can provide. Therefore it is 
hoped that with the involvement of industry, the development of practical therapies for 
mitochondrial disease may finally become a reality.  
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8 Addendum 
Subsequent to the completion of this thesis, repeat experiment have shown that Ugi200 
does not cause a decrease in the expression of COXICOXI protein.  
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9 Appendix A 
9.1. COMPLETE DRUG SCREEN DATA SET 
Compound 
Mean 
TMRM 
TMRM 
SD 
Mean 
Hoechst 
Hoechst 
SD 
TMRM/Hoechst 
ratio 
Gradient 
BP2_G4 6310.755 243.720 315.980 9.861 19.972 4.600 
BP6_D6 5534.225 213.128 295.850 9.886 18.706 3.484 
RP8_F2 2694.675 408.464 114.985 2.084 23.435 3.070 
BP6_F4 7083.625 310.843 402.295 11.198 17.608 2.986 
BP2_D1 6725.860 723.059 376.370 80.252 17.870 2.909 
JB10_F11 6382.750 177.444 363.000 7.165 17.583 2.866 
RP8_C10 2743.170 204.421 125.355 9.417 21.883 2.847 
RP2_A9 5349.250 288.774 301.250 14.315 17.757 2.794 
RP13_G5 8133.750 877.366 474.000 29.029 17.160 2.729 
RP8_F11 3939.685 395.850 212.585 36.740 18.532 2.669 
R6_E6 4919.955 384.350 277.855 14.310 17.707 2.666 
RP8_C7 3578.565 431.046 184.525 51.706 19.393 2.642 
RP8_F9 2923.730 260.095 145.790 10.183 20.054 2.627 
BEZAFIBRATE 8398.406 329.004 502.600 18.646 16.710 2.556 
JB10_H7 7775.500 596.870 463.500 22.398 16.776 2.358 
RP8_A7 3224.765 508.099 174.765 15.086 18.452 2.348 
JB10_H12 5949.750 315.694 350.750 18.927 16.963 2.305 
JB10_H4 6819.000 1941.409 406.000 123.329 16.796 2.252 
RP8_H7 2544.920 303.191 126.270 4.725 20.155 2.247 
RP2_E10 7669.250 2096.471 415.500 175.038 18.458 2.223 
RP8_C8 2839.245 108.195 148.230 18.913 19.154 2.199 
RP8_F6 3946.395 543.510 226.310 29.726 17.438 2.185 
RP8_H11 3268.380 125.219 181.780 10.110 17.980 2.098 
JB10_H11 8228.500 195.121 502.000 17.512 16.391 2.031 
RP8_D12 8964.255 284.296 548.390 19.482 16.346 2.026 
RP8_H8 4641.490 544.314 272.060 53.020 17.061 2.022 
R6_H7 8134.350 385.310 498.065 16.650 16.332 1.989 
JB10_H2 8462.500 285.005 519.000 12.832 16.305 1.974 
RP8_B3 8624.790 680.495 528.870 47.964 16.308 1.974 
RP8_B10 7671.360 261.668 469.090 22.285 16.354 1.967 
NO DOSE 8078.377 717.863 501.586 23.300 16.106 1.963 
JB10_C1 8317.750 444.737 511.000 19.096 16.277 1.945 
RP8_E11 4526.200 179.095 268.705 21.741 16.844 1.939 
RP8_E12 8874.890 476.311 545.950 20.475 16.256 1.933 
BP2_H5 6965.895 812.866 419.985 87.932 16.586 1.923 
RP8_F10 6633.140 585.360 405.345 35.336 16.364 1.920 
BP2_F6 6029.545 847.206 358.070 93.426 16.839 1.917 
RP8_F12 4230.960 355.190 251.015 22.371 16.855 1.905 
R6_D1 8014.180 1376.380 494.100 48.412 16.220 1.902 
RP8_H6 2540.955 281.411 135.115 8.762 18.806 1.885 
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JB10_F12 7319.500 460.321 450.750 15.735 16.238 1.869 
BP2_H10 7359.345 289.196 450.485 48.508 16.336 1.868 
RP8_A3 8393.295 768.545 518.805 54.917 16.178 1.845 
BP2_C1 7156.520 292.978 443.165 16.104 16.149 1.768 
BP2_D2 7371.240 288.840 457.195 11.504 16.123 1.766 
JB10_G5 7703.500 360.430 478.500 21.331 16.099 1.744 
RP8_H2 3088.430 245.511 178.425 3.504 17.309 1.730 
RP13_H4 5755.250 158.895 354.500 9.849 16.235 1.728 
BP2_G1 7107.720 288.376 442.555 10.418 16.061 1.695 
RP8_B12 7957.145 455.718 496.845 40.184 16.015 1.677 
RP8_F8 5702.585 248.402 352.885 12.175 16.160 1.662 
RP8_E10 4242.855 430.768 257.725 32.848 16.463 1.630 
JB10_A3 8508.500 142.027 534.750 20.516 15.911 1.607 
JB10_G11 7595.750 437.471 477.000 8.287 15.924 1.596 
RP8_E1 2439.390 327.549 135.420 5.364 18.014 1.591 
RP8_D9 2891.400 260.403 168.360 15.528 17.174 1.555 
RP8_H5 4883.050 365.997 302.560 28.245 16.139 1.526 
BP2_H1 7222.095 390.902 455.060 29.533 15.871 1.526 
BP2_G6 4452.695 176.115 274.195 20.081 16.239 1.519 
BP2_H4 7833.620 458.861 495.625 22.282 15.806 1.513 
JB10_A10 8753.250 537.877 554.500 23.798 15.786 1.513 
JB10_A5 5580.500 195.873 349.250 8.694 15.979 1.512 
RP8_E2 4575.915 312.116 283.650 13.457 16.132 1.494 
JB10_B4 7808.750 681.284 494.750 22.081 15.783 1.490 
JB10_B1 5500.000 419.659 345.750 15.521 15.907 1.461 
R6_H6 8022.415 305.472 509.350 26.682 15.750 1.457 
RP8_G11 3152.480 160.830 188.795 10.929 16.698 1.452 
R6_G11 8112.085 349.380 515.450 15.891 15.738 1.450 
RP8_B5 7752.795 1248.674 494.710 62.799 15.671 1.432 
R6_H11 8126.115 283.375 517.585 17.549 15.700 1.420 
RP8_A12 8608.625 415.292 548.085 50.019 15.707 1.393 
JB10_D11 8349.250 371.226 532.750 12.685 15.672 1.392 
RP8_H9 2781.905 234.042 164.395 18.566 16.922 1.367 
RP8_B8 7178.175 669.472 454.450 68.700 15.795 1.364 
JB10_D1 8305.750 540.491 531.750 30.412 15.620 1.361 
BP2_E1 7098.265 592.904 453.840 20.293 15.640 1.350 
BP2_C4 7823.860 237.287 498.675 31.648 15.689 1.349 
RP8_H1 5834.955 216.357 370.270 22.595 15.759 1.343 
JB10_F3 5456.250 1619.122 345.500 108.433 15.792 1.318 
JB10_F10 8108.750 696.008 521.000 18.673 15.564 1.315 
RP8_A1 6117.385 795.229 390.705 32.238 15.657 1.303 
JB10_C4 7584.000 833.496 487.750 12.010 15.549 1.294 
RP8_D11 8613.505 417.805 555.100 24.319 15.517 1.272 
RP8_E9 2930.745 211.102 177.815 15.508 16.482 1.257 
RP8_C11 5271.620 165.600 336.110 7.875 15.684 1.251 
RP2_G2 7152.500 606.881 456.250 36.936 15.677 1.247 
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BP2_H6 7937.015 129.179 511.485 17.379 15.518 1.241 
RP8_A8 8453.380 609.101 543.815 64.228 15.545 1.237 
BP2_C10 7912.920 396.928 510.265 20.880 15.507 1.233 
BB4_F2 5191.500 411.516 322.750 74.011 16.085 1.229 
BP6_B9 5195.675 298.303 331.535 16.410 15.672 1.224 
BP2_H7 7901.330 325.080 509.960 28.612 15.494 1.223 
BP2_G5 7833.010 273.399 505.995 7.140 15.480 1.222 
R6_H4 7805.560 392.076 503.555 37.263 15.501 1.219 
JB10_F7 6957.750 334.776 445.750 51.629 15.609 1.219 
RP8_D8 4124.210 491.680 259.555 38.751 15.890 1.215 
BP2_F2 7142.185 367.105 460.550 27.416 15.508 1.214 
JB10_B11 8621.750 365.965 557.750 10.996 15.458 1.214 
BB4_G9 8258.250 643.589 534.250 18.536 15.458 1.199 
R6_H1 7692.710 312.343 496.845 37.063 15.483 1.186 
RP8_H3 2733.410 436.478 166.530 13.749 16.414 1.185 
BP6_B10 6393.715 445.370 411.445 34.955 15.540 1.180 
JB10_F1 5021.000 307.455 321.750 14.660 15.605 1.176 
JB10_B9 8338.250 186.325 540.500 18.788 15.427 1.170 
BP6_B12 7444.745 489.529 482.510 19.044 15.429 1.166 
RP2_D12 7532.000 413.396 487.250 24.350 15.458 1.162 
BP6_E1 7505.440 186.874 487.085 8.533 15.409 1.147 
JB10_G3 5061.750 251.139 325.750 7.228 15.539 1.128 
BP2_H8 8006.250 201.628 520.330 24.267 15.387 1.126 
BP2_B7 7988.560 143.068 519.110 18.054 15.389 1.124 
BP2_E2 7713.755 305.297 501.420 24.257 15.384 1.122 
BP2_F7 7775.975 149.745 505.690 12.815 15.377 1.119 
RP2_G3 7178.750 524.944 466.750 22.911 15.380 1.119 
BP2_E7 7216.910 762.089 463.905 86.396 15.557 1.114 
BP2_F9 6959.185 269.169 452.010 14.724 15.396 1.112 
R6_H8 7805.255 182.306 508.435 10.418 15.352 1.102 
BP2_E12 7514.895 58.622 487.390 34.065 15.419 1.100 
BP6_H12 7034.520 154.226 457.500 17.567 15.376 1.089 
JB10_B5 8204.250 310.192 535.750 10.935 15.314 1.082 
BP2_F5 7711.925 182.917 502.640 13.585 15.343 1.081 
BP2_H9 7795.495 254.725 508.740 17.339 15.323 1.078 
BP6_F6 7566.440 475.607 493.185 8.474 15.342 1.075 
BP2_H12 7712.840 199.765 503.555 11.461 15.317 1.064 
BP6_G9 7424.920 192.500 484.950 1.220 15.311 1.057 
JB10_D10 8132.250 426.654 531.750 19.602 15.293 1.053 
R6_G2 7619.205 238.768 498.065 18.566 15.298 1.048 
R6_F11 8141.365 480.440 533.140 19.545 15.271 1.042 
RP2_G8 7669.000 489.518 501.500 20.486 15.292 1.034 
BP6_E12 5884.365 560.257 383.690 22.507 15.336 1.024 
R6_H3 7743.340 119.879 505.995 34.613 15.303 1.021 
BP2_D11 7880.895 604.838 516.670 14.792 15.253 1.017 
R6_E12 7641.165 335.970 499.895 29.740 15.286 1.016 
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RP8_H10 8127.030 112.445 532.835 16.945 15.252 1.009 
JB10_F9 8009.000 394.939 525.500 15.610 15.241 1.004 
RP2_D6 7102.000 522.895 465.750 9.535 15.249 0.999 
BP2_B5 7869.000 148.182 516.365 20.228 15.239 0.996 
R6_C1 7591.145 412.424 497.455 40.590 15.260 0.993 
R6_G9 8104.155 326.484 532.835 11.504 15.210 0.985 
RP8_H4 8228.290 610.643 541.375 25.089 15.199 0.984 
JB10_C8 6600.000 323.098 433.000 6.633 15.242 0.974 
JB10_F4 4930.000 362.712 320.500 9.110 15.382 0.973 
RP8_F1 4787.585 294.118 309.270 36.769 15.480 0.972 
RP2_F2 7329.000 619.355 481.500 11.504 15.221 0.969 
JB10_E10 8369.000 684.776 551.500 15.610 15.175 0.956 
JB10_G8 8078.000 329.164 532.250 11.026 15.177 0.942 
BP2_B3 7774.755 280.475 512.400 17.454 15.173 0.940 
JB10_E12 7358.750 413.273 485.000 17.010 15.173 0.933 
BP6_C1 6904.895 530.983 453.840 44.325 15.214 0.931 
BP2_D5 7767.130 318.842 512.400 16.757 15.158 0.929 
RP8_A5 8070.300 589.820 532.835 40.135 15.146 0.923 
RP13_G3 6879.500 330.122 453.000 16.432 15.187 0.918 
R6_F7 8115.440 552.370 536.495 22.036 15.127 0.918 
JB10_A4 8394.500 202.011 553.000 39.387 15.180 0.912 
R6_H9 7968.735 227.510 527.040 11.574 15.120 0.899 
BP6_D1 6742.940 509.377 444.690 35.978 15.163 0.896 
JB10_D9 8263.000 526.519 547.000 4.243 15.106 0.895 
RP8_E4 4768.675 106.550 311.100 22.319 15.328 0.892 
BB4_G5 7972.750 418.561 527.250 16.641 15.121 0.877 
JB10_A2 8033.750 261.320 532.500 11.818 15.087 0.862 
BP6_H11 7403.570 318.842 490.440 22.976 15.096 0.857 
RP8_D1 5060.255 271.130 331.840 21.108 15.249 0.854 
JB10_H1 7750.500 481.760 514.500 26.602 15.064 0.851 
JB10_G12 6467.750 319.272 427.750 15.650 15.120 0.850 
BP2_D4 7549.360 428.279 501.115 7.804 15.065 0.848 
R6_G6 8076.705 255.231 536.495 9.779 15.055 0.838 
RP8_E5 8551.590 194.888 568.520 6.829 15.042 0.836 
R6_F1 7618.595 283.130 506.300 16.216 15.048 0.829 
BP6_B11 7014.085 393.807 465.430 24.833 15.070 0.826 
BP2_D7 7946.165 216.566 528.565 13.040 15.033 0.822 
RP8_F7 4815.340 466.422 316.590 38.919 15.210 0.820 
RP8_G7 8636.075 202.111 574.620 13.402 15.029 0.818 
BP2_B2 7604.565 281.797 505.690 15.058 15.038 0.816 
JB10_E11 7914.000 128.735 525.250 30.913 15.067 0.814 
RP8_D5 4287.690 537.821 278.465 56.642 15.398 0.804 
BB4_F10 8073.500 590.174 538.500 11.561 14.993 0.798 
JB10_D2 6292.500 368.306 417.000 39.606 15.090 0.795 
RP8_G12 2728.835 121.370 174.460 12.561 15.642 0.784 
RP8_A10 6777.405 308.403 450.790 30.321 15.035 0.782 
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BP6_H8 7298.650 158.677 486.170 15.319 15.013 0.778 
R6_F10 7773.840 481.671 518.805 25.618 14.984 0.778 
RP8_F4 4137.630 307.434 270.535 33.163 15.294 0.773 
R6_H2 7815.015 231.510 520.330 36.769 15.019 0.769 
BB4_G7 7927.000 319.487 529.500 14.731 14.971 0.763 
JB10_H9 7288.750 157.085 485.750 22.589 15.005 0.763 
BP2_H2 7612.190 410.464 508.435 16.916 14.972 0.761 
BP2_D6 7892.790 188.482 527.345 7.804 14.967 0.757 
JB10_D8 8070.750 636.153 539.500 17.823 14.960 0.749 
JB10_C2 5342.250 433.690 355.750 17.462 15.017 0.743 
RP8_A9 2644.960 167.565 168.665 19.530 15.682 0.742 
R6_D2 7692.405 300.083 514.535 15.667 14.950 0.741 
JB10_H3 7701.250 318.394 515.000 22.730 14.954 0.740 
RP2_H4 7288.250 546.411 487.750 19.856 14.943 0.738 
R6_D11 7832.095 301.032 521.855 49.269 15.008 0.732 
JB10_E9 8049.250 542.628 539.500 13.528 14.920 0.730 
RP8_B11 2595.245 146.963 164.700 22.385 15.757 0.728 
BP2_H11 8218.530 136.286 550.220 15.750 14.937 0.727 
RP2_E1 7084.250 515.518 474.000 11.690 14.946 0.723 
RP2_C10 7364.250 479.629 492.000 22.906 14.968 0.723 
BP6_F12 7099.485 359.406 473.970 25.985 14.979 0.720 
RP8_F5 2838.330 408.495 184.525 3.643 15.382 0.711 
BP2_G9 8025.465 299.677 538.325 15.086 14.908 0.708 
RP2_C11 5955.250 408.980 397.000 28.694 15.001 0.706 
JB10_A9 8191.500 321.499 549.750 19.397 14.900 0.704 
BP2_A9 8053.525 115.260 538.630 37.517 14.952 0.703 
BP2_B12 7696.065 160.464 516.060 24.703 14.913 0.689 
RP8_B4 2819.420 258.220 183.610 13.567 15.355 0.685 
JB10_B10 8172.000 281.978 547.750 38.690 14.919 0.682 
BB5_F1 7953.250 176.296 534.250 18.410 14.887 0.681 
BB4_G2 8273.250 188.952 555.500 18.628 14.893 0.681 
RP8_F3 7200.135 403.145 483.730 19.251 14.885 0.681 
BP2_A8 7586.875 161.650 509.045 20.081 14.904 0.680 
JB10_E6 6169.000 404.272 413.250 20.123 14.928 0.680 
BP2_B10 7822.030 221.639 524.905 21.787 14.902 0.679 
BP2_B6 7876.930 121.374 528.565 29.857 14.902 0.678 
JB10_B12 7909.750 273.231 531.750 12.920 14.875 0.676 
BP2_G11 8285.935 348.460 557.540 9.911 14.862 0.666 
R6_G7 8160.885 222.605 549.305 4.152 14.857 0.665 
RP2_E2 7427.000 214.777 498.500 23.445 14.899 0.665 
R6_B12 7771.705 205.609 521.550 30.711 14.901 0.663 
R6_E2 7760.420 305.910 522.160 20.942 14.862 0.660 
BP2_E10 8075.180 590.740 543.815 11.633 14.849 0.659 
BP2_G2 7733.580 461.603 520.330 35.784 14.863 0.649 
BP6_E9 7101.010 350.863 477.935 0.610 14.858 0.649 
BP6_H7 7508.490 240.043 504.775 32.696 14.875 0.647 
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RP2_D7 7045.000 351.461 473.500 15.264 14.879 0.644 
R6_G10 8109.950 255.075 546.865 9.041 14.830 0.640 
BP6_G7 7373.070 355.619 496.540 14.158 14.849 0.639 
BP6_G12 7252.900 226.017 488.610 13.159 14.844 0.638 
JB10_C5 5177.500 360.112 347.500 7.141 14.899 0.635 
BB4_H1 7852.000 276.595 529.000 19.765 14.843 0.626 
R6_F8 8035.530 453.212 542.900 14.741 14.801 0.618 
JB10_A6 8351.750 285.823 563.500 16.623 14.821 0.617 
BP6_C12 7194.340 427.350 485.255 25.089 14.826 0.616 
RP8_G9 6903.675 1001.195 465.735 66.371 14.823 0.613 
BP2_B8 7647.265 124.847 515.145 33.786 14.845 0.607 
R6_G1 7605.175 286.892 513.620 28.646 14.807 0.602 
JB10_C12 5768.500 411.127 388.250 30.956 14.858 0.598 
R6_H5 7370.935 327.800 498.065 24.931 14.799 0.596 
JB10_B2 8093.750 100.739 547.250 20.172 14.790 0.591 
RP8_B7 7654.890 725.719 516.365 64.421 14.825 0.590 
BB4_H7 8003.000 418.687 541.500 13.404 14.779 0.584 
BP2_B4 7605.175 59.571 514.230 18.729 14.789 0.583 
JB10_G9 4892.250 245.075 329.250 8.098 14.859 0.582 
JB10_D7 6128.000 470.184 414.250 23.599 14.793 0.578 
R6_E3 7674.410 568.561 519.720 30.000 14.766 0.570 
R6_E1 7530.450 191.517 509.655 21.650 14.776 0.569 
BP6_H4 6979.010 186.184 472.445 17.379 14.772 0.567 
R6_D12 7803.120 176.337 526.735 40.246 14.814 0.565 
BP6_F7 7443.830 236.863 503.555 22.148 14.783 0.564 
RP8_H12 2724.260 67.693 178.120 20.728 15.295 0.564 
RP13_H7 7093.500 267.602 479.500 25.331 14.794 0.564 
R6_A1 7506.355 448.913 507.215 50.335 14.799 0.562 
RP2_F1 6724.500 489.793 454.500 20.290 14.795 0.560 
BP6_D5 7036.350 382.893 476.715 20.951 14.760 0.560 
RP2_C1 6535.500 1510.335 445.000 62.199 14.687 0.557 
R6_F12 7302.920 376.898 494.710 20.524 14.762 0.557 
RP8_G2 7576.505 112.286 513.315 18.512 14.760 0.556 
RP13_F10 6783.750 169.183 459.250 16.153 14.771 0.548 
RP2_G4 7381.500 944.108 498.250 26.750 14.815 0.547 
RP8_B1 2906.040 121.817 192.455 8.986 15.100 0.544 
R6_E8 7832.705 340.165 531.920 16.817 14.725 0.543 
JB10_D5 5911.250 398.545 400.500 16.862 14.760 0.539 
R6_D6 7345.315 457.124 498.370 21.881 14.739 0.536 
R6_G8 7779.635 306.954 528.260 15.107 14.727 0.535 
BB4_H4 7977.750 388.726 542.250 8.421 14.712 0.532 
BP6_A5 7293.770 314.874 493.795 41.124 14.771 0.528 
BP2_G10 8163.020 490.759 555.405 21.673 14.697 0.524 
RP8_D7 5606.815 210.813 379.115 28.722 14.789 0.516 
BP2_A7 7699.725 396.127 522.160 47.250 14.746 0.515 
R6_F3 7502.390 321.427 510.265 6.008 14.703 0.514 
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BP6_F1 7287.365 93.982 495.930 12.969 14.694 0.502 
R6_E7 7824.775 526.805 533.750 17.553 14.660 0.490 
BP6_B8 6936.310 132.468 471.530 24.532 14.710 0.481 
BP2_B1 7137.000 151.165 486.170 16.564 14.680 0.480 
RP8_D6 2827.960 308.331 189.100 11.048 14.955 0.479 
BP6_H10 6892.390 81.795 469.700 10.775 14.674 0.477 
RP8_B2 6821.935 143.568 464.515 14.754 14.686 0.476 
RP2_C8 5342.000 376.736 362.750 20.123 14.726 0.474 
BP6_F11 7595.110 334.284 518.195 10.513 14.657 0.473 
RP2_E9 6438.500 404.442 438.750 10.935 14.675 0.459 
R6_G3 7668.615 192.725 523.990 8.769 14.635 0.457 
R6_H10 7445.660 264.377 508.740 17.167 14.635 0.451 
BP6_B1 6814.615 750.629 465.430 50.719 14.642 0.451 
BP2_D3 7490.190 203.684 512.095 10.370 14.627 0.449 
RP8_G8 8296.610 303.108 567.605 11.844 14.617 0.443 
R6_G12 7633.235 214.864 522.160 10.110 14.619 0.436 
JB10_F6 6751.500 578.904 462.250 21.077 14.606 0.434 
BP2_E5 7443.830 141.136 509.350 17.524 14.614 0.427 
RP13_B6 6834.500 291.541 467.750 11.442 14.611 0.425 
RP2_H3 6410.500 708.809 436.750 42.797 14.678 0.424 
BP6_E8 7469.145 395.882 511.485 4.712 14.603 0.424 
BB4_H9 7897.750 420.345 541.500 18.285 14.585 0.417 
RP13_G8 7086.000 355.409 485.500 7.767 14.595 0.412 
BP6_G6 7430.410 245.820 509.045 13.816 14.597 0.412 
BB4_G12 8476.500 485.330 581.750 25.277 14.571 0.410 
BP6_H9 7202.575 337.954 494.100 18.178 14.577 0.404 
BB4_A2 8096.750 432.434 555.500 16.422 14.576 0.402 
JB10_D4 4099.750 281.750 279.500 10.017 14.668 0.401 
BP6_G5 7102.840 166.126 486.780 15.907 14.591 0.401 
JB10_A7 4098.000 287.414 279.250 9.708 14.675 0.394 
BB5_A2 8251.500 478.136 567.000 26.038 14.553 0.393 
R6_F6 7791.225 350.321 534.665 15.636 14.572 0.392 
BB4_G10 8084.500 508.069 555.500 22.942 14.554 0.388 
RP8_G10 8375.300 73.653 575.535 7.676 14.552 0.387 
R6_B5 7940.980 70.781 545.340 17.196 14.562 0.386 
JB10_C11 8179.750 439.374 561.250 24.240 14.574 0.385 
BB4_H2 7733.250 408.364 531.500 3.109 14.550 0.383 
BP6_A4 7437.730 367.011 509.960 40.549 14.585 0.379 
BP6_E7 7281.570 437.182 500.200 7.907 14.557 0.377 
BP2_C5 7582.300 141.769 520.940 18.609 14.555 0.375 
BP2_F3 6797.230 275.577 466.955 19.402 14.556 0.374 
R6_B1 7784.820 383.823 535.580 15.496 14.535 0.370 
BP6_A3 7071.730 259.831 483.730 49.512 14.619 0.369 
BP6_D7 7117.175 355.288 489.525 8.237 14.539 0.369 
BP2_E11 8032.175 586.212 552.355 24.224 14.542 0.367 
BP2_C6 7836.975 269.132 538.935 13.452 14.542 0.366 
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RP13_G4 6775.500 376.573 465.500 25.645 14.555 0.365 
RP8_D2 2909.090 300.857 197.640 9.811 14.719 0.363 
R6_A3 7459.080 109.393 512.705 22.238 14.548 0.363 
RP8_E8 3248.250 83.820 220.820 9.811 14.710 0.361 
BP2_D10 7723.820 396.927 531.615 14.171 14.529 0.359 
BB4_F6 2348.500 94.016 157.750 2.630 14.887 0.359 
BP2_C3 7772.925 267.284 535.275 12.849 14.521 0.354 
JB10_G10 4808.000 173.038 329.500 10.083 14.592 0.354 
BP2_D12 7908.040 365.721 544.120 11.445 14.534 0.354 
BP2_E8 8057.490 118.256 554.795 14.788 14.523 0.352 
JB10_B8 7746.750 321.793 533.250 10.275 14.527 0.351 
RP2_C4 4537.250 847.654 311.500 13.102 14.566 0.349 
BP6_E10 6889.645 388.983 474.580 5.977 14.517 0.347 
RP8_G1 2666.615 331.577 181.170 12.815 14.719 0.342 
BP6_F3 6631.615 299.490 456.890 11.379 14.515 0.342 
JB10_A1 4602.000 366.336 316.500 12.793 14.540 0.335 
BP6_A8 7164.450 298.280 493.795 20.593 14.509 0.329 
RP8_D3 8267.635 455.015 570.655 28.514 14.488 0.327 
RP13_H9 6976.000 271.003 480.250 20.887 14.526 0.326 
RP2_H9 7178.250 479.444 495.000 11.605 14.502 0.320 
BP6_H1 6885.375 101.127 474.885 18.459 14.499 0.315 
BP6_H5 7291.025 210.808 503.555 8.416 14.479 0.314 
RP2_H7 7055.500 580.381 487.250 8.770 14.480 0.314 
BP6_E11 7142.185 408.030 493.185 9.150 14.482 0.312 
BP6_A9 7282.790 201.320 500.200 40.155 14.560 0.306 
JB10_G4 3632.750 351.088 249.750 8.421 14.546 0.304 
RP13_D8 7030.250 360.653 485.250 15.521 14.488 0.304 
BP6_C9 7021.710 618.714 485.865 23.156 14.452 0.294 
BB4_H6 7722.250 424.143 534.500 17.020 14.448 0.294 
JB10_C7 7837.750 458.722 542.500 16.258 14.447 0.288 
BP2_E3 7526.485 257.555 520.940 15.074 14.448 0.286 
R6_D8 7683.255 374.159 532.225 9.470 14.436 0.281 
R6_H12 7104.975 596.590 491.355 13.192 14.460 0.279 
RP2_F3 7127.500 570.237 493.750 13.865 14.435 0.278 
JB10_A8 4619.750 352.828 319.250 4.573 14.471 0.274 
BP6_G1 7095.215 117.511 491.355 12.964 14.440 0.271 
JB10_B7 6165.500 308.463 427.000 15.122 14.439 0.269 
BP6_D9 7096.740 270.158 491.660 8.627 14.434 0.268 
R6_E10 7929.390 418.196 549.915 12.964 14.419 0.263 
JB10_F2 7227.250 237.036 501.000 19.305 14.426 0.261 
BP6_A11 6954.000 473.128 482.510 13.007 14.412 0.259 
BP2_E9 7759.200 157.441 538.020 13.026 14.422 0.255 
BP6_C8 7204.405 276.062 498.980 17.708 14.438 0.253 
JB10_G7 7549.500 362.882 524.000 9.487 14.407 0.252 
JB10_H8 7415.750 337.900 514.750 13.598 14.407 0.249 
BP2_A11 7404.790 517.459 513.315 45.434 14.425 0.247 
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BB4_A4 7932.750 392.268 550.750 4.272 14.404 0.245 
RP8_G3 6683.465 217.138 463.295 17.521 14.426 0.243 
R6_E9 7593.280 492.266 527.650 24.613 14.391 0.239 
JB10_A11 3754.000 135.691 259.250 6.185 14.480 0.238 
R6_C8 7680.510 268.765 533.445 16.769 14.398 0.231 
JB10_C10 7924.750 292.544 550.250 21.203 14.402 0.229 
RP2_E6 7036.500 438.615 489.000 13.292 14.390 0.227 
BP2_C2 6954.305 176.172 483.425 6.928 14.385 0.226 
BB4_D6 7624.250 551.278 530.250 3.500 14.379 0.225 
R6_A11 7759.810 467.066 538.935 38.675 14.398 0.221 
BB4_G8 7885.750 504.627 548.500 21.048 14.377 0.219 
JB10_D12 7938.750 306.508 551.500 27.441 14.395 0.218 
BP2_B9 7640.555 286.622 530.700 27.497 14.397 0.218 
RP8_G4 7456.030 1045.737 518.500 72.265 14.380 0.212 
BB4_F12 7864.250 460.019 547.500 33.601 14.364 0.208 
RP2_F8 7342.750 473.513 508.500 46.148 14.440 0.205 
RP8_B9 5250.880 656.794 365.390 38.483 14.371 0.205 
BB5_D9 6728.750 964.285 470.500 29.183 14.301 0.197 
BP6_D10 7042.755 360.939 490.745 18.646 14.351 0.192 
RP2_H12 7299.000 308.209 508.750 14.198 14.347 0.190 
R6_C10 7712.230 238.206 537.105 23.559 14.359 0.189 
BP2_E4 7635.980 288.412 532.530 13.857 14.339 0.189 
RP2_E3 6926.000 309.077 482.500 12.261 14.354 0.182 
RP2_F11 7239.500 453.085 504.500 14.248 14.350 0.177 
BP2_G12 7527.400 180.365 524.905 17.293 14.340 0.176 
BP6_A7 7287.365 313.862 507.520 31.673 14.359 0.173 
BP6_C4 6454.715 437.927 449.875 35.630 14.348 0.172 
R6_A5 7767.130 170.912 541.680 30.524 14.339 0.169 
BP2_F4 7213.860 279.558 503.860 13.102 14.317 0.168 
RP13_H8 7045.500 337.818 491.500 24.678 14.335 0.168 
R6_F2 7336.775 231.916 512.705 9.150 14.310 0.162 
RP13_D12 7208.000 214.544 503.250 14.198 14.323 0.158 
RP2_E7 6846.250 370.233 478.000 11.804 14.323 0.155 
RP13_H6 6794.750 240.088 474.250 24.622 14.327 0.150 
RP8_G5 7628.355 1147.873 535.580 30.589 14.243 0.150 
BB4_A1 7907.750 214.882 553.250 13.048 14.293 0.144 
R6_G4 7514.895 243.184 525.820 12.200 14.292 0.144 
R6_F9 7290.110 360.722 510.265 13.852 14.287 0.142 
RP13_C5 6851.750 381.979 479.500 13.229 14.289 0.142 
R6_B4 7512.150 112.039 525.210 23.667 14.303 0.141 
BP6_C2 7043.975 384.816 492.575 31.913 14.300 0.141 
BP2_G3 6822.545 350.136 477.325 25.306 14.293 0.140 
BP6_F5 7202.880 275.790 504.165 1.535 14.287 0.140 
BB5_E11 8244.250 365.127 577.250 2.217 14.282 0.139 
RP8_A2 7802.205 688.676 545.950 50.445 14.291 0.139 
R6_B8 7480.735 69.110 522.770 24.103 14.310 0.137 
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R6_D7 7681.120 413.582 538.325 10.418 14.269 0.130 
RP13_E2 6820.000 394.109 477.750 9.251 14.275 0.130 
R6_C12 7428.885 355.414 518.805 41.461 14.319 0.128 
RP8_E3 2684.000 294.321 186.965 3.050 14.356 0.127 
BP6_C11 7523.435 192.485 526.430 19.251 14.291 0.127 
BP6_C7 7210.505 408.736 505.690 9.986 14.259 0.119 
BP2_C11 7467.925 360.850 522.770 22.196 14.285 0.119 
JB10_C6 6851.000 646.707 481.000 14.765 14.243 0.116 
JB10_G1 3834.500 276.722 268.500 10.017 14.281 0.115 
RP13_E3 6691.500 464.247 468.250 19.015 14.290 0.113 
RP2_D5 6967.250 533.736 488.500 11.561 14.263 0.106 
JB10_B6 7787.000 330.424 546.750 12.606 14.242 0.100 
RP13_D11 7007.750 366.643 492.000 13.038 14.243 0.093 
BP2_A4 7258.695 1010.141 511.180 40.987 14.200 0.091 
R6_B11 7654.890 195.610 534.665 53.997 14.317 0.090 
JB10_A12 3538.750 75.332 247.750 9.287 14.284 0.089 
BP6_D2 6713.660 581.499 470.920 50.919 14.256 0.085 
R6_A6 7721.990 248.162 541.070 44.330 14.272 0.084 
RP13_D7 6854.000 481.455 481.750 14.660 14.227 0.084 
RP13_H1 6735.250 227.900 472.750 20.918 14.247 0.082 
R6_C7 6971.995 334.044 490.440 10.682 14.216 0.076 
BP6_B5 7194.950 204.049 505.080 25.533 14.245 0.073 
R6_E5 7683.560 342.625 539.850 40.358 14.233 0.067 
RP2_G7 3693.000 141.579 259.500 9.147 14.231 0.067 
BB4_E7 7568.000 355.249 532.750 12.842 14.206 0.066 
BB4_H3 7655.250 400.790 538.750 12.945 14.209 0.063 
BB5_F10 7934.750 654.436 558.500 10.376 14.207 0.061 
RP13_G9 6877.250 362.010 484.250 9.179 14.202 0.055 
BB4_G6 7705.250 489.098 543.000 7.394 14.190 0.055 
R6_D3 7623.170 471.607 536.800 32.797 14.201 0.053 
BP6_A12 6997.310 356.381 491.965 37.595 14.223 0.053 
BB4_F8 7788.750 539.358 549.000 17.569 14.187 0.053 
R6_C4 7243.140 370.758 510.265 23.027 14.195 0.052 
BP2_F12 6699.935 108.387 471.530 22.241 14.209 0.044 
JB10_F5 7611.500 514.995 537.250 8.461 14.168 0.039 
BP2_D9 7687.220 165.294 541.985 19.171 14.183 0.037 
BB4_G11 7987.250 600.649 564.000 10.551 14.162 0.037 
R6_F4 7505.440 323.512 529.175 21.069 14.183 0.035 
BP6_C5 7224.840 184.008 509.960 8.274 14.167 0.030 
RP2_D4 6760.000 496.406 477.250 8.539 14.164 0.028 
BP6_D4 6797.230 345.600 479.765 21.581 14.168 0.027 
RP13_B10 7086.000 410.803 500.500 11.818 14.158 0.025 
BB4_F11 7798.500 296.029 550.500 18.717 14.166 0.024 
BB4_A5 8057.250 314.173 569.250 4.193 14.154 0.021 
RP2_D10 6896.750 518.644 487.000 16.021 14.162 0.018 
BP6_D11 6665.165 193.565 470.920 17.339 14.153 0.004 
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RP13_G7 6921.500 325.455 489.750 9.535 14.133 0.001 
RP2_C9 6439.250 1037.744 455.500 66.796 14.137 0.000 
RP13_F7 6789.750 302.552 479.750 15.756 14.153 -0.002 
R6_D4 7387.100 319.868 522.770 20.231 14.131 -0.002 
R6_A8 7482.565 207.207 528.870 24.186 14.148 -0.003 
BB5_E9 7680.250 430.521 543.750 7.632 14.125 -0.007 
RP13_E8 6896.000 419.321 488.000 15.684 14.131 -0.008 
JB10_E4 3580.750 133.315 253.250 9.287 14.139 -0.011 
R6_C11 7593.280 155.533 535.885 42.031 14.170 -0.011 
RP13_H3 6955.500 148.653 492.500 6.137 14.123 -0.013 
RP13_F6 6782.500 311.254 480.250 8.995 14.123 -0.014 
JB10_G6 4016.250 340.408 284.750 17.173 14.104 -0.014 
BP2_D8 7612.495 294.655 538.935 14.171 14.125 -0.023 
RP13_E1 6856.500 325.603 485.750 10.782 14.115 -0.024 
BP6_A2 6819.800 368.448 482.815 37.143 14.125 -0.024 
BP6_E6 6924.110 396.426 491.050 9.048 14.101 -0.024 
BP6_C10 7040.010 157.541 498.065 29.405 14.135 -0.026 
BB4_D7 6849.750 712.012 485.000 48.436 14.123 -0.029 
R6_A9 7594.805 202.602 536.190 46.140 14.164 -0.034 
BB4_C12 7762.000 432.807 550.000 41.288 14.113 -0.038 
BP6_D12 6584.340 291.543 467.565 12.457 14.082 -0.045 
BB4_D10 7810.250 571.247 555.000 19.149 14.073 -0.053 
R6_B3 7520.080 130.218 533.445 28.496 14.097 -0.056 
RP13_H12 6927.500 235.811 492.000 14.071 14.080 -0.057 
BB4_A3 8103.250 370.622 575.500 15.330 14.080 -0.058 
BB4_G1 7156.250 760.315 509.000 30.232 14.059 -0.059 
BB4_H11 8027.000 344.746 570.500 20.728 14.070 -0.060 
BP2_F10 7677.155 346.602 545.645 14.987 14.070 -0.063 
JB10_E2 7292.750 261.899 518.250 13.817 14.072 -0.063 
BP6_G4 6911.300 150.260 491.355 15.347 14.066 -0.064 
BB5_A11 8034.000 611.527 571.750 21.061 14.052 -0.064 
RP2_F7 7163.500 432.492 509.500 11.902 14.060 -0.072 
BP6_B4 6976.570 381.678 495.930 30.614 14.068 -0.073 
BB5_A7 8231.250 695.473 586.750 25.078 14.029 -0.080 
BB4_D5 7593.500 485.292 540.250 10.532 14.056 -0.080 
RP2_G11 7226.750 498.241 514.500 8.347 14.046 -0.081 
RP13_E7 6763.750 361.118 481.000 20.510 14.062 -0.082 
R6_G5 6598.675 206.343 469.700 11.488 14.049 -0.084 
BP6_D3 6918.925 277.791 491.965 36.045 14.064 -0.087 
BP6_B7 6841.150 529.085 486.780 26.524 14.054 -0.089 
R6_C2 7467.925 98.744 531.005 32.833 14.064 -0.094 
JB10_D3 7636.500 348.926 544.000 22.435 14.038 -0.094 
BP6_C3 6867.380 526.717 488.915 43.253 14.046 -0.096 
RP2_H6 6738.500 446.899 480.500 8.699 14.024 -0.097 
R6_C3 7622.255 319.824 542.900 33.677 14.040 -0.101 
BB4_H10 7842.250 460.649 559.500 11.030 14.017 -0.103 
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BB4_F1 7841.500 336.113 558.500 17.311 14.040 -0.104 
BP6_C6 6925.635 366.230 494.405 21.350 14.008 -0.110 
R6_D10 7427.055 179.696 529.785 14.065 14.019 -0.111 
R6_B9 7726.870 159.792 550.220 33.203 14.043 -0.113 
R6_B2 7444.745 251.548 531.005 27.880 14.020 -0.117 
BP2_F11 7391.065 217.049 527.345 16.886 14.016 -0.120 
BB5_D5 7645.500 272.335 545.500 22.825 14.016 -0.122 
BB4_E12 7691.500 554.568 549.750 23.085 13.991 -0.123 
BP6_B3 7326.100 97.514 522.465 24.550 14.022 -0.128 
JB10_C3 7519.000 304.432 537.250 18.998 13.995 -0.132 
RP13_C4 6613.500 452.363 473.250 9.639 13.975 -0.134 
BP6_H3 6872.260 76.104 491.050 14.418 13.995 -0.135 
R6_E11 7324.270 514.750 523.990 17.665 13.978 -0.141 
BP2_H3 6843.895 303.376 489.830 13.964 13.972 -0.142 
RP2_A11 7553.250 418.082 539.000 21.510 14.013 -0.143 
JB10_C9 7601.000 402.950 543.750 12.500 13.979 -0.146 
RP13_A5 6987.250 353.240 500.250 16.460 13.968 -0.149 
RP13_B8 6769.250 297.554 484.750 12.971 13.964 -0.156 
BB4_C1 7903.000 457.234 565.750 5.909 13.969 -0.158 
BP6_H2 7190.375 54.627 515.145 8.705 13.958 -0.162 
R6_C6 7499.950 379.868 537.410 19.225 13.956 -0.163 
BB4_G3 7680.000 571.732 550.250 19.923 13.957 -0.171 
RP2_H2 5270.250 624.444 379.250 20.023 13.897 -0.175 
RP13_A1 7182.000 410.820 515.500 10.472 13.932 -0.181 
RP13_D5 6775.250 349.916 485.500 15.610 13.955 -0.182 
JB10_E1 7475.500 463.243 536.250 40.302 13.940 -0.186 
BB5_G7 7653.000 391.388 549.750 14.660 13.921 -0.191 
BP6_D8 6938.445 561.035 498.980 23.720 13.905 -0.191 
RP2_G12 7211.500 524.877 518.000 12.247 13.922 -0.193 
RP2_E12 7062.500 377.695 507.000 14.306 13.930 -0.199 
RP13_G2 6807.000 178.675 489.250 9.605 13.913 -0.199 
BP6_B2 7285.535 103.652 523.075 26.680 13.928 -0.205 
R6_E4 7507.880 373.620 539.850 11.891 13.907 -0.207 
RP13_F3 6560.000 442.679 471.750 15.607 13.906 -0.209 
RP13_A8 6950.750 308.088 500.000 12.517 13.902 -0.212 
RP13_C6 6900.500 286.312 496.500 9.883 13.898 -0.213 
BP2_A12 3243.675 156.155 233.020 26.147 13.920 -0.214 
RP13_C7 6720.750 258.758 483.750 5.679 13.893 -0.214 
RP2_D2 6657.000 462.550 478.750 11.236 13.905 -0.217 
RP13_C10 6984.250 407.655 503.000 6.481 13.885 -0.220 
RP8_C2 6892.695 452.342 496.235 32.757 13.890 -0.226 
BB4_C6 7805.500 318.457 561.500 13.279 13.901 -0.226 
BB4_E8 7586.000 409.009 546.500 7.047 13.881 -0.229 
BB4_E9 7559.750 576.998 544.750 14.080 13.877 -0.230 
BP6_E3 6866.465 273.259 494.710 19.785 13.880 -0.233 
BB5_B7 7828.000 442.792 564.250 21.670 13.873 -0.242 
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BB5_A4 8029.250 453.399 579.250 24.268 13.861 -0.247 
BB4_E1 7982.500 481.776 574.750 18.154 13.889 -0.251 
RP8_C1 7038.790 385.443 507.215 37.476 13.877 -0.251 
BB5_F11 7879.500 723.283 568.000 7.874 13.872 -0.253 
R6_C9 7546.615 177.423 543.510 32.985 13.885 -0.254 
BP6_F10 6152.155 392.319 444.690 18.218 13.835 -0.255 
RP13_F1 6780.500 277.625 489.500 4.359 13.852 -0.256 
BB4_H12 7547.750 382.110 544.750 25.526 13.855 -0.257 
BB4_B4 7486.250 414.766 540.500 9.950 13.851 -0.262 
RP13_C12 6806.000 315.608 491.750 16.800 13.840 -0.263 
RP13_D2 6657.000 415.387 481.000 6.377 13.840 -0.266 
RP8_B6 6939.055 519.438 501.725 25.772 13.830 -0.270 
BB4_D8 7629.000 491.998 551.500 17.078 13.833 -0.273 
BB5_B8 7865.250 711.500 569.000 10.360 13.823 -0.274 
RP2_H11 6982.250 514.257 504.750 10.905 13.833 -0.283 
BB5_H7 7766.750 260.529 561.500 15.330 13.832 -0.285 
RP13_A4 6974.000 269.734 504.750 8.655 13.817 -0.286 
BB5_F12 8229.750 454.690 595.500 12.342 13.820 -0.295 
BB5_G1 7485.500 389.853 542.250 27.256 13.805 -0.305 
JB10_H6 6574.750 100.970 476.000 23.022 13.813 -0.306 
RP13_B11 6927.250 358.426 502.250 3.594 13.792 -0.308 
RP2_A5 6990.250 335.709 506.750 8.180 13.794 -0.309 
BB5_H6 7597.750 398.518 550.750 6.238 13.795 -0.311 
RP13_F5 6661.250 214.301 483.000 9.832 13.791 -0.313 
BP6_A1 6291.540 463.029 455.365 33.118 13.816 -0.315 
BB4_D11 7472.250 403.844 542.000 18.601 13.786 -0.319 
RP2_B10 7268.250 346.566 526.500 20.404 13.805 -0.320 
RP2_B8 6931.000 381.961 502.500 15.780 13.793 -0.321 
RP2_D11 6881.500 445.734 499.000 23.137 13.791 -0.332 
RP13_B5 6543.500 312.676 475.500 12.450 13.761 -0.333 
BB4_E4 7685.500 708.238 557.000 14.765 13.798 -0.333 
RP13_E6 6692.000 187.682 486.250 10.178 13.762 -0.340 
BB4_F9 7503.250 507.317 545.500 6.952 13.755 -0.343 
RP13_F11 6944.250 271.976 505.000 3.742 13.751 -0.348 
BP6_E4 6856.095 387.213 498.980 19.444 13.740 -0.352 
BP2_A6 6910.385 432.809 502.335 35.713 13.757 -0.364 
RP13_D3 6798.500 410.481 494.750 10.626 13.741 -0.367 
RP2_E5 6750.000 526.205 491.500 9.399 13.733 -0.368 
RP2_C12 7183.500 425.871 523.000 14.832 13.735 -0.375 
BB4_F3 7549.750 535.917 547.750 26.887 13.783 -0.377 
RP2_F4 6266.250 516.474 457.500 10.247 13.697 -0.377 
RP2_B11 7289.750 423.076 530.500 15.330 13.741 -0.381 
RP13_A3 6929.500 383.157 505.500 19.122 13.708 -0.381 
BB4_B9 7797.750 527.834 568.500 11.676 13.716 -0.383 
RP13_F9 6738.750 189.222 491.500 7.594 13.711 -0.383 
BB5_C6 7572.250 353.806 552.750 9.287 13.699 -0.398 
Appendix A 
207 
 
BB5_A5 7937.250 593.238 580.000 23.466 13.685 -0.402 
BB5_G9 7669.000 262.041 560.000 10.677 13.695 -0.403 
BP6_G3 6872.260 183.274 502.030 14.925 13.689 -0.403 
BP2_C12 5318.285 509.887 387.350 53.740 13.730 -0.405 
RP13_B12 6779.500 352.491 495.750 13.475 13.675 -0.408 
RP13_G1 6838.250 337.485 500.250 14.104 13.670 -0.414 
BP2_A5 6693.225 280.201 489.220 23.699 13.681 -0.416 
RP13_E9 6599.250 271.796 482.500 13.379 13.677 -0.416 
R6_A2 7196.475 169.433 525.515 34.035 13.694 -0.428 
RP13_B2 6930.000 336.366 507.000 12.356 13.669 -0.430 
BB4_A8 8063.500 176.152 590.000 11.576 13.667 -0.434 
RP13_F4 6469.000 316.466 473.000 22.760 13.677 -0.438 
RP8_A6 5878.875 281.390 430.965 25.129 13.641 -0.440 
RP2_C6 6841.500 481.487 501.250 9.430 13.649 -0.444 
RP2_C3 3791.000 1158.305 272.500 82.124 13.912 -0.453 
BB5_E12 8050.250 456.853 590.250 8.180 13.639 -0.468 
BP6_G2 6836.880 47.366 502.030 12.180 13.618 -0.469 
BB5_H5 7711.500 385.989 566.250 10.340 13.619 -0.474 
BP6_F2 5354.275 147.593 394.365 11.886 13.577 -0.476 
RP2_F12 6923.500 568.377 508.250 8.057 13.622 -0.477 
BB4_B11 7905.000 406.623 580.750 22.692 13.612 -0.479 
RP13_B3 6724.500 251.362 494.500 12.342 13.599 -0.479 
BB5_H8 7730.750 255.450 568.000 8.406 13.610 -0.481 
BB4_A11 8114.000 368.836 596.000 19.528 13.614 -0.482 
RP13_G6 6715.250 316.242 493.750 14.315 13.601 -0.496 
RP13_G10 6694.500 248.346 492.750 11.177 13.586 -0.498 
BB4_C4 7163.750 561.024 527.250 24.891 13.587 -0.500 
R6_A4 6586.170 192.862 484.645 29.151 13.590 -0.506 
RP13_G12 6855.500 231.244 505.000 14.468 13.575 -0.510 
BB5_E10 7988.250 505.649 588.500 9.883 13.574 -0.521 
RP2_E8 6408.250 579.271 472.250 37.053 13.570 -0.522 
RP13_D1 6731.750 325.916 496.750 8.461 13.552 -0.526 
BB5_B12 8169.750 376.640 601.750 13.326 13.577 -0.527 
RP13_C9 6427.500 269.822 475.250 12.842 13.524 -0.543 
BB4_C7 7311.000 264.997 540.750 8.500 13.520 -0.560 
RP13_F8 6531.000 362.342 483.000 10.424 13.522 -0.561 
RP13_G11 6948.750 259.521 514.500 4.435 13.506 -0.567 
RP2_D1 5348.500 329.653 396.750 21.793 13.481 -0.570 
RP13_F12 6640.250 361.141 492.000 13.089 13.496 -0.572 
BP2_B11 6818.275 310.388 504.470 28.982 13.516 -0.574 
RP2_B3 7072.250 332.966 524.250 8.180 13.490 -0.587 
RP13_E5 6796.000 495.504 503.750 19.670 13.491 -0.588 
BB5_A6 8376.500 713.035 621.250 28.628 13.483 -0.594 
RP13_A10 7004.500 284.975 519.750 13.226 13.477 -0.595 
BB4_G4 2132.750 90.345 164.500 5.066 12.965 -0.598 
R6_A12 6481.555 645.135 481.595 43.023 13.459 -0.614 
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RP13_C1 6757.750 418.247 502.500 13.102 13.448 -0.616 
RP13_H5 6358.000 293.472 473.250 7.805 13.435 -0.626 
BB4_F5 7252.750 673.180 539.250 2.754 13.450 -0.627 
R6_B6 6937.530 171.697 515.450 15.254 13.459 -0.627 
RP2_A4 7073.000 267.294 525.500 15.199 13.460 -0.627 
R6_B7 6656.625 264.288 494.710 27.434 13.456 -0.628 
RP13_B7 6806.000 219.399 506.500 17.673 13.437 -0.641 
BB5_C7 7547.500 202.268 561.250 15.735 13.448 -0.642 
RP13_A11 6888.250 273.278 513.500 14.201 13.414 -0.652 
BB5_F8 7747.500 683.049 577.500 19.053 13.416 -0.660 
BB5_B11 7966.500 464.854 593.750 8.808 13.417 -0.663 
R6_A7 6580.375 323.686 490.440 36.478 13.417 -0.667 
RP2_B2 5473.500 963.066 411.250 38.222 13.309 -0.670 
BB4_E3 7370.000 674.825 550.000 5.099 13.400 -0.678 
BB5_D6 7353.000 452.279 548.750 12.971 13.400 -0.680 
RP13_C8 6613.750 343.529 494.000 19.950 13.388 -0.684 
BB4_F4 7534.750 639.642 561.500 18.484 13.419 -0.687 
BB5_E7 7442.750 371.920 555.750 13.817 13.392 -0.688 
R6_C5 6442.820 283.772 482.205 8.297 13.361 -0.691 
RP13_C3 6518.750 365.148 488.000 2.828 13.358 -0.699 
BB5_C1 7702.000 409.341 576.000 4.397 13.372 -0.702 
RP13_D10 6493.750 241.892 486.250 17.289 13.355 -0.708 
RP2_C5 4837.750 407.941 364.250 6.238 13.281 -0.711 
BB5_C12 7891.000 814.965 590.250 6.131 13.369 -0.714 
R6_F5 6610.570 210.474 495.320 18.716 13.346 -0.718 
BB5_D11 7490.750 530.184 562.000 16.104 13.329 -0.731 
R6_A10 7131.205 234.141 532.530 51.765 13.391 -0.735 
BB5_H3 7610.500 385.309 570.000 21.649 13.352 -0.736 
BB5_F4 7368.250 437.898 552.500 12.069 13.336 -0.737 
BB4_E5 7456.500 433.238 558.500 16.941 13.351 -0.737 
BB4_B3 7686.500 222.034 576.250 8.016 13.339 -0.739 
BB4_B7 7349.000 303.326 551.250 12.148 13.332 -0.742 
RP2_E4 6616.250 416.570 497.250 3.775 13.306 -0.744 
BB5_H11 7455.000 216.962 559.500 9.678 13.324 -0.748 
BP2_C8 5387.520 1388.036 407.785 95.894 13.212 -0.758 
BB4_A10 8085.750 207.924 607.250 9.811 13.315 -0.765 
BB4_A9 7846.000 257.873 589.500 13.000 13.310 -0.768 
BB4_D2 6995.000 489.294 525.000 21.954 13.324 -0.770 
BB5_D2 7172.500 308.269 539.500 27.767 13.295 -0.778 
BB4_A12 7745.000 262.028 582.000 24.125 13.308 -0.780 
BB4_E6 4962.000 287.935 376.000 12.055 13.197 -0.782 
BB4_D3 7397.000 363.132 556.750 22.940 13.286 -0.795 
BB4_E11 7472.500 476.264 563.750 27.439 13.255 -0.806 
RP13_E4 6460.750 321.118 487.750 16.761 13.246 -0.820 
RP2_H10 5671.250 288.132 429.500 9.950 13.204 -0.823 
RP2_C7 4363.750 417.927 332.500 10.149 13.124 -0.831 
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BB5_F7 7430.500 443.099 561.500 7.937 13.233 -0.833 
R6_D5 6067.365 398.467 459.940 25.338 13.192 -0.834 
BB5_B5 7618.000 457.089 576.250 8.655 13.220 -0.841 
BB4_E10 7400.500 582.703 560.250 25.158 13.209 -0.841 
R6_D9 6758.495 125.125 511.485 15.636 13.213 -0.845 
BB4_A6 7934.750 190.989 599.750 14.175 13.230 -0.849 
RP13_A2 6584.250 154.675 499.500 13.404 13.182 -0.866 
RP2_D3 6271.500 326.133 476.250 19.619 13.169 -0.878 
RP2_B6 6670.750 510.539 507.500 9.678 13.144 -0.891 
BB5_F9 7434.250 416.294 564.750 7.411 13.164 -0.896 
BB5_C5 7458.250 402.434 566.750 16.721 13.160 -0.898 
RP13_C11 6912.500 256.349 525.500 12.923 13.154 -0.902 
BB5_C8 7632.500 589.308 579.500 16.114 13.171 -0.907 
RP8_D10 4921.175 426.107 376.675 46.375 13.065 -0.940 
BB5_G3 7449.500 581.824 567.750 10.689 13.121 -0.942 
RP2_B5 4931.250 653.441 379.250 5.377 13.003 -0.963 
RP2_A1 6726.250 203.800 514.750 5.737 13.067 -0.967 
RP13_A7 3409.000 260.427 266.500 8.386 12.792 -0.972 
RP13_F2 5590.250 268.516 429.500 5.972 13.016 -0.976 
RP13_D6 6251.000 367.937 479.750 7.228 13.030 -0.990 
RP2_B7 5102.000 262.657 393.000 14.720 12.982 -0.997 
BB5_B10 7277.500 853.972 558.500 42.681 13.030 -0.998 
BB5_C9 7265.250 489.584 557.250 10.046 13.038 -1.002 
BB5_C11 7582.250 472.068 581.250 11.354 13.045 -1.011 
RP2_B4 5038.500 352.525 389.500 4.655 12.936 -1.012 
BB5_C3 7336.750 398.486 563.000 20.785 13.032 -1.013 
BP2_A3 6556.280 420.327 504.165 13.563 13.004 -1.024 
BB5_H2 7353.250 428.093 564.250 25.145 13.032 -1.035 
BB5_D4 7403.250 212.625 568.250 19.225 13.028 -1.037 
BB5_H12 7459.750 261.223 574.000 9.092 12.996 -1.054 
RP2_D8 5925.000 309.099 457.500 11.387 12.951 -1.062 
BB4_C2 7206.750 265.305 554.250 36.207 13.003 -1.066 
RP2_A10 6887.000 313.323 530.500 26.851 12.982 -1.074 
RP13_B9 6236.000 191.465 481.750 20.056 12.944 -1.074 
RP13_C2 6387.750 355.948 493.750 16.174 12.937 -1.084 
BB5_G5 6806.500 254.570 524.250 37.044 12.983 -1.086 
RP2_A12 6802.000 208.290 524.750 33.540 12.962 -1.089 
BB5_D12 8026.000 442.640 619.250 7.719 12.961 -1.099 
BB5_E4 7280.750 496.701 563.250 11.587 12.926 -1.111 
RP8_E6 5480.240 704.475 425.170 63.553 12.890 -1.112 
BB5_D8 5415.750 699.388 422.000 12.884 12.834 -1.118 
RP13_A6 4506.750 228.323 352.500 18.877 12.785 -1.120 
BB5_B1 7419.000 565.085 574.750 25.131 12.908 -1.129 
BB5_E8 7102.000 373.092 550.250 17.821 12.907 -1.132 
BB5_C10 7447.250 457.333 577.250 10.874 12.901 -1.148 
BB4_H5 4741.750 164.441 372.000 6.683 12.747 -1.159 
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RP8_D4 6498.940 523.734 505.385 45.183 12.859 -1.172 
BB4_C9 7001.500 274.210 545.500 11.561 12.835 -1.190 
BB5_F3 7334.500 440.803 571.250 27.837 12.839 -1.194 
RP13_D9 6330.500 256.068 494.750 14.818 12.795 -1.214 
BB5_E5 7183.250 370.924 560.750 5.377 12.810 -1.221 
RP2_G1 2374.500 171.617 196.750 11.206 12.069 -1.227 
JB10_E5 6567.250 473.815 516.500 9.256 12.715 -1.283 
BB5_G4 7380.250 429.299 579.000 17.474 12.747 -1.295 
BB4_E2 4912.500 774.735 390.750 11.758 12.572 -1.298 
BB5_D1 6830.750 317.267 538.000 6.325 12.697 -1.313 
JB10_H10 6343.000 257.802 500.500 11.902 12.673 -1.324 
BB4_C3 6529.250 173.492 514.750 26.437 12.684 -1.331 
RP13_A12 6718.250 355.369 530.250 22.202 12.670 -1.332 
RP2_H5 4162.750 2427.047 346.250 151.364 12.022 -1.370 
RP13_D4 5761.000 224.228 458.000 10.296 12.579 -1.381 
RP8_E7 6754.225 342.907 535.275 13.304 12.618 -1.386 
BB5_G2 7540.750 369.345 595.750 38.612 12.658 -1.398 
BP6_B6 3512.075 878.978 276.025 98.880 12.724 -1.408 
RP13_H2 4534.250 1583.669 370.500 96.186 12.238 -1.427 
BB5_B4 7422.500 459.418 590.750 14.728 12.565 -1.451 
BB4_B10 5928.250 486.492 475.000 13.292 12.481 -1.465 
RP2_A2 4520.750 471.820 365.500 9.000 12.369 -1.488 
JB10_D6 4872.500 223.030 393.500 11.619 12.382 -1.495 
BB5_F5 7087.250 312.642 566.250 11.786 12.516 -1.501 
BB4_C10 6856.500 397.305 549.000 16.753 12.489 -1.503 
BP6_A6 4488.685 2067.808 370.575 137.730 12.113 -1.505 
BB5_B6 6467.000 533.491 519.750 20.370 12.443 -1.528 
BB5_A10 7595.750 515.773 608.250 24.744 12.488 -1.534 
BB5_A3 7105.250 504.641 572.250 23.754 12.416 -1.579 
BP2_A10 6170.455 286.125 497.455 34.020 12.404 -1.586 
BP6_E5 4858.650 264.312 396.195 17.033 12.263 -1.594 
BB5_C4 7189.500 359.244 580.750 17.671 12.380 -1.620 
BB5_B3 7424.500 296.344 598.500 25.801 12.405 -1.621 
RP8_C4 3090.870 284.602 261.385 17.149 11.825 -1.659 
BP2_A2 6052.725 250.044 493.185 16.379 12.273 -1.687 
BB5_B2 7421.750 369.088 603.250 32.387 12.303 -1.717 
RP13_E11 6209.000 224.627 507.750 11.177 12.228 -1.733 
BB4_D12 6143.250 526.620 503.500 21.810 12.201 -1.735 
RP13_H10 5947.500 47.226 488.500 19.672 12.175 -1.775 
BB5_F2 7330.000 456.849 604.250 22.157 12.131 -1.885 
RP2_G10 5532.750 1284.629 464.500 70.382 11.911 -1.898 
RP2_E11 2220.750 109.804 203.500 7.937 10.913 -1.972 
BP2_A1 5859.965 218.575 491.050 28.359 11.934 -1.990 
BB4_D9 5736.500 398.103 484.500 15.969 11.840 -2.050 
BB5_D10 6558.750 495.790 554.000 11.662 11.839 -2.101 
RP2_G9 2812.250 36.573 253.250 5.852 11.105 -2.139 
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BB5_D7 4568.500 686.597 394.750 20.123 11.573 -2.156 
BB5_C2 7411.750 350.058 624.000 41.110 11.878 -2.160 
RP2_B1 4311.750 526.435 374.750 17.595 11.506 -2.188 
RP13_A9 5651.000 299.890 485.000 7.528 11.652 -2.226 
RP2_A3 4155.500 749.372 365.250 6.185 11.377 -2.308 
RP8_C3 4597.265 278.419 410.530 6.719 11.198 -2.538 
RP2_F10 4350.000 335.438 390.250 32.108 11.147 -2.609 
BP6_A10 3490.115 270.314 321.470 13.083 10.857 -2.628 
BB5_A1 6645.250 678.250 588.000 16.269 11.301 -2.637 
BB5_G8 5159.750 239.109 462.000 17.029 11.168 -2.646 
JB10_B3 5669.750 166.748 505.750 18.927 11.211 -2.655 
RP2_G6 4413.250 409.867 400.750 26.750 11.012 -2.667 
BB5_G10 5922.750 556.200 539.750 16.701 10.973 -2.885 
BB5_A9 4222.750 2462.129 414.250 132.588 10.194 -2.919 
RP2_A6 3940.000 482.010 374.750 8.500 10.514 -3.051 
RP2_H8 4089.500 1261.897 394.250 58.631 10.373 -3.064 
BB4_C11 2276.750 70.287 235.250 23.329 9.678 -3.070 
BB5_H1 5259.500 207.898 490.750 16.601 10.717 -3.074 
RP2_A8 3579.250 357.692 349.000 5.774 10.256 -3.170 
BB5_G11 5537.500 271.871 522.000 20.510 10.608 -3.212 
RP2_A7 3751.000 445.664 366.750 6.602 10.228 -3.268 
BB4_B5 2449.500 124.265 263.500 7.047 9.296 -3.499 
BB5_E1 3513.750 760.030 368.750 12.894 9.529 -3.818 
JB10_G2 3483.500 559.589 369.750 9.500 9.421 -3.926 
BB5_F6 2422.750 123.716 281.000 17.833 8.622 -4.150 
BB5_E2 3423.500 144.549 375.750 25.979 9.111 -4.248 
BB4_B1 2398.750 90.669 284.500 13.964 8.431 -4.298 
BB5_H4 3897.750 215.290 432.000 11.165 9.023 -4.468 
JB10_H5 3823.000 157.654 427.000 13.711 8.953 -4.517 
RP13_H11 2374.000 106.496 294.500 7.681 8.061 -4.648 
BB4_C5 2526.750 109.463 312.250 6.946 8.092 -4.742 
BB4_D1 2268.750 105.256 288.750 9.069 7.857 -4.752 
BB5_A8 2278.750 45.353 291.750 12.633 7.811 -4.816 
BB5_G6 3561.000 100.701 416.500 13.699 8.550 -4.841 
BB4_H8 2554.000 187.378 320.750 9.032 7.963 -4.891 
RP2_B12 2308.000 75.714 306.250 10.720 7.536 -5.139 
BB5_H10 3342.500 357.104 416.000 14.652 8.035 -5.270 
RP2_B9 3023.750 218.971 390.000 12.111 7.753 -5.434 
BB5_H9 2903.500 69.467 378.750 19.889 7.666 -5.459 
BB4_D4 2308.500 159.203 320.000 1.414 7.214 -5.485 
BB5_B9 2601.500 202.824 351.500 19.434 7.401 -5.532 
5uM FCCP 2938.672 207.228 395.246 87.905 7.435 -6.994 
10uM FCCP 3003.263 238.224 408.086 91.823 7.359 -7.110 
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